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Abstract 
 
 Domino amination/conjugate addition reactions have been used to synthesize a new 
class of 4-quinolones. An efficient route for the synthesis of benzo[b]pyrazolo[5,1-
f][1,6]naphthyridines via silver triflate-catalyzed one-pot tandem reactions has also been 
developed which proceeds with good functional group tolerance under mild conditions with 
high efficiency and excellent selectivity. A high yielding route for the synthesis of fluorinated 
arenes, which are difficult to obtain, has been developed by direct acyl-alkylation of benzyne. 
 
 Domino Aminierungs / Michael-Typ Reaktionen wurden verwendet, um eine neue 
Klasse von 4-Chinolonen zu synthetisieren. Weiterhin wurde ein effizienter Weg zur Synthese 
von Benzo[b]pyrazolo[5,1-f][1,6]Naphthyridine über Silbertriflat-katalysierte Eintopf-Tandem-
Reaktionen entwickelt, die mit guter Toleranz gegenüber funktionellen Gruppen, unter milden 
Bedingungen, mit hoher Effizienz und ausgezeichneter Selektivität verlaufen. Fluorierte 
Aromaten, die anderweitig schwer zu erhalten sind, wurden erstmals durch direkte Acyl-
Alkylierung von Benz-in hergestellt. 
 
 
 
 
 
 
 
 
 
 
 
1 
 
1.  An efficient [5+1] strategy for the synthesis of benzo-[1,8]-naphthyridine-4(1H)-
ones by domino amination / conjugate addition reaction of 1-(2-chloroquinolin-3-
yl)-3-phenylprop-2-yn-1-ones with amines. 
 
1.1 General Introduction to Quinolones 
Over the years nitrogen-containing heterocycles have been gaining much importance in 
medicinal, photochemical and synthetic chemistry.
1
 Among these, naphthyridinone and 
quinolones are bioactive members of nitrogen-containing heterocycles. 
Synthetic quinolone antibiotics were discovered by George Lesher and coworkers as a 
byproduct of chloroquine manufacture in the 1960s.
2 
Nalidixic acid is the first of the synthetic 
quinolone antibiotics found to be effective against both gram-positive and gram-negative 
bacteria. Particularly interesting from a biological point of view are 3-carboxyquinolin-4-ones 
and 3-carboxy-1,8-naphthyridin-4-ones which are well known antibacterial agents.
3 
 F. J. Dutko 
and coworker studied, that quinolin-4-ones, substituted at position 3 by electron-withdrawing 
functionalities, such as amide or sulfinyl groups, also possess strong antiviral activity.
4
 K. 
Robinson explored flosequinan as a drug for the treatment of congestive heart failure.
5
 Although 
compounds with antibacterial activities have been known as natural products for centuries, 
synthetic antibiotics evolved starting from the pioneering discoveries of penicillin by Fleming in 
1928 and sulphonamides in 1935.
6 
The original potent quinolone was 1,8-naphthyridine-
nalidixic acid and the synthetic 4-quinolones, which were later prepared by J. T. Smith, are 
analogues of the original molecule.
7
 Nalidixic acid possesses limited in-vitro activity against 
Gram-negative bacteria and its use was restricted to oral treatment of patients with urinary tract 
infections. Modifications to this drug in the 1970s gave rise to similar compounds (oxolinic 
acid, rosoxacin, cinoxacin and flumequine) which were also available only for use in patients 
with urinary tract infections. A piperazine substitution at position 7 of the naphthyridine core 
and fluorination at position 6 resulted in improved activities against Gram-negative and Gram-
positive pathogens, respectively. These are nowadays the so-called fluoroquinolone antibiotics. 
In 1980, H. Koga and coworkers reported norfloxacin as the first of the fluoroquinolones to 
possess an increased activity against Gram-negative bacteria; including Pseudomonas 
aeruginosa.
8 
Its use was restricted to the treatment of patients with urinary tract infections. 
Quinolones proved to be a unique class of molecules which act against bacteria by inhibiting 
DNA gyrase. This is an enzyme which is necessary for the replication of nucleic acid. These 
agents were first described by Lescher et al.
9
 Since then, more than 10,000 quinolone 
2 
 
derivatives have been synthesized world-wide. Very few have entered into clinical development 
and less than ten have been approved for clinical use.
10
 Some important 1,8-naphthyridinones 
are shown in Figure 1. 
 
Figure 1. Important 1,8-naphthyridinones. 
 
Numerous synthetic routes to 1,8-naphthyridones have been reported. Stephen L. 
Buchwald reported an approach to 2-aryl-4-quinolones by copper-catalyzed amidation of o-
halophenones followed by a base-promoted Camps cyclization of the resulting N-(2-
ketoaryl)amides.
11 
G. M. Coppola developed a 4-quinolone synthetic route, by the reaction of 
isatoic anhydrides with enolates of ketones.
12-15 
K. Lemr and coworkers established a novel 
strategy via cyclization of N-substituted phenacyl or acetonyl anthranilates in polyphophoric 
acid.
16 
G. I. Georg reported a quinolone synthesis via cyclization of substituted anthranilic acid 
derived ynone intermediates under mild conditions.
17
 F. W. Heinemann and coworkers 
estsblished an interesting transformation of electron-deficient alkynes to quinolones, 
thiochromones and pyrazoles via activated Michael systems.
18
 Djakovitch and co-workers 
explored a one-pot two-step multi-catalyzed synthesis of 4-quinolone.
19
 Several interesting 
methodologies were also found, including cycloaddition of aniline derivatives,
20
 palladium-
catalyzed carbonylative Sonogashira coupling of 2-iodoaniline with arylacetylene,
21
 and metal 
free intramolecular amination.
22
 Although these methods are effective and give relatively high 
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yields,
23,24
 most of them give 1-unsubstituted and 2-substituted 4-quinolones, or 1,3-
disubstituted 4-quinolones. Only a few examples were reported in the literature for 1,2-
disubstituted 4-quinolone syntheses. 
1.2      1,8-Naphthyridin-4-ones 
In my thesis, I have studied, together with my colleague Dr. Ingo Knepper (dissertation, 
University of Rostock, 2011), the synthesis of 1,8-naphthyridines based on formal [5 + 1]-
cyclizations of 1-(2-chloropyridin-3-yl)prop-2-yn-1-ones with a set of aromatic and aliphatic 
amines (Scheme 1).
25
 
 
Scheme 1. Conditions for the synthesis of 1,8-naphthyridin-4(1H)-ones.: (i) Pd(PPh3)4 (10 
mol%), K2CO3 (2 equiv.), DMF 150 °C, under dry Ar, 16 hr. (ii) Catalyst free, K2CO3 (2 
equiv.), DMF 150 °C, under dry Ar, 16 hr.  
 
1.3      Synthetic scope of Benzo[b][1,8]naphthyridin-4(1H)-ones 
To the best of my knowledge, 1,2-disubstituted benzo[b][1,8]naphthyridin-4(1H)-ones 
have not been reported so far. In view of the prime biological reputation among the family of 
1,8-naphthyridin-4(1H)-ones, I was encouraged to extend my synthetic work to the synthesis of 
novel benzo[b][1,8]-naphthyridin-4-ones based on [5 + 1]-cyclization of 1-(2-chloroquinolin-3-
yl)-3-phenylprop-2-yn-1-ones using different aromatic and aliphatic amines in good to excellent 
yields (Scheme 3 & 4, below). 
 
1.3.1   Results and Discussion 
My focus was to synthesize novel 1,2-disubstituted naphthyridinones starting from 
cheap starting materials. In this effort, I started from acetanilide (1, 400 mg scale), after 
formylation with POCl3 in DMF and got 2-chloroquinoline-3-carbaldehyde (2) in higher yield 
(93%) than reported in literature (80%).
26
 During the synthesis of compound 2, I faced as a 
main problem the neutralization of POCl3 in the reaction mixture. As reported in the literature, 
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we have to neutralize the reaction mixture after refluxing the reaction mixture for 10 hr. 
However, the litereature procedure proved to be less effective regarding the yield and the 
possibility to have an effective separation of the compound from the aqueous mixture. I was 
able to solve the problem by a change of the procedure. After reflux for 10 h at 80 °C, the 
reaction mixture was carefully added to crushed ice with constant stirring. In this process, 
compound 2 was separated by precipitation, filtered and washed with water to remove the 
excess of POCl3. While adding the reaction mixture to ice, it is important to make sure that the 
temperature should not increase. This was achieved by adding small amounts of the reaction 
mixture and batch-wise recovery of the product. When the temperature increased, then the 
separation of the desired compound was very difficult. This method proved to be extremely 
suitable for the synthesis of pure compound 2 in higher yield as reported in the literature. The 
next step was to convert compound 2 to compound 4; for that I considered two pathways. 
Path A. 
 
Scheme 2. Possible conditions for the synthesis of 4: (i) Oxidation. (ii) SOCl2, Reflux. (iii) 1-
Alkyne, PdCl2(PPh3)2 (2 mol%), CuI (4 mol%), THF, dry Ar. 
A familiar and straightforward route was path A. Compound 2 can easily be converted to 
compound A by using a variety of oxidants. Compound B can be achieved by treating acid A 
with SOCl2 under anhydrous conditions and finally compound 4 can be synthesized using well-
established conditions
25
 from compound 3. This route was already studied by me together with 
Dr. Ingo Knepper for a different substrate. Although path A might be feasible, my interest 
remained on a new synthetic path, i.e. path B.  
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Path B. 
 
Scheme 3, Conditions for the synthesis of 4: (i) n-BuLi, PhCCH, THF, -78C. (ii) MnO2, 
CH2Cl2, reflux (30 min). 
Path B proved to be efficient for the generation of substrate 4.
27
 In the first step, 
compound 2 was introduced to a Schlenk flask fitted with argon supply, anhydrous THF was 
used to dissolve compound 2, followed by addition of the alkyne and of n-BuLi at -78°C. The 
most important point in this step was to control the temperature during the addition of n-BuLi, 
otherwise the yield dropped. After addition of n-BuLi, the temperature was increased to room 
temperature. The reaction mixture was allowed to stir for 3 hr and subsequently quenched with 
a saturated NH4Cl solution in H2O, followed by extraction with ethyl acetate. Purification of 
compound 3 was very challenging as some unreacted starting material was still found along 
with product 3, even with extended reaction times. Initially, I purified compound 3 by using a 
capillary column, but this could not be helpful to synthesize the compound in higher amount. 
Therefore, it was really important for me to find a solution of this problem. Fortunately, when I 
was evaporating the ethyl acetate extract, addition of DCM resulted in precipitation of a white 
solid. This, on analysis, was found to be analytically pure compound 3. The final established 
procedure was very simple and high yielding. I washed the dried ethyl acetate extract with 
DCM to get the pure compound 3. Confirmation of this transformation was done by using 
1
H-
NMR, GC-MS, CHN-analysis. In the 
1
H-NMR, the aldehyde proton (δ, 10.78) of compound 2 
was diagnostic as it is not observed in compound 3. For the preparation of compound 4, I used 
the mild oxidizing reagent MnO2. Optimized reaction conditions were found after a series of 
experiments. It was important to apply the following conditions: 2 equivalents of MnO2 or 
pyridiniumchlorochromate (PCC) in DCM were refluxed for 30 min. Extended reflux time 
resulted in decomposition of compound 4 to give compound 2. Analytical techniques were used 
for the confirmation of this transformation. In the ESI-TOF/MS analysis for compound 3 a quasi 
molecular ion peak was found at 294.0677 [M+H]
+
 and for compound 4 a peak at 292.0524 
[M+H]
+
 was found. 
1
H-NMR was also helpful for comparison of these two compounds. The 
propargylic alcohol proton signal (δ, 6.72) of compound 3 was not observed in compound 4. In 
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the 
13
C-NMR spectrum, appearance of a signal at δ, 174.6 was observed for compound 4 
confirmed the oxidation of alcoholic carbon of compound 3 to carbonyl carbon. The application 
of this method, to the best of my knowledge has not been reported for this substrate so far. It is 
noteworthy that both compounds 3 and 4 were synthesized by me in higher yields than 
previously reported. Finally, compound 4 was transformed to 5. It required a lot of 
optimizations to establish conditions which gave high yields and a facile conversion. Several 
reaction conditions were applied and various conditions were used (catalyst, base, solvent and 
temperature). I started without catalyst in DMF, use of an inorganic base K2CO3. The reaction 
took 9 hr at 120 °C for completion and only gave 23% isolated product 5. It was observed that 
the use of organic bases, like DIPA, did not improve the course of the reaction significantly. 
Therefore, my focus remained with inorganic bases. Among various parameters, I found K2CO3 
as best base, DMF as best solvent, Pd(PPh3)4 as most suitable catalyst, 120 °C best temperature 
and 3 hr as best reaction time. 
 
Scheme 4. Conditions for synthesis derivatives of 2-phenylbenzo[b][1,8]naphthyridin-4(1H)-
ones: (i) RNH2, Pd(PPh3)4 (5 mol%), K2CO3 (2 equiv.),  DMF, 120 °C, under dry Ar, 3hr. 
  
During the optimization of the reaction conditions, I have found that the use of 
Pd(PPh3)4 (10 mol%) as a catalyst, 2.0 equiv. of  K2CO3, and DMF as a solvent (120 °C) was 
essential to get good yields of 5a-l. These conditions were optimized for aliphatic and benzylic 
amines (Table 1, Scheme 5). 
 
Scheme 5. Reaction condition optimization for 5k: (i) Pd(PPh3)4 (5 mol%), K2CO3 (2 equiv.), 
DMF, 120 °C, under dry Ar, 3hr. 
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I have investigated product 5k by using all analytical techniques, NMR, CHN-analysis, 
X-ray and HRMS (ESI-TOF), in order to confirm structure 5k.  
Table 1. Reaction condition optimizations for 5k 
Entry Catalyst Solvent Base T (°C) Time(hr) 5k(%)
a
 
1 Pd(PPh3)4 Toluene K2CO3 90 6  67 
2 Pd(PPh3)4 DMF K2CO3 120 3  86 
3 Pd(PPh3)4 Toluene Cs2CO3 90 6  77 
4 Pd(PPh3)4 DMF K3PO4 120 7  73 
5 PdCl2/PPh3 DMF K2CO3 120 6  69 
6 Pd(OAc)2 DMF K2CO3 120 6  58 
7 Pd(dba)2/PPh3 Toluene K2CO3 90 7  54 
8 Pd(PPh3)4 CH3CN K2CO3 90 7  53 
9 Pd(PPh3)4 
/BINAP  
DMF K2CO3 90 3  96 
10 Pd(PPh3)4 Toluene DIPA 90 9  17 
11 Catalyst Free DMF K2CO3 120 9  23 
 
a 
yields of isolated products. 
 
Aliphatic and benzylic amines are considerably more nucleophilic than anilines and their 
reactions proceeded smoothly, while anilines required improved reaction conditions (Table 2).  
 
    
 
Scheme 6. Reaction condition optimization for 5m: (i) Pd(PPh3)4 (5 mol%), Cs2CO3 (2 equiv.), 
Toluene, 90 °C, under dry Ar, 6 hr. 
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For more comprehensive understanding about the scope of cyclization, I have further 
extended my studies using a variety of anilines. However, the yields of expected products were 
very low under the established reaction conditions. It was noted that a higher amount of catalyst 
did not improve the yield. The whole procedure was revised under different reaction conditions. 
Best reaction conditions were observed when I used Pd(PPh3)4 (0.05 mmol), aniline (0.7 mmol), 
Cs2CO3 (1.2 mmol), 4 (0.6 mmol), and toluene as a solvent for 5-6 hr at 90 °C (Table 3). The 
solvent always played a crucial role during the optimization (table 2). 
 
Table 2. Optimization of the reaction conditions (5m) 
Entry Catalyst Solvent Base T(°C) Time(hr) 5m(%)
a
 
1 Pd(PPh3)4 Toluene Cs2CO3 90 6  73 
2 Pd(PPh3)4 DMF Cs2CO3 120 6  63 
3 Pd(PPh3)4 Toluene K2CO3 90 6 57 
4 Pd(PPh3)4 Toluene K3PO4 100 7 67 
5 PdCl2/PPh3 Toluene Cs2CO3 90 6 68 
6 Pd(OAc)2 Toluene Cs2CO3 90 6 57 
7 Pd(dba)2/PPh3 Toluene Cs2CO3 90 7 45 
8 Pd(PPh3)4 CH3CN Cs2CO3 90 7 55 
9 Pd(PPh3)4, BINAP  Toluene Cs2CO3 90 3 87 
10 Pd(PPh3)4 Toluene DIPA 90 9 17 
11 Catalyst Free Toluene Cs2CO3 90 9 23 
 
a 
yields of isolated products. 
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1.3.2    Proposed Mechanism 
Mechanistic studies, for the cyclization either with or without catalyst, were taken into 
account.
25 
The proposed catalyst-free mechanism is given in Scheme 7. 
 
 
 
Scheme 7. Proposed catalyst free reaction mechanism and cyclization pattern. 
 
In the presence of a catalyst several mechanistic paths are possible (Scheme 8). The 
reaction might proceed by formation of intermediate 6 by conjugate addition of the amine to the 
ynone moiety. Oxidative addition of Pd(0) to 6 resulted in the formation of organopalladium 
species 10 (path A). The reaction with base gave intermediate 11. Intramolecular Buchwald–
Hartwig reaction via organopalladium species 12 and reductive elimination of Pd (0) gave 
product 5. On the other hand, intermediate 11 can be alternatively formed by a slightly different 
path. Initial oxidative addition of Pd to halide 4 may result in the formation of intermediate 13. 
The addition of the amine might deliver intermediate 11 (path B). Intermediate 13 can also be 
10 
 
directly attacked by the amine (Buchwald–Hartwig reaction) to deliver intermediate 14. The 
latter can undergo a cyclization by intramolecular Michael addition giving rise to products 5 
(path C). Isolation of intermediates 6 in a related reaction suggests that the reaction preceded via 
path A. Analysing the literature, I have found some controversial arguments
27 
for some of the 
paths of the mechanism presented in this thesis. 
 
 
 
Scheme 8. Proposed Pd (0) catalyzed mechanism of cyclization.
25,27 
 
Using the optimized conditions in hand, I have synthesized a variety of 1,2-disubstituted 
benzonaphthyridones using commercially available aliphatic and benzylic amines (products 5a-
l) and various anilines (products 5m-u) (Table 3). Different anilines with strong electron 
donating groups and with electron withdrawing groups were tried. It was noted that electron 
donating groups improved the reaction and resulted in high yields, whereas anilines with strong 
electron withdrawing groups were found to be less reactive. Anilines with electron-withdrawing 
groups took longer reaction times and proceed in very low yields.  
11 
 
 
Table 3. Synthesis of 1-(2-chloroquinolin-3-yl)-3-phenylprop-2-yn-1-one 5 
5 R 5(%)
a
 
a Cy 72 
b C6H5CH2 85 
c 4-(MeO)C6H4 64 
d PhC2H4 46 
e n-C7H16 65 
f cPr 57 
g H 96 
h 3-morpholinopropyl 86 
i 2-(OH)C2H4 72 
j 3-(MeO)C6H4 52 
k 2-ClC6H4 86 
l 3-(1H-imidazol-1-yl)propyl 70 
m 4-(MeO)C6H4 73 
n 3,4-(MeO)2C6H3 76 
o 3,5-(MeO)2C6H3 64 
p 3,4,5-(MeO)3C6H2 77 
q 3,5-(Me)2C6H3 58 
r 2,4-(MeO)2C6H3 58 
s 4-(Et2N)C6H4 77 
t 4-EtC6H4 50 
u 2-FC6H4 30 
 
a 
yields of isolated products. 
 
The established methodology was tested on several molecules. I got very interesting 
transformations with 2-chloroquinoline-3-carbaldehyde (2). I have tried this methodology on 
some other molecules, like 2,5-dichloro-1-methyl-1H-pyrrole-3,4-dicarbaldehyde (15) and 2-
chloro-1-methyl-1H-indole-3-carbaldehyde (17). 
 
12 
 
 
 
Scheme 9. Conditions used for the synthesis of compound 16: (i) n-BuLi, PhCCH, THF, -78C. 
 
 
 
 
Scheme 10. Conditions used for the synthesis of compound 18: (i) n-BuLi, PhCCH, THF, -78C. 
 
In these transformations, which were unsuccessful, the most crucial step was the 
nucleophillic addition of phenylacetylene to the aldehyde group in the presence of n-BuLi. I 
have tried different reaction conditions in term of bases, like n-BuLi, NaH, Cs2CO3 and 
different inert solvents, like toluene, THF and acetonitrile. To my surprise, neither 2,5-dichloro-
1-methyl-1H-pyrrole-3,4-dicarbaldehyde (15) nor 2-chloro-1-methyl-1H-indole-3-carbaldehyde 
(17) gave desired results. Investigations are in progress in the Langer group to find, based on 
my initial studies, suitable reaction conditions for this transformation. 
 
1.4       Structural description 
 
1.4.1   Structure description for compound 5e 
The structure of 5e was independently confirmed by X-ray crystal structure analysis 
(Figure 2). The colourless crystals showed a triclinic crystal lattice with C25H26N2O as the 
empirical formula.  The heterocyclic system was in plane and the phenyl group was twisted out 
13 
 
of plane. Two bulky groups present at adjacent positions caused repulsion, so torsion was 
observed. For example, the torsion angle between C4-C5-C13-C18 was 96.38, and the torsion 
angle between C4-C5-C13-C14 was found to be –79.53. This difference in torsion angles 
contributed to the different repulsion caused by the acyclic side chain. As far as bond lengths 
were concerned, C-N bond lengths were found to be 1.377 ppm, which is specific for aromatic 
nitrogen containing heterocycles. All other bond lengths and dihedral angles were found to be 
more or less according to reported values.  
 
Figure 2. ORTEP illustration of compound 5e. 
  
1.4.2    Structure description for compound 5f 
The structure of compound 5f was also confirmed by X-ray crystal structure analysis 
(Figure 3). The colourless crystal showed a monoclinic crystal system with C21H16N2O 
(empirical formula). The fused hetrocyclic rings showed ring strain in which N1 and O1 were 
twisted out of plane by 2° and 7.08°, respectively, which was attributed to stonger repulsion 
between phenyl and cyclopropyl rings at adjacent positions. At position C5, phenyl showed 
torsion angles of 47.06° (C4-C5-C16-C17) and 49.65° (N2-C5-C16-C21). The cyclopropyl 
group showed a 13.42° twist out of the main system. Torsion angles for the cyclopropyl rings 
were found to be -55.99° (C1-N2-C6-C7) and 50.16° (C5-N2-C6-C8). The bond length for C6-
N2 was found to be 1.452 ppm which is 0.017 ppm shorter than the normal C-N bond length 
(1.469), attributed to sp
2 
hybridized N. Extended torsional strain and angle strain resulted in 
slight abnormality of bond lengths in the entire system. 
14 
 
 
Figure 3. ORTEP illustration of compound 5f. 
 
1.4.3    Structure description for compound 5k 
Similarly the compound 5k was also subjected to X-ray crystal structure analysis (Figure 
4) to verify its structure. The colourless crystal showed a monoclinic crystal system with 
C25H17N2OCl as the empirical formula.  
 
Figure 4. ORTEP illustration of compound 5k. 
 
1.4.4    Structure description for compound 5t 
The structure of compound 5t was confirmed by X-ray crystal structure analysis as well 
(Figure 5). The colourless crystal showed a monoclinic crystal system with C21H16N2O 
(empirical formula). Both aryl substituents were twisted out of plane of the main heterocyclic 
skeleton. The heterocyclic system was by 2.57° (N1-N2-C9) twisted out of plane. The torsion 
angle between both aryl groups was found to be -9.95° (C19-N1-C5-C13). Torsion angles -
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88.20° (C1-N1- C19-C24) and -75.99° (C5-N1-C19-C20) were observed. The bond length for 
carbonyl group 1.243 (O1-C3) showed no significant deviation with respect to literature values. 
 
 
 
Figure 5. ORTEP illustration of compound 5t. 
 
The heterocyclic system experienced very little torsional strain, 2.78° (C5-C7-C9) and 
3.1° (C2-N1-N2) out of plane. The phenyl and 2-chlorobenzyl groups were found twisted out of 
plane. The 2-chlorobenzyl was twisted by 7.5° out of plane. Torsional angles for 2-chlorobenzyl 
was -32.89° (N2-C13-C14-C19) and 146.95° (N2-C13-C14-C15) on either sides of plane, 
reflected the effect of chloro in benzyl group. Bond lengths for C=O 1.236 (C9-O1) and for C-
Cl 1.736 (C15-Cl1) were in accordance to literature values.  
 
 
1.5 Conclusion 
I have developed an efficient approach for the synthesis of novel benzo-1,8-
naphthyridin-4(1H)-ones from commercially available starting materials based on a domino 
amination/conjugate addition protocol. Scope and limitations of the reaction have been studied. 
Further studies related to the application of the methodology to the synthesis of other nitrogen-
based heterocycles are currently under way by other students in our group. The molecules 
prepared can be excellent candidates for testing as antibiotics and enzyme inhibition. 
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2. Facile Assembly of benzo[b]pyrazolo[5,1-f][1,6]naphthyridines via silver triflate-
catalyzed one-pot reaction of 2-alkynylquinoline-3-carbaldehyde, tosylhydrazine and 
carbonyl compounds. 
 
2.1      Introduction 
The 1,6-naphthyridine nucleus is one of the most abundant structural motifs found in 
natural products and biologically active molecules,
28
 as recognized by K. W. Bentley. The 
versatile skeleton attracts attention for applications in pharmaceutical science, display devices 
and synthetic chemistry.  
 
Figure 6. Some important naphthyridines. 
 
1,6-Naphthryridines exhibit a broad range of pharmacological activity, including 
antifungal, antimalarial, antihypertensive, antitumor, and antihistaminic activity.
29-32
 Georg 
Merck discovered the alkaloid papaverine, used as a vasodilator.
33
 S. Hong and coworkers, 
discovered that decumbenine B is efficient for inhibition of spontaneous contraction of the 
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intestine.
29
 Fused isoquinolines have attracted much attention. The lamellarin alkaloids, which 
constitute a family of novel marine natural products, contain a highly substituted fused 1,2-
dihydroisoquinoline core.
32
 Lamellarin D has been discovered as a potent inhibitor of human 
topoisomerase-1
32
 and lamellarin α-20-sulfate displays selective inhibition against HIV-1 
integrase in vitro.
34
 J. Wu and coworkers found that pyrazolo[5,1-a]isoquinolines are effective 
for inhibition of PTP1B (protein tyrosine phosphatase 1 B, IC50 1.75 μg/mL).
35
 Herpes simplex 
virus type-1 (HSV-1) is the primary cause of facial lesions (mouth, lips, and eyes) in humans. 
The widespread use of acyclovir and nucleoside analogues has led to emergence of HSV strains 
that are resistant to these drugs. Recently, Z. Chen discovered non-nucleoside anti-HSV 
compounds
34
 which have received considerable attention. 1,6-Naphthyridines are a class of 
heterocyclic compounds that exhibit a broad spectrum of biological activities,
35
 such as inhibitor 
of HIV-1 integrase, HCMV, FGF receptor-1 tyrosine kinase, and the enzyme 
acetylcholinesterase (Figure 6, above). 
 
It was confirmed that 1,6-naphthyridines constitute a versatile class of display devices. J. 
Dresner used 1,6-naphthyridines for the fabrication of practical electroluminescent (EL) 
devices.
36
 Initially K. H. Drexhage explored that 1,6-naphthyridines exhibit extremely high 
fluorescence quantum efficiencies in the visible spectrum
37,38
 including the blue region, some 
approaching 100%. In this regard, these are ideally suited for multicolor display applications. 
For full color applications, red, green, and blue (RGB) emissions are required. An efficient blue 
emission is of particular interest because other colors can be converted from the blue emission. 
There are a number of efficient blue dyes developed in the past several years.
39-45
 Some of them 
possess reasonable or high glass transition temperature, Tg. This property has been suggested to 
be desirable for morphological stability reasons.
46-48 
There is increasing interest in the 
development of efficient fluorescent materials, particularly those emitting in the blue spectral 
region. These materials are potential candidates for use in opto- or optoelectronic devices, such 
as tuneable lasers and amplifers, optical fibres, switches or modulators. They have a variety of 
applications in optical communications, photonics, medicine, optical spectroscopy and 
information displays, for example, organic electroluminescent devices.
49-53 
From these, it was 
observed that the photophysical properties of pyrazolonaphthyridines were little explored. Thus, 
suitable blue emitters with high brightness along with good thermostability still remain to be 
developed. Thus, the development of new syntheses for a rapid approach to functionalized 
isoquinolines under mild conditions is very important. 
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Only few attempts have been made in recent years to develop simple synthetic routes, 
for this promising family of compounds. A.M. Kolodziejczyk used multicomponent reactions 
for the synthesis of such structures.
54
 These reactions are important for construction of natural 
product-like compounds. In 2007, K. Orito reported studies toward the design and synthesis of 
pyrazolonaphthyridines.
32
 Jie Wu and coworkers reported a multi-component reaction for the 
construction of pyrazolo[5,1-a]isoquinolines via silver triflate-catalyzed one-pot tandem 
reaction of 2-alkynylbenzaldehyde, tosylhydrazine, and ketone or aldehyde under mild 
conditions in good yields.
55
 W. A. Denny  prepared  3-aryl-7-halo-1,6-naphthyridin-2-amines 
and 3-aryl-7-halo-1,6-naphthyridin-2(1H)-ones by diazotization of 3-aryl-1,6-naphthyridine-
2,7-diamines.
56 
These reactions were ideally suited for the construction of natural product-like 
libraries.
57
 Herein, I reported, for the first time, an efficient one-pot strategy for the synthesis of 
novel benzo[b]pyrazolo[5,1-f][1,6]naphthyridine 17 via a AgOTf catalyzed multicomponent 
approach (Scheme 12). The reaction proceeded smoothly with high yields under established 
reaction conditions.  
 
2.2      Results and discussion 
 
Starting from already synthesized 2-chloroquinoline-3-carbaldehyde
26
 (2), I got 2-
(phenylethynyl)quinoline-3-carbaldehyde
58
 (19a) after Sonogashira coupling. In Sonoghashira 
coupling main problem was dimmer formation, I solved this issue by maintaining inert 
atmosphere throughout reaction and use of least amount of solvent. These two preventions gave 
me two benefits; firstly argon bubbling in reaction mixture avoid moisture and atmospheric 
gases to come in contact, secondly amount of solvent was kept low in  reaction mixture which 
also avoid moisture. In addition to phenylacetylene, I have used 1-heptyne, 
cyclopropylacetylene and trimethylsilylacetylene. By this I was able to minimize dimer 
formation to a great extent. 
            
 
Scheme 11. Conditions for Sonogashira coupling 19: PdCl2(PPh3)2 (4 mol%), HCCR
1
, CH3CN, 
80 °C, dry Ar, 3 hr. 
19 
 
 
Table 5. Synthesis of 2-(alkylethynyl)quinoline-3-carbaldehyde 
19 R
1
 19 (%)
a
 
a Ph 88 
b n-C5H11 84 
c cPr 74 
d (CH3)3Si 71 
 
a 
yields of isolated products. 
 
2.2.1    Synthetic scope for benzo[b]pyrazolo[5,1-f][1,6]naphthyridines 21 
 
 
 
Scheme 12. Synthesis of derivatives of benzo[b]pyrazolo[5,1-f][1,6]naphthyridines 21. 
Conditions: (i) POCl3, DMF, 10 hr, 80 °C (ii) PdCl2(PPh3)2 (4 mol%), HCCR
1
, CH3CN, 80 °C, 
dry Ar, 3hr. (iii) NH2NHOTs, ETOH, AgOTf, K3PO4, Reflux, 3 hr. 
 
Initially, a set of experiments were carried out using 2-(phenylethynyl)quinoline-3-
carbaldehyde (19a), tosylhydrazine, and pentanal (20a) as model substrates (Scheme 13) The 
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condensation worked efficiently in EtOH for the reaction of 2-(phenylethynyl)quinoline-3-
carbaldehyde (19a) with tosylhydrazine, and AgOTf was demonstrated as the most effective 
catalyst for the subsequent 6-endocyclization.
55
 Therefore, at the outset the reactions were 
catalyzed by AgOTf (10 mol%) in EtOH in the presence of different bases.  
. 
 
 
Scheme 13. Optimization studies for 21a. Conditions: (i) ETOH, AgOTf, K3PO4, Reflux, 3 hr.   
 
Table 6. Optimization of the reaction condition for 21a 
ntry Catalyst Solvent Base T(°C) Time(hr) 21a(%)
a
 
1 AgOTf EtOH K3PO4 70 6 82 
2 AgOTf EtOH K2CO3 70 6 73 
3 AgOTf EtOH DIPA 70 6 27 
4 AgOTf EtOH proline 70 7 36 
5 AgOTf EtOH piperidine 70 6 28 
6 AgOTf EtOH TEA 70 6 37 
7 Catalyst Free EtOH K3PO4 70 7 15 
8 AgOTf MeCN K3PO4 90 7 55 
9 Pd(PPh3)2Cl2 Toluene K3PO4 90 3 67 
10 Pd(PPh3)4 Toluene K3PO4 90 9 47 
11 AgOTf Toluene K3PO4 90 9 34 
 
a 
yields of isolated products. 
 
To my delight, small amounts of product (21a) was formed when diisopropylamine 
(DIPA), proline, or piperidine were utilized in the reaction. However, the large major product 
isolated was the isoquinolium-2-yl amide. 
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 Table 7. Synthesis of benzo[b]pyrazolo [5, 1-f][1,6]naphthyridines 21 
R
1
 R
2
 R
3
 21 21 (%)
a
 
C6H5 H n-C3H7 a 82 
C6H5 H n-C6H13 b 75 
C6H5 H n-C8H17 c 68 
C6H5 H n-C10H21 d 70 
C6H5 H 1-C9H17 e 60 
C6H5 CH3 H f 91 
C6H5 C2H5 C2H5 g 84 
C6H5 -(CH2)3- h 64 
C6H5 -(CH2)4- i 87 
C6H5 -CH(CH3)-CH2-(CH2)2- j 75 
C6H5 -(CH2)5- k 63 
C6H5 -(CH2)6- l 60 
C6H5 CO2CH3 CH3 m 84 
C6H5 CH3 C6H5 n 64 
C6H5 H p-(CH3O)C6H4 o 62 
n- C5H11 CH3 H p 72 
n- C5H11 H n-C3H7 q 72 
n- C5H11 -(CH2)4- r 66 
n- C5H11 -CH2-CH(CH3)-(CH2)2- s 75 
n- C5H11 -(CH2)3- t 76 
n- C5H11 C2H5 CH3 u 89 
cPr -CH2-CH(CH3)-(CH2)2- v 75 
cPr H n-C3H7 w 74 
cPr -(CH2)4- x 76 
H H n-C3H7 y 72 
 
a 
yields of isolated products. 
 
Elevating the reaction temperature or increasing the amount of pentanal could not 
improve the result. I then shifted my focus on inorganic bases. Gratifyingly, the reaction 
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proceeded smoothly in the presence of K2CO3 at 70 °C, which gave rise to the desired product 
(21a) in 73% isolated yield. Further investigation revealed that K3PO4 was the best choice with 
an 82% isolated yield (Table 6, above). This silver-catalyzed formation of 
benzo[b]pyrazolo[5,1-f][1,6]naphthyridines 21 was found to be workable for esters, 
acetophenones, cyclic and acyclic ketones, and aldehydes. In addition to phenyl groups attached 
to the triple bond, 2-alkynylquinoline-3-carbaldehydes 19 with cyclopropyl, n-pentyl and TMS 
groups were found to be suitable as well to generate the desired products in good yields 
(Scheme 12, Table 7). For example, a high yield (87%) of compound 21i was obtained.  
 
Using the mild conditions [AgOTf (10 mol %), K3PO4 (3.0 equiv.), EtOH, 70 °C], the 
mechanism was studied in view of other cascade reactions
59
 using 2-alkynylbenzaldehydes as 
versatile building blocks for the construction of heterocycles.
57 
Based on these results, I have 
developed an efficient route for the construction of nitrogen containing heterocycles starting 
from 2-(phenylethynyl)quinoline-3-carbaldehyde (19). Prompted by the advancement of multi-
component reactions, I conceived that benzo[b]pyrazolo[5,1-f][1,6]naphthyridines 21 might be 
easily accessible via a one-pot tandem reaction of 2-(alkynyl)quinoline-3-carbaldehydes 19, 
tosylhydrazine, and carbonyl compounds (Scheme 12). 2-(Alkynyl) quinoline-3-carbaldehyde 
(19) could be easily obtained via a Sonogashira reaction of 2-chloroquinoline-3-carbaldehyde 
with alkynes.
58 
After condensation with tosylhydrazine, 2-chloroquinoline-3-carbaldehyde (2), 
N'-(2-alkynylquinolinidene) tosylhydrazine (22), would be afforded. Subsequently, the 6-endo-
cyclization would occur to generate the (benzo[b][1,6]naphthyridin-2-ium-2-yl)(tosyl)amide 
(23) in the presence of a suitable Lewis acid. In this step, the formation of a π-complex via 
coordination of the alkynyl moiety of 19 to the Lewis acid would be involved, thus activating 
the triple bond for further cyclization. Meanwhile, the in situ formed enolate (derived from 
ketone or aldehyde in the presence of base) would attack the (benzo[b][1,6]naphthyridin-2-ium-
2-yl)(tosyl)amide (23) to produce intermediate 24. Subsequent intra-molecular condensation 
and aromatization would give rise to the desired benzo[b]pyrazolo[5,1-f][1,6]naphthyridine 
(21). However, there are several questions associated with the proposed synthetic route, such as 
selectivity, compatibility, and relative rates. Thus to verify the practicability of the proposed 
route as shown in Scheme 14, I have initiated the search for suitable conditions for this 
transformation. This synthetic methodology worked efficiently with quinoline moiety, but 
purification required attention. I did purification by flash column chromatography, with the use 
of diethylamine for basifying silica. It was recommended that solvent saturated with little 
diethylamine facilitated smooth and high yield separation of product.  
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Scheme 14. Possible route for one-pot tandem reaction of 2-(alkynyl)quinoline-3-carbaldehyde 
(19), tosylhydrazine, and carbonyl compounds. 
 
 
 
 
Scheme 15. Failed trial for compound 28. Reaction conditions: (i) PdCl2(PPh3)2 (4 mol%), 
HCCR
1
, CH3CN, 80 °C, dry Ar, 3hr. (ii) NH2NHOTs, ETOH, AgOTf, K3PO4, Reflux, 3 hr.    
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            Encouraged by findings I got for synthesis of compounds 21a-y, I have utilized 2-
chloro-1-methyl-1H-indole-3-carbaldehyde (26) as a starting material for the synthesis of 
compound 28. It was noted that established transformation which worked really well for 
quinoline moiety 19, did not work with indole moiety 26. It was observed that 2-chloro-1-
methyl-1H-indole-3-carbaldehyde (26) underwent a Sonogashira coupling under established 
conditions. To my surprise, 1-methyl-2-(phenylethynyl)-1H-indole-3-carbaldehyde (27) could 
not be transformed to the final product.  
 
Table 8. Optimization of the reaction condition for compound 28 
Entry Catalyst Solvent Base T(°C) Time(hr) 17a(%)
a
 
1 AgOTf EtOH K3PO4 70 6-10 ----- 
2 AgOTf EtOH K2CO3 70 6-10 ----- 
3 AgOTf EtOH DIPA 70 6 ----- 
4 AgOTf EtOH proline 70 7 ----- 
5 AgOTf EtOH piperidine 70 6 ----- 
6 AgOTf EtOH TEA 70 6 ----- 
7 Catalyst Free EtOH K3PO4 70 7 ----- 
8 AgOTf MeCN K3PO4 90 7 ----- 
9 Pd(PPh3)2Cl2 Toluene K3PO4 90 8 trace 
10 Pd(PPh3)4 Toluene K3PO4 90 9 ----- 
11 AgOTf Toluene K3PO4 90 9 ----- 
 
a 
yields of isolated products. 
        During this investigation, the first step was to treat compound (27) with tosylhydrazide 
in a variety of solvents at room temperature; no significant transformation was observed. 
Finally, at 70 °C a partial transformation to the Schiff base was observed. After separation 
of this intermediate, I treated it further with AgOTf to induce a cyclization, but this was not 
observed even at extended reaction time and high temperatures. Herein, I summarized 
reaction conditions utilized for this domino transformation (Table 8). Only trace amount of 
product was observed by GC-MS when Pd(PPh3)2Cl2 (catalyst), K3PO4 (base), toluene 
(solvent) were used (8 hr at 90 °C). Further investigations are in progress to find out 
suitable conditions for this conversion. 
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2.3  Structural description 
 
2.3.1     Structure description for compound 21i 
 
The structure of compound 21i was confirmed by X-ray crystal structure analysis as well 
(Figure 7). The colourless crystal showed a triclinic crystal system with C24H19N3 (empirical 
formula). The heterocyclic system was in plane and the phenyl group is twisted out of plane. 
The fused cyclohexyl ring was found to be by 18.17° twisted out of plane. One bond fused with 
the pyrazol ring caused torsional strain, by -49.02° (C1-C2-C3-C4), by 63.11° (C2-C3-C4-C5), 
by -40.63° (C3-C4-C5-C6), and by 0.11° (C4-C5-C6-C1). For the phenyl ring, which was by 
7.71° twisted out of plane, torsional angles were -45.02° (N1-C18-C19-C20) and -41.96° (C17-
C18-C19-C24). A difference in C-C bond lengths was observed, i.e. fused aromatic C8-C16 
bond length of 1.435 pm and isolated aromatic C8-C9 bond length of 1.378 pm. This C-C bond 
length abnormality attributed to torsional strain imparted by substituents and by the presence of 
nitrogen in the ring (electronic situation of the pyridine moiety). 
 
 
 
Figure 7. ORTEP illustration of compound 21i (50% probability ellipsoids) 
 
2.3.2    Structure description for the compound 21q 
 
The structure of compound 21q was confirmed by X-ray crystal structure analysis as 
well (Figure 8). The colourless crystal showed a triclinic crystal system with C22H25N3 
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(empirical formula). The heterocyclic system was partially twisted with by 3.33°(C11-C13-C1) 
and by 2.16° (C8-N3-C5) out of plane. The pyrazol ring was out of plane by 5.37°. The pyrazol 
ring torsional strain was not significant as acyclic substituent offered least steric effect. Here 
also bond abnormality was observed, i.e. 1.38 pm (C13-C14) and 1.419 pm (C12-C7). This 
bond abnormality reflected the unequal electronic distribution over all centers which in turn 
were because of heteroatoms and ring strain imposed by substituents. 
 
 
  
 
Figure 8. ORTEP illustration of compound 21q (50% probability ellipsoids) 
 
2.3.3    Structure description for the compound 21w 
 
The structure of compound 21w was confirmed by X-ray crystal structure analysis as 
well (Figure 9). The yellow crystal showed a monoclinic crystal system with C20H19N3 
(empirical formula). Hexagonal fused aromatic rings were lying in a plane, but pyrazol 
experienced a slight distortion by 4.61°. It was observed that both substituents, cyclopropyl at 
N1 and n-propyl at C2, were oriented in opposite directions. The cyclopropyl ring was twisted 
by 7.08° above the plane of the main skeleton. A torsion angle for the cyclopropyl ring was 
found to be -15.51° (C9-C10-C11-C12), and 85.84° (C9-C10-C11-C13). The cyclopropyl ring 
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with bond angles 60.51°, 59.95°, and 59.53° confirmed a high degree of torsional strain 
and angle strain associated with it. 
 
 
Figure 9. ORTEP illustration of compound 21w (50% probability ellipsoids) 
 
2.4 Conclusion 
 
In conclusion, I have described a novel and efficient route for the generation of 
benzo[b]pyrazolo[5,1-f][1,6]naphthyridines 21 via AgOTf-catalyzed one-pot tandem reaction of 
2-(alkanylethynyl)quinoline-3-carbaldehyde (19), tosylhydrazine, and carbonyl compounds. 
This reaction proceeded with good functional group tolerance under mild conditions with high 
efficiency and excellent selectivity.  
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3. An efficient approach for the synthesis of fluorinated arenes via direct acyl-
alkylation of benzyne. 
3.1      Introduction 
 
            Organofluorine molecules play an important role as synthetic drugs.
60
 5-Fluorouracil 
was the first fluorinated drug which was developed as an anti-tumor agent in 1957.
61
 The 
importance of fluorine containing compounds is based on their metabolic stability and 
lipophilicity and, thus, high bioavailability. The incorporation of fluoroalkyl groups and 
particularly the trifluoromethyl (CF3) group in pharmaceutically and agrochemically relevant 
molecules have a significant impact on their physical and biological properties.62 Fluorinated 
aceto- and benzophenones, containing a 1,5-dicarbonyl unit connected by a benzene moiety, are 
of considerable relevance as synthetic intermediates in medicinal chemistry. For example, 
benzophenone A, prepared by a multistep synthetic synthesis starting from 3-(4-
fluorophenyl)propanoic acid, was used as a key intermediate during the synthesis of fluorinated 
pteridines which were reported to act as anti-viral drugs for the treatment of liver diseases 
(HCV).
63
 Trifluoroacetophenone B, available by a multistep synthesis starting with 3-bromo-5-
iodobenzoic acid, was reported to show considerable activity against pain.
64
 
Trifluoroacetophenone C, which was also prepared in many steps, was reported to exhibit a 
pronounced antithrombotic activity (figure 10 ).
65
 
 
 
 
Figure 10.  Some important fluorinated 1,5-dicarbonyl compounds 
 
Herein, I report a new and convenient synthesis of fluorinated aceto- and benzophenones 
based on the reaction of benzyne with fluorinated 1,3-dicarbonyl compounds. First evidence for 
the existence of an aryne was reported in 1902 at the University of Rostock: Stoermer and 
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Kahlert observed the formation of 2-ethoxybenzofuran on treatment of 3-bromobenzofuran with 
bases in ethanol and postulated the formation of ortho-didehydrobenzofuran.
66 
In 1927, W. E. 
Bachmann and H. T. Clarke suspected benzyne as a reactive intermediate of the Wurtz-Fittig 
synthesis.
67 
Wittig, in 1942, suggested the existence of benzyne.
68
 During the last 50 years, the 
discovery of benzyne had a strong impact in the field of organic chemistry.
69
 Despite of the 
indirect evidence for the existence of benzyne, a direct proof was not reported before 2001.
70
 It 
was Professor John D. Roberts, who in 1953 published a communication on the existence of 
benzyne; an electronically neutral and unstable benzene ring with a triple bond which bears 
diradical character.
 
This structural explaination of benzyne was made in context of Professor 
Robert's work to elucidate the mechanism for forming anilines from substituted chloroarenes 
and metal amides. Before 1953, many chemists believed that metal amides attacked the 
aromatic ring in SnAr fashion, but this mechanism could not account for all the experimental 
data on the amination of unsymmetrical haloarenes. Professor Robert suggested the transient 
existence of benzyne during the amination of halobenzenes (Scheme 16).
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Scheme 16. Mechanistic evidance for benzyne generation 
 
Benzyne as a reagent in synthetic organic chemistry suffered from several drawbacks, 
such as its high reactivity and the harsh basic conditions required for its generation by the 
classic protocol.
69
 In 1983, Kobayashi described a mild method for the generation of benzyne at 
moderate temperature which relies on a fluoride-induced 1,2-elimination reaction of ortho-
(trimethylsilyl)aryltriflates.
72
 Because of their extreme reactivity, arynes must be generated in 
situ in the presence of reaction partners. This has limited their use in the development of 
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selective organic reactions because the harsh conditions that are used to generate arynes may 
have an adverse effect on other reactants. In 1983 Kobayashi described a mild method for the in 
situ preparation of benzyne at moderate temperatures that exploits the fluoride-induced 
elimination of ortho-silyl aryltriflates (Scheme 17).
72 
Recently, this method has been used to 
develop mild reactions involving aryne intermediates. 
 
Scheme 17. Generation of benzyne. 
 
         Although Stoermer and Kahlert discovered benzyne 100 years ago, only recently have 
organic chemists realized the potential for this reactive intermediate to insert directly into -
bonds. Recently, Stoltz and coworkers reported the insertion of benzyne into б-bonds of 1,3-
dicarbonyl compounds to give (2-acylphenyl)acetates and related products.
73
 It was presumed 
that the reaction proceeds by formal [2+2] cycloaddition and subsequent fragmentation. While 
benzyne insertions into metal-metal, heteroatom-metal, heteroatom-heteroatom, carbon-metal, 
and carbon-heteroatom б-bonds had been reported before, the work of Stoltz represented the 
first mild and direct insertion of benzyne into a carbon-carbon б-bond. Herein, we report what 
is, to the best of our knowledge, the first application of this method to fluorinated 1,3-
dicarbonyl compounds (Scheme 18). The transformations reported herein provide an efficient 
access to fluorinated aceto- and benzophenones which contain a 1,5-dicarbonyl unit connected 
by a benzene moiety. The products are not readily available by other methods. 
3.2     Synthetic scope 
 
 
 
Scheme 18. Synthesis of 35a-j. Conditions: (i) CsF, MeCN, 80 °C, 40-60 min. 
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During my thesis, I had the task to apply the methodology of Stoltz to fluorinated -
ketoesters and 1,3,5-tricarbonyl compounds. 
 
3.3      Results and Discussion 
 
The CsF mediated reaction of fluorinated β-ketoesters 31a-d with ortho-silylaryltriflate 
30, following conditions reported by Brian M. Stoltz, afforded the desired acyl-alkylation 
products 35a-j in good yields (Table 9). Additionally, the substitution pattern of fluorine on β-
ketoesters was varied (31a-d), and the efficiency of the reaction was thus studied. For example, 
fluorinated, trifluoromethyl- and perfluoroalkyl-substituted ketoesters and diketones gave the 
desired acyl-alkylation products in good yields. I further examined the coupling of aryne 
precursor 30 with fluorinated β-diketones 31f-j. To my delight these β-diketones reacted with 
30 to produce side-chain fluorinated ortho-disubstituted arenes 35f-j in good yields.  
 
Table 9. Acyl-alkylation of benzyne 
31 R
1
 R
2
 R
3
 35 35(%)
a
 
a Me EtO F a 71 
b CF3 EtO H b 71 
c 4-FC6H4 MeO H c 87 
d 4-FC6H4 EtO H d 79 
e 4-(NO2)C6H4 EtO H e 85 
f CF2CF2CF3 t-Bu H f 50 
g CF3 Ph H g 73 
h CF3 2-Naphthyl H h 57 
i CF3 Me H i 67 
j CF3 2-Furyl H j 70 
 
a 
yields of isolated products. 
 
In this reaction two carbon-carbon bonds are formed in a single step, often with exquisite 
regiocontrol. The acyl-alkylation reaction is the net result of benzyne insertion into the , (C-
C) single bond of the -ketoesters and -diketones, presumably by a formal [2+2] 
cycloaddition/fragmentation cascade.
73
 The insertion of benzyne into the α,β (C-C) single bond 
of the β-ketoesters and β-diketones presumably proceeds by a domino [2+2] 
32 
 
cycloaddition/fragmentation reaction via intermediates 32, 33, and 34 (Scheme 19). Related 
domino reactions were reported by other authors.
74,75
 
 
 
 
Scheme 19. Proposed mechanism of benzyne insertion to 1,3-dicarbonylcompounds.
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3.4      Structural description for compounds 35a-j 
 
3.4.1   Structural description for compound 35b 
  
 
 
 
Figure 11 Possible regiomers of 35b (with calculated shift values). 
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Structure and regioselectivity was investigated by NMR and MS spectroscopy. I took 
into account two molecules 35b with -ketoester and 35g with -diketone moiety, respectively 
(Figure 11above). First of all, I took into accout the position of the CH2 group, either connected 
to COCF3 or to CO2Et. By NMR, it was suggested that the CH2 group was not attached to the 
COCF3 group, as no splitting was observed in 
13
C NMR which should be present in case of 
possibility H. The comparisons between calculated and observed δ values were in favour of 
regiomer G, where δ for CH2 was observed to be 41.1. Mass fragmentation pattern was 
extremely helpful for confirmation of regioselectivity. It was cleared from GC-MS that the [M
+
] 
peak appeared at m/z, 260 (9.8%). The base peak was of great importance, with m/z, 187 which 
gave evidence for the directly bonded trifluoroacetyl group to benzene. This base peak could be 
obtained by sequential loss of ethyl and CO2. In case of possibility H, there should be two 
fragments, i.e one with m/z, 111 and second ethyl benzoate with m/z, 150. Both of these 
fragments were found to be absent, which clearly favour possibility G as the only regeoisomer. 
Possibility G showed the expected fragments shown in scheme (20). 
 
 
 
Scheme 20. Mass fragmentation pattern of 35b. 
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3.4.2 Structural description for compound 35g 
 
 
Figure 12. Possible regiomers of 35g (with calculated shift values) 
 
In the 
13
C-NMR spectra, I took the CH2 group in account to locate its attachment either 
to the trifluoroacetyl or benzoyl group. I got a first clue that CH2 appeared at , 37.1 which was 
quite different from the theoretical calculated value (δ, 28.2) and disfavoured isomer J, but 
favoured isomer isomer I. Secondly, if there was any possibility for the existence of isomer J 
then there should be splitting of the CH2 carbon signals, because of the CF3. Furthermore, no 
long-rang splitting of the CH2 signal was observed indicating that CH2 was not bonded to the 
trifluoroacetyl group, supporting the absence of isomer J and existence of isomer I. Thus, on the 
basis of 
13
C-NMR spectroscopy, the formation of isomer I is strongly favoured. 
 
 
 
Figure 13. HMBC interpretation of 35g 
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Finally structure I was independently confirmed by 2D-NMR. Also I took both carbonyl 
groups into account. It was found that carbonyl group with δ, 198.3 showed a clear HMBC 
interaction with the protons of CH2 (δ, 37.1), also one HMBC interaction between a proton at δ, 
7.72 and carbon of COCF3 group confirmed direct bonding of the COCF3 group with the 
aromatic system. Further position of each proton and carbon was located by NOESY, COSY, 
13
C-NMR and 
1
H-NMR.  
 
3.4.3 Structural description for compound 35e 
 
 
 
 
Figure 14. HMBC, NOESY and COSY interpretation of 35e. 
 
The structure of 35e was verified by 2D NMR experiments (COSY, HMBC, NOESY). 
Here two carbonyl groups were taken into account. A clear HMBC correlation of the carbonyl 
carbon (δ ,196.2) with two protons (δ, 7.89) of the first benzene ring (having a nitro group) and 
another HMBC correlation with a proton (δ, 7.46) of the second benzene ring. The ester 
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carbonyl carbon showed a clear correlation with the proton of both CH2 groups (δ, 3.88 and 
3.95) on its either sides. I further studied COSY interactions to locate the exact position of 
correlating protons. NOESY correlations were also useful to confirm the structure as shown in 
figure 14 (above). 
 
3.5      Conclusion 
 
I have developed a mild, direct, and efficient approch for the acyl-alkylation of arynes to 
produce interesting ortho-disubstituted arenes via an unusual reaction cascade. Overall, the 
transformation results in the formation of two new C−C bonds by the net insertion of an arene 
unit into the ,-single bond of fluorinated -ketoester or -diketones. This facile methodology 
provides a convergent, single-step, high-yielding access to a variety of side chain fluorinated, 
ortho-disubstituted arenes structures that would otherwise be difficult to be obtained.  
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4.  AgNO3-catalyzed domino intramolecular cyclization: a facile and efficient 
approach to the synthesis of benzimidazole based polycyclic indole derivatives. 
 
4.1 General Introduction.   
All heterocyclic compounds have a great interest in pharmaceutical chemistry. Out of 
these heterocyclic compounds the benzfuzed heterocyclic i.e Benzimidazole and Indole 
derivatives have wide variety of biological activities. Indole-based fused heterocycles belong to 
the most widely distributed naturally occurring compounds, isolated from plants, fungi and 
marine organisms.
76 
The range of applications for these therapeutically relevant compounds 
include protein kinase C inhibitors, 5-HT agonists, melatonin agonists and glucocorticoid 
receptor modulators, displaying cytotoxic, antiviral, antimicrobial, antiparasitic, anti-
inflammatory, antiserotonin, Ca2þ, calmodulinantagonistic and antitopoisomerase-I activities
77
 
These polyheterocycles frequently feature structurally diverse novel frameworks and remain a 
source of new natural product-inspired
78 
chemical entities for chemical biology research. 
 
Figure 15. Important indole derivatives 
In addition to that, benzimidazoles have played a very important role in the development 
of theory in heterocylic chemistry and also extensively in organic synthesis.
79
 Extensive 
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biochemical and pharmacological studies have confirmed that derivatives are effective against 
various strains of microorganisms. One reason for a special interest of researchers toward 
benzimidazole derivatives has been 5,6-dimethylbenzimidazole which is a constituent of 
naturally occurring vitamin B12. Although vitamin B12 is capable of inducing the growth of 
bacteria, the benzimidazole component and some of its derivatives repress the bacterial growth. 
Due to the structural similarity to purine, antibacterial ability of benzimidazoles is explained by 
their competition with purines resulting in inhibition of the synthesis of bacterial nucleic acids 
and proteins.
80
 Benzimidazole drugs are widely used for prevention and treatment of parasitic 
infections.  
 
Figure 16. Important benzopyrazol derivatives. 
Thiabendazole (TBZ) was the first benzimidazole to be marketed over 40 years ago. It 
has been widely used for the treatment of gastrointestinal nemtodes, lungworms and as a 
fungicidal agent. Incouraged by this discovery, a number of alternative benzimidazoles offering 
similar activity came to the market, such as parbendazole (PAR), cambendazole (CAM), 
mebendazole (MBZ) and oxibendazole (OXI). Benzimidazoles possessing sulphide and 
sulpoxide functional groups are offering a wide spectrum of activity and efficiacy. Albendazole 
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(ABZ), fenbendazole FBZ) and oxfendazole (OFZ) were the first such imidazoles to be 
successfully used in the treatment of all growth stages of gastrointestinal nematodes. 
Triclabendazole (TCB) was introduced as an antihelmenthic agent for treatment of all growth 
stages of liver fluke, but it is ineffective against nematodes. Luxabendazole (LUX) is another 
benzimidazole-sulphide used in the food producing animals, but is not lisenced in the Europe.
81
 
Several synthetic routes were reported: Huang-Che Ouyang
82
 and coworkers reported an 
efficient tandem route to the synthesis of iodoisoquinoline-fused benzimidazole derivatives via 
tandem iodocyclization reaction with benzenediamines and 2-ethynylbenzaldehydes in DMSO. 
Noriko Okamoto and co-workers
83
 introduced direct efficient syntheses of the benzimidazo[2,1-
a]isoquinoline ring system  from 2-bromoarylaldehydes, terminal alkynes, and 1,2-
phenylenediamines by a microwave-accelerated tandem process in which a Sonogashira 
coupling, 5-endo cyclization, oxidative aromatization, and 6-endo cyclization can be performed 
in a single synthetic operation. In addition, isoquinoline-fused benzimidazoles have attracted 
considerable interest, due to their outstanding biological activities, such as anti-HIV-1, 
anticancer, antimicrobial and antifungal properties.
84
 Thus, the development of novel and 
important compounds, like indole-fused benzimidazoles, will be an interesting addition to 
existing biologically active compounds. In this regard, some progress has been accomplished 
via tandem nucleophilic addition and electrophilic cyclization using o-alkylbenzaldehyde and 
phenylenediamine in the presence of various alkynophilic Lewis acid catalysts.
85 
Vineeta 
Rustagi,
86
 and coworkers introduced a straightforward methodology for the synthesis of 
isoquinolino[2,1-a]pyrrolo/indolo[2,1-c]quinoxalines and benzimidazo[2,1-a]isoquinolines via a 
AgNO3-catalyzed one-pot tandem sequence in water using o-alkynylaldehydes andiamines with 
tethered nucleophiles. 
 
4.2 Synthetic scope 
  
Herein, I am going to report a facile synthesis of benzo-[4',5']-imidazo-[1',2':1,2]-pyrido-
[4,3-b]indole 37, which combine benzimidazol and indole moieties. This heterocyclic core 
structure has, to the best of my knowledge, not been previously reported (scheme 21). 
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Scheme 21. Synthesis of benzo[4',5']imidazo[1',2':1,2]pyrido[4,3-b]indoles 37. Conditions: (i) 
PdCl2(PPh3)2 (4 mol%), HCCPh, DMF, 20 °C, Et3N, under dry Ar, 3hr. (ii) AgNO3, H3O. 
 
 
4.3       Results and discussion 
 
Starting from compound 26, compound 27 was prepared according to literature reported 
procedure 
87
. In water, 1-methyl-2-(phenylethynyl)-1H-indole-3-carbaldehyde (27) was heated 
with benzene-1,2-diamine at various time and temperature. It was observed that reaction 
proceeded in good yield and afforded product 37 in good yield, when water was the solvent. I 
have used different Lewis acids and solvents to check the course of reaction. The most 
important results were obtained with water and AgNO3 as a catalyst. Here, lower temperature 
and long reaction time favour the yield of reaction, whereas high temperature did not give high 
yields of product. It was noted that the reaction proceeded in comparative yield, when DMF was 
used as solvent at 120°C for 3 hr (Table 10).  
 
Table 10. Optimized reaction conditions for compound 37a. 
 
Entry Catalyst Solvent T °C Time(hr) Yield (%)
a
 
1 AgOTf Toluene 90 8 23 
2 PdCl2 Toluene 90 8 ---- 
3 Pd(OAc)2 Toluene 90 8 ---- 
4 AgI Toluene 90 8 ---- 
5 AgNO3 Toluene 90 8 48 
6 AgNO3 DMF 120 3-9 62 
7 AgNO3 THF 80 8 37 
8 AgNO3 H2O 80 8 83 
9 AgNO3 H2O 85 3 32 
10 AgNO3 H2O 85 4 43 
11 AgNO3 H2O 85 6 61 
12 AgNO3 H2O 85 8 73 
13 AgNO3 EtOH 80 8 41 
a 
yields of isolated products. 
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 I have employed various benzene-1,2-diamines to check the scope of this reaction. To my 
delight, my methodology worked in good to very good yields. Further studies in order to study 
regioselectivity for various phenylene diamines are in the prosses of investigation.  
 
Mechanistic studies were carried out by Vineeta Rustagi,
 86
 where 27 and 36 underwent 
condensation to generate specie 38 which was activated by AgNO3, resulted in the nucleophillic 
attack from the free NH2 group to generate dihydroimidazole ring 39.  
 
 
 
Scheme 22. Proposed mechanism for 37 
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In the next step, a proton shift produced intermediate 40. π-Complexation between the 
alkyne and Ag(1) rendered a regioselective 2
nd
 intramolecular attack of the nucleophilic NH 
onto the alkyne to form intermediate 41, which on subsequent deprotonation led to the 
formation of cyclized product 42. Finally, aromatization via oxidation resulted in final product 
37. 
 
It was observed that different benzene-1,2-diamines followed well this transformation 
with different isolated yields. Although still different variations in term of substitution pattern 
will be studied, I got several examples with different benzene-1,2-diamines (Table 11). 
Structures were verified by using IR, NMR and mass spectroscopic methods.  
 
Table 11. Synthesis of benzo[4',5']imidazo[1',2':1,2]pyrido[4,3-b]indole (37). 
 
37 36 37(%)
a
 
a 1,2-(NH2)2C6H4 81 
b 4,5-(Cl)2-1,2-(NH2)2C6H2 66 
 
a 
yields of isolated products. 
 
 
4.4        Conclusion 
 
             I have developed a novel combination of two versatile moieties, the indole and 
benzimidazole, in a single heterocyclic system in very good yields. This new class can be 
extremely useful in medicinal and display devices. Owing to the great diversity of the 
substitution pattern, this developed chemistry can be used for the generation of libraries of 
various heterocyclic systems. Further investigations in this area are currently under way and 
will be reported in due course. 
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5         Experimental Section 
 
General Remarks: Reactions were carried out under inert atmosphere (Argon 4.6) in order to 
simultaneously exclude oxygen and water when appropriate. Pressure tubes were used to avoid 
condenser. Solvents for reactions were dried and distilled by standard methods or purchased 
from Merck
®
, Aldrich
®
, Acros Organics
®
, and others whenever exclusion of water was desired. 
Solvents for liquid chromatography and extraction were always distilled prior to use and partly 
reused after fractional distillation (n-heptane, ethyl acetate).  
 
5.1      Equipment, Chemicals and Work Technique 
 
NMR Spectroscopy: Bruker AC 250, Bruker ARX 300, Bruker ARX 500. For NMR 
characterization the one-dimensional 
1
H NMR, proton-decoupled 
13
C NMR, and DEPT 135 
spectra were collected. If necessary other techniques (NOESY, COSY, HMQC, and HMBC) 
were applied as well. All NMR spectra presented in this work, were collected in DMSO-d6 and 
CDCl3 solution. All chemical shifts were given in ppm. References (
1
H NMR): TMS (δ, 0.00) or 
residual CHCl3 (δ, 7.26) were taken as internal standard. References (
13
C NMR): TMS (δ, 0.0) 
or residual CHCl3 (δ, 77.0) were taken as internal standard. Multiplicities are given as follows: s 
= singlet, d = doublet, t = triplet, q = quartet, m = Multiplet, br = broad signal. More complex 
coupling patterns are represented by combinations of the respective symbols. For example, td 
indicates a triplet of doublets with the larger coupling constant associated with the first symbol 
(here: triplet).  
 
Infrared Spectroscopy (IR): Nicolet 205 FT-IR, Nicolet Protége 460 FT-IR Peaks are given 
the following assignments: w = weak, m = medium, s = strong, br = broad.  
 
Mass Spektrometry (MS): AMD MS40, Varian MAT CH 7, MAT 731 (EI, 70 eV), Intecta 
AMD 402 (EI, 70 eV and CI), Finnigan MAT 95 (CI, 200 eV).  
 
High Resolution Mass Spectrometry (HRMS): Varian MAT 311, Intecta AMD 402.  
 
Elemental Analysis: LECO CHNS-932 Thermoquest Flash EA 1112.  
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Melting Points: Micro heating table HMK 67/1825 Kuestner (Büchi Apparatus). Leitz Labolux 
12 Pol with heating table Mettler FP 90. Melting points are uncorrected.  
 
X-ray crystal structure analysis: Bruker X8Apex Diffractometer with CCD-Kamera (Mo-Ka 
und Graphit Monochromator, λ  =  0.71073 Å) or Bruker Apex Kappa-II CCD diffractometer 
using graphite monochromated Mo Kα radiation (λ = 0.71073). 
 
Thin Layer Chromatography (TLC): Merck Kieselgel 60 F254 on aluminium foil from 
Macherey-Nagel. Detection was carried out under UV light at 254 nm and 365 nm. As 
colourizing reagent the following mixtures were used: 1-2/100 p-Anisaldehyde or vanillin, 
10/100 glacial acetic acid, 5/100 sulphuric acid, 83-84/100 methanol.  
 
Column Chromatography: Column chromatography was performed with Merck Silica Gel 60 
or Macherey-Nagel Silica Gel 60 (0.063-0.200 mm, 70-230 mesh). The finer Merck Silica Gel 
60 (0.040-0.063 mm, 230-400 mesh) was chosen when appropriate. 
 
5.2      Procedures and Spectroscopic Data 
 
Synthesis of benzo[1,8]-naphthyridine-4(1H)-ones 
 
Compounds 2, 3 and 4 were prepared according to a method reported in literature.
26, 27 
 
1-(2-Chloroquinolin-3-yl)-3-phenylprop-2-yn-1-ol (3):
26,27
 The reaction was carried out 
following the reported procedure starting with 2-chloroquinoline-3-
carbaldehyde (2) (400 mg, 2.1 mmol), phenylacetylene (257 mg, 
2.5 mmol) and n-BuLi (1.0 ml, 2.5 mmol). After stirring for 1 hr at 
-78 °C, the solution was allowed to warm to 25 °C. HCl (10%, 25 
ml) was added, and the organic layers were extracted with ethylacetate (3 × 50 ml). The 
combined organic layers were dried, filtered and concentrated under reduced pressure. The 
residue was purified by chromatography (silica gel, n-heptane/EtOAc = 9:1) to give 3 a white 
solid (600 mg, 98%), m.p. = 194-196 
o
C.
 1
H-NMR (300 MHz, DMSO-d6):  = 5.95 (d, J = 5.2 
Hz, 1H, CH), 6.72 (d, J = 5.6 Hz, 1H, OH), 7.40-7.45 (m, 5H, Ar), 7.65-7.68 (m, 1H, Ar), 7.89-
7.92 (m, 1H, Ar), 8.11 (d, J = 7.4 Hz, 1H, Ar), 8.21 (d, J = 6.9 Hz, 1H, Ar), 8.75 (s, 1H, Ar); 
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13
C-NMR (75 MHz, DMSO-d6):  = 60.3 (CHOH), 84.6, 89.2 ( ), 121.8, 127.0 (C), 127.5, 
127.9, 128.3, 128.7, 128.8, 130.1, 130.9, 131.4, (CH), 133.5 (C), 135.9, 136.5 (CH), 146.4, 
148.3 (C); IR (ATR): ~  = 3233, 3065, 2228, 1591 (w), 1489, 1329 (m), 1165 (w), 1068, 929 
(m), 857 (w), 779 (m), 747 (s) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 295 [M
+
,
37
Cl], 293 
[M
+
,
35
Cl], 258 (100), 241 (9), 228 (24), 101 (10.61), 75 (9.58). Anal.calcd. (%) for C18H11OClN 
(293.747): C = 73.60, H = 4.12, N = 4.77; Found: C = 73.63, H = 4.15, N = 4.77. HRMS (ESI-
TOF): calcd. For C18H12NClO [(M+H)
+
,
35
Cl]: 294.0680. Found: 294.0680. 
 
1-(2-Chloroquinolin-3-yl)-3-phenylprop-2-yn-1-one (4):
26,27
 The reaction was carried out 
following the reported procedure starting with 1-(2-chloroquinolin-
3-yl)-3-phenylprop-2-yn-1-ol (3) (400 mg, 1.4 mmol) and activated 
MnO2 (299 mg, 3.5 mmol), 4 was isolated after column 
chromatography (silica gel, n-heptane/EtOAc = 9:1) as a yellow 
solid (362 mg, 91 %), m.p. = 101-103 
o
C.
 1
H-NMR (300 MHz, DMSO-d6):  = 7.57-7.61 (m, 
3H, Ar), 7.80-7.82 (m, 3H, Ar), 8.01-8.06 (m, 2H, Ar), 8.36 (d, J = 8.1 Hz, 1H, Ar), 9.31 (s, 1H, 
Ar). 
13
C-NMR (75 MHz, DMSO-d6):  = 87.5, 94.2 ( ), 118.7, 125.8 (C), 127.7, 128.3 
(CH), 129.0 (C), 129.1, 129.2, 129.8, 131.8, 133.2, 133.3, 133.8, 144.1 (CH), 145.6, 147.7 (C), 
174.6 (C=O). IR (ATR): ~  = 3062 (w), 2194 (m), 1630 (s), 1557, 1485 (m), 1392 (w), 1319 
(m), 1212 (w), 1096 (s), 1000 (w), 978 (m), 805 (w), 775 (m), 749 (s), 597 (m) cm
–1
. GC-MS 
(EI, 70 eV): m/z (%) = 294 (4.
 37
Cl, [M + H]
+
), 293 (23, 
37
Cl ), 292 (14, 
35
Cl, [M + H]
+
), 291 
(M
+
, 64), 263 (96), 228 (32), 129 (100), 101 (22), 75 (27). Anal. calcd. (%) for C18H10OClN 
(291.747): C = 74.11, H = 3.46, N = 4.8. Found: C = 73.98, H = 3.56, N = 4.77.  HRMS (ESI-
TOF): calcd. For C18H11NClO [(M+H)
+
, 
35
Cl] : 292.0524. Found: 292.0524. C18H11NClO 
[(M+H)
+
, 
37
Cl] : 294.0500. Found: 294.0500. 
 
General procedure for 5a-l: A mixture of 4 (0.6 mmol), amine (0.7 mmol), K3CO3 (1.2 
mmol), and Pd(PPh3)4 (0.05 mmol) was refluxed in 10 ml of DMF for 3 hr at 120
 o
C. The 
reaction mixture was quenched with a saturated aq. solution of NH4Cl, followed by extraction 
with ethyl acetate (3 × 15 ml). The residue then was obtained after removing solvent under 
reduced pressure and was purified by column chromatography on silica gel to afford the pure 
product. 
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General procedure for compounds 5m-u: A mixture of 4 (0.6 mmol), amine (0.7 mmol), 
Cs2CO3 (1.2 mmol), Pd(PPh3)4 (0.05 mmol) was refluxed in 10 ml of toluene for 6 hr at 90 
o
C. 
The reaction mixture was quenched with saturated NH4Cl, followed by extraction with ethyl 
acetate (3 × 15 ml). The residue then obtained, after removing the solvent under reduced 
pressure and was purified by column chromatography on silica gel to afford the pure product. 
 
1-Cyclohexyl-2-phenylbenzo[b][1,8]naphthyridin-4(1H)-one (5a): Starting with 1-(2-
chloroquinolin-3-yl)-3-phenylprop-2-yn-1-one (4), (170 mg, 0.6 
mmol), cyclohexylamine (70 mg, 0.7 mmol), K2CO3 (162 mg, 1.2 
mmol), Pd(PPh3)4 (5 mol%) and DMF (10 ml), reflux at 120 
o
C for 3 
hr, 5a was isolated after column chromatography (silica gel, n-
heptane/EtOAc = 2:1) as a yellow solid (150 mg, 73%), m.p. = 280–
282 
o
C.
 1
H-NMR (300 MHz,CDCl3):  = 0.90-0.93 (m, 2H, CH2), 
1.19-1.22 (m, 1H, CH2), 1.52 (d, J = 6.8 Hz, 1H, CH2), 1.87-1.91 (m, 4H, CH2), 3.12-3.15 (m, 
2H, CH2), 4.01-4.04 (m, 1H, CH), 6.08 (s, 1H, Ar), 7.36-7.41 (m, 6H, Ar), 7.70-7.74 (m, 1H, 
Ar), 7.94 (dd, J = 8.5, 9.3 Hz, 2H, Ar), 9.19 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 25.3, 
26.5, 26.6, 30.5, 30.5 (CH2), 63.8, 111.4 (CH), 121.5, 125.1 (C), 125.6, 127.4, 127.5, 128.1, 
128.8, 128.8, 129.2, 129.4, 131.9, 137.1 (CH), 137.2, 148.3, 150.1, 158.3, 178.6 (C=O). IR 
(ATR): ~  = 3046 (w), 2940, 1616 (m), 1578 (s), 1420 (m), 1164 (w), 1116, 1041 (m), 893 (w), 
976, 844 (s), 796 (m), 758 (s), 617, 537 (m) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 354 ([M]
+
, 6), 
273 (23.16), 272 (100), 244 (31.79), 140 (6.82). Anal.calcd. (%) for C24H22N2O (354.1732: C = 
81.33, H = 6.26, N = 7.90. Found: C = 80.98, H = 6.46, N = 7.75. HRMS (ESI-TOF): calcd. For 
C24H23N2O [M+H]
+
: 355.1805. Found: 355.1805. 
 
1-Benyl-2-phenylbenzo[b][1,8]naphthyridin-4(1H)-one (5b): Starting with 1-(2-
chloroquinolin-3-yl)-3-phenylprop-2-yn-1-one (4), (170 mg, 0.6 
mmol), benzylamine (75 mg, 0.7 mmol), K2CO3 (162 mg, 1.17 
mmole), Pd(PPh3)4 (5 mol%) and DMF (10 ml), reflux at 120 
o
C for 3 
hr, 5b was isolated after column chromatography (silica gel, n-
heptane/EtOAc = 2:1) as a yellow solid (180 mg, 84.91 %), m.p. = 
238-239 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 5.71 (s, 2H, CH2), 6.21 (s, 1H, CH), 6.78-6.81 
(m, 2H, Ar), 7.06-7.08 (m, 3H, Ar), 7.18-7.22 (m, 2H, Ar), 7.28-7.49 (m, 4H, Ar), 7.69-7.74 (m, 
1H, Ar), 7.91 (d, J = 8.1 Hz, 1H, Ar), 7.98 (d, 1H, J = 8.1 Hz, Ar), 9.26 (s, 1H, Ar). 
13
C-NMR 
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(75 MHz, CDCl3):  = 49.4 (CH2), 111.6 (CH), 120.6, 125.5 (C), 125.7, 126.7, 126.7, 127.1, 
128.2, 128.3, 128.3, 128.3, 128.3, 128.4, 128.5, 129.3, 129.6, 132.2 (CH), 135.6 (C), 137.7 
(CH), 137.9, 149.1, 149.6, 157.4 (C), 178.8 (CO). IR (ATR): ~  = 3048 (w), 1616 (s), 1552 (m), 
1494 (w), 1328 (m), 1184 (w), 1145 (m), 1072 (w), 1023 (m), 928 (w), 831 (s), 790 (m), 755 
(s), 609 (m) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 363 ([M+H]
 +
, 11), 362 ([M]
+
, 50), 361 (100), 
91 (22). Anal.calcd. (%) for C25H18N2O (362.1419): C = 82.85, H = 5.01, N = 7.73; Found: C = 
82.84, H = 5.06, N = 7.71. HRMS (ESI-TOF): calcd. For C25H19N2O [M+H]
+
: 363.1492. 
Found: 363.1495. 
 
1-(4-Methoxybenyl)-2-phenylbenzo[b][1,8]naphthyridin-4(1H)-one (5c): Starting with 1-(2-
chloroquinolin-3-yl)-3-phenylprop-2-yn-1-one (4), (170 mg, 0.6 
mmol), p-methoxybenzylamine (96 mg, 0.7 mmol), K2CO3 (162 mg, 
1.17 mmole), Pd(PPh3)4 (5 mol%) and DMF (10 ml), reflux at 120 °C 
for 3 hr, 5c was isolated after column chromatography (silica gel, n-
heptane/EtOAc = 3:1) as a yellow solid (146 mg, 64 %), m.p. = 174-
176 
o
C.
 1
H-NMR (300 MHz,CDCl3):  = 3.64 (s, 3H, CH3), 5.65 (s, 
2H, CH2), 6.59 (d, J = 8.1 Hz, 2H, Ar), 6.74 (d, J = 8.2 Hz, 2H, Ar), 7.21-7.49 (m, 7H, Ar), 
7.70-7.73 (m, 1H,  Ar), 7.96 (dd, J = 7.5,7.7 Hz, 2H, Ar), 9.25 (s, 1H, Ar). 
13
C-NMR (75 MHz, 
CDCl3):  = 48.8 (CH2), 55.2 (CH3), 111.7, 113.6, 113.6 (CH), 120.7, 125.5 (C), 125.7, 128.2, 
128.3, 128.3, 128.4, 128.4, 128.5, 128.5, 129.3, 129.5 (CH), 129.9 (C), 132.2 (CH), 135.7 (C), 
137.5, 137.6 (CH), 149.6, 157.4, 158.7 (C), 178.8 (CO). IR (ATR): ~ = 2958 (w), 1580 (s), 
1511 (m), 1478 (s), 1282 (m), 1245 (s), 1145 (m), 845 (m), 828 (s), 787 (m), 568 (m) cm
–1
. GC-
MS (EI, 70 eV): m/z (%) = 393([M+ H]
 +
, 18), 392 ([M]
+
, 59), 391 (27), 121 (100); Anal. calcd. 
(%) for C26H20N2O2 (392.1525): C = 79.57, H = 5.14, N = 7.14. Found: C = 79.56, H = 5.15, N 
= 7.14. HRMS (ESI-TOF): calcd. For C26H21N2O2 [M+H]
+
: 393.1598. Found: 393.1605. 
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1-Phenethyl-2-phenylbenzo[b][1,8]naphthyridin-4(1H)-one (5d): Starting with 1-(2-
chloroquinolin-3-yl)-3-phenylprop-2-yn-1-one (4), (170 mg, 0.586 
mmol), 2-phenylethanamine (85 mg, 0.7 mmol), K2CO3 (162 mg, 1.2 
mmol), Pd(PPh3)4 (5 mol%)  and DMF (10 ml), reflux at 120 
o
C for 3 
hr, 5d was isolated after column chromatography (silica gel, n-
heptane/EtOAc = 3:1) as a yellow solid (99 mg, 46 %), m.p. = 232-
233 
o
C.
 1
H-NMR (300 MHz,CDCl3):  = 2.81 (t, J = 8.1 Hz, 2H, 
CH2), 4.42 (t, J = 8.1 Hz, 2H, CH2), 6.01 (s, 1H, CH), 6.71 (d, J = 6.7 Hz, 2H, Ar), 6.98-7.04  
(m, 3H, Ar), 7.09-7.12 (m, 2H, Ar), 7.28-7.39 (m, 4H, Ar), 7.63-7.68 (m, 1H, Ar), 7.90 (dd, J = 
9.3, 8.1 Hz, 2H, Ar), 9.13 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 35.4, 48.4 (CH2), 110.9 
(CH), 125.5 (C), 125.8, 126.6, 128.1, 128.1, 128.3, 128.3, 128.6, 128.6, 128.7, 128.7, 128.8, 
129.4, 129.6, 132.4 (CH), 135.6 (C), 137.7 (CH), 138.2, 148.2, 148.5, 149.1, 149.3 (C), 157.4 
(CO). IR (ATR): ~  = 3044 (w), 1582 (s), 1552 (m), 1514 (w), 1477 (s), 1445, 1329, 1146, 976 
(m), 829 (s), 573 (s) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 376 ([M]
+
, 4), 285 (46), 284 (13), 273 
(18), 272 (100). Anal.calcd. (%) for C26H20N2O (376.1576): C = 82.62, H = 5.27, N = 7.71. 
Found: C = 82.63, H = 5.26, N = 7.72. HRMS (ESI-TOF): calcd. For C26H21N2O [M+H]
+ 
: 
377.1648. Found: 377.1654. 
 
1-Heptyl-2-phenylbenzo[b][1,8]naphthyridin-4(1H)-one (5e): Starting with 1-(2-
chloroquinolin-3-yl)-3-phenylprop-2-yn-1-one (4), (170 mg, 0.6 
mmol), n-heptylamine (81 mg, 0.7 mmol), K2CO3 (162 mg, 1.17 
mmol), Pd(PPh3)4 (5 mol%) and DMF (10 ml), reflux at 120 
o
C for 3 
hr, 5e was isolated after column chromatography (silica gel, n-
heptane/EtOAc = 2:1) as a yellow solid (140 mg, 64.8 %),  m.p. = 
315-316 
o
C. 
1
H-NMR (250 MHz, CDCl3):  = 0.76 (t, J = 6.8 Hz, 3H, 
CH3), 1.09-1.18 (m, 8H, CH2), 1.62 (t, J = 6.9 Hz, 2H, CH2), 4.34 (t, J 
= 8.0 Hz, 2H, CH2), 6.14 (s, 1H, Ar), 7.37-7.50 (m, 6H, Ar), 7.71-7.78 (m, 1H, Ar), 7.98 (d, J = 
8.1 Hz, 2H, Ar), 9.24 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 14.1(CH3), 22.5, 26.5, 28.5, 
28.9, 31.3, 46.7 (CH2), 111.04 (CH), 120.7, 125.3 (C), 125.5 (CH), 127.8 (C), 128.1, 128.1, 
128.5, 128.6, 129.2, 129.4, 132.0 (CH), 135.9 (C), 137.3 (CH), 148.9, 149.1, 157.1 (C), 178.5 
(CO). IR (ATR): ~  = 3048 (w), 2918 (m), 1632 (s), 1411, 1332 (m), 1126, 1074 (w), 976, 774 
(m), 753 (s), 719, 611 (m) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 370 ([M]
+
, 28), 313 (13), 285 
(41), 272 (100), 244 (26), 128 (11), 77 (2). Anal.calcd. (%) for C25H26ON2 (370.2045): C = 
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81.05, H = 7.07, N = 7.56. Found: C = 80.98, H = 7.078, N = 7.49. HRMS (ESI-TOF): calcd. 
For C25H27O N2 [M+H]
+
: 371.2118; Found: 371.2118. 
 
1-Cyclopropyl-2-phenylbenzo[b][1,8]naphthyridin-4-(1H)-one (5f): Starting with 1-(2-
chloroquinolin-3-yl)-3-phenylprop-2-yn-1-one (4), (170 mg, 0.6 
mmol), cyclopropylamine (40 mg, 0.7 mmol), K2CO3 (162 mg, 1.2 
mmole), Pd(PPh3)4 (5 mol%) and DMF (10 ml), reflux at 120 
o
C for 3 
hr, 5f was isolated after column chromatography (silica gel, n-
heptane/EtOAc = 4:1) as a yellow solid (61 mg, 57 %), m.p. = 193-
194 
o
C.
 1
H-NMR (250 MHz, CDCl3):   = 0.46 (q, J = 8.8 Hz, 2H, CH2), 0.89-0.97 (m, 2H, 
CH2), 3.40-3.49 (m, 1H, CH), 6.24 (s, 1H, Ar), 7.43-7.56 (m, 6H, Ar), 7.75-7.81 (m, 1H, Ar), 
7.99 (d, J = 8.1 Hz, 1H, Ar), 8.10 (d, J = 8.1 Hz, 1H, Ar), 9.21 (s, 1H, Ar), 
13
C-NMR (75 MHz, 
CDCl3):  = 12.7, 12.7 (CH2), 32.2 (CH), 111.6 (CH), 120.8, 125.4 (C), 125.6, 128.2, 128.4, 
128.4, 128.5, 128.5, 129.3, 129.4, 132.1 (CH), 136.8 (C), 137.1 (CH), 148.9, 151.7, 158.2 (C), 
179.3 (CO). IR (ATR): ~ = 3060 (w), 1633 (s), 1616 (m), 1350 (w), 1263 (m), 1143 (w), 1031 
(m), 931, 885 (w), 791 (m), 773, 744 (s), 605 (m) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 312 
([M]
+
, 26), 311 (100), 283 (22), 181 (4), 140(6).  Anal.calcd. (%) for C21H16O N2 (312.1263): C 
= 80.75, H = 5.16, N = 8.97. Found: C = 79.98, H = 5.06, N = 8.97. HRMS (ESI-TOF): calcd. 
For C21H17O N2 [M+H]
+
: 313.1335. Found: 313.1335. 
 
2-Phenylbenzo[b][1,8]naphthyridin-4(1H)-one (5g): Starting with 1-(2-chloroquinolin-3-yl)-
3-phenylprop-2-yn-1-one (4), (170 mg, 0.6 mmol), allylamine (40 
mg, 0.7 mmol), K2CO3 (162 mg, 1.17 mmol), Pd(PPh3)4 (5 mol%) 
and DMF (10 ml), reflux at 120 
o
C for 3 hr, 5g was isolated after 
column chromatography (silica gel, n-heptane/EtOAc = 2:1) as a 
yellow solid (61 mg, 96 %), m.p. = 286-288 
o
C.
 1
H-NMR (250 MHz, 
DMSO-d6):  = 6.37 (s, 1H, CH), 7.51-7.58 (m, 5H, Ar), 7.84-7.91 (m, 3H, Ar), 7.99 (d, J = 8.0 
Hz, 1H, Ar), 8.23 (d, J = 8.1 Hz, 1H, Ar), 9.2 (s, 1H, Ar), 12.33 (s, 1H, NH), 
13
C-NMR (75 
MHz, DMSO-d6):  = 106.2 (CH), 119.3 (C), 125.2, 126.7, 127.7, 127.7, 128.8, 128.8, 129.8, 
130.8, 132.5, 133.6 (CH), 136.6, 148.7, 149.0, 150.2, 153.1 (C), 178.2 (CO). IR (ATR): ~ = 
1650 (w), 1540 (m), 1454 (m), 1227 (w), 1266 (m), 1154 (w), 958 (w), 855 (m), 791 (m), 740 
(s), 690 (s), 613 (m), 547 (s) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 273 (19), 272 ([M]
+
, 100), 27 
(14), 245 (19), 244 (78), 243 (15), 242 (12), 122 (11). Anal.calcd. (%) for C18H12ON2 
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(272.0949): C = 79.39, H = 4.44, N = 10.29.  Found: C = 79.19, H = 4.46, N = 10.26. HRMS 
(ESI-TOF): calcd. For C18H13O N2 [M+H]
+
: 273.1022. Found: 273.1022. 
 
1-(3-Morpholinopropyl)-2-phenylbenzo[b][1,8]naphthyridin-4(1H)-one (5h): Starting with 
1-(2-chloroquinolin-3-yl)-3-phenylprop-2-yn-1-one (4), (170 mg, 
0.6 mmol), 3-(4-morpholinyl)propylamine (101 mg, 0.7 mmol), 
K2CO3 (162 mg, 1.17 mmole), Pd(PPh3)4 (5 mol%)  and DMF (10 
ml), reflux at 120 
o
C for 3 hr, 5h was isolated after column 
chromatography (silica gel, n-heptane/EtOAc = 3:1) as a solid (200 
mg, 86.6 %), m.p. = 188-189 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 
1.71-1.82 (m, 2H, CH2), 2.13-2.21 (m, 6H, CH2), 3.49 (t, J = 5.2 Hz, 4H, CH2), 4.43 (dd, J = 
8.1, 8.1 Hz, 2H, CH2), 6.11 (s, 1H, CH), 7.37-7.49 (m, 6H, Ar), 7.71-7.76 (m, 1H, Ar), 7.94 (dd, 
J = 12.5, 12.5 Hz, 2H, Ar), 9.22 (s, 1H, Ar), 
13
C-NMR (75 MHz, CDCl3):  = 25.8, 45.1, 53.4, 
53.4, 55.9, 66.8, 66.9 (CH2), 111.2 (CH), 120.9, 125.4 (C), 125.6, 128.1, 128.2, 128.2, 128.7, 
128.7, 129.4, 129.5, 132.2 (CH), 135.8 (C), 137.6 (CH), 149.1, 149.3, 157.0 (C), 178.6 (CO). IR 
(ATR): ~ = 2914 (w), 2814 (w), 1633 (s), 1551 (m), 1474 (5), 1353 (w), 1264 (m), 1114 (s), 
1036 (m), 995 (w), 937 (m), 835 (s) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 399 ([M]
+
, 73), 313 
(21), 299 (24), 286 (25), 285 (100), 273 (66), 244 (14), 128 (18), 100 (26). Anal.calcd. (%) for 
C25H25O2N3 (399.1950): C = 75.16, H = 6.31, N = 10.52. Found: C = 74.98, H = 6.36, N = 
10.54.  HRMS (ESI-TOF): calcd. For C25H26O2N3 [M+H]
+
: 400.2021. Found: 400.2029. 
 
1-(2-Hydroxyethyl)-2-phenylbenzo[b][1,8]naphthyridin-4(1H)-one (5i):  Starting with 1-(2-
chloroquinolin-3-yl)-3-phenylprop-2-yn-1-one (4), (170 mg, 0.6 
mmol), ethanolamine (32 mg, 0.7 mmol), K2CO3 (162 mg, 1.2 
mmol), Pd(PPh3)4 (5 mol%) and DMF (10 ml), reflux at 120 
o
C for 3 
hr, 5i was isolated after column chromatography (silica gel, n-
heptane/EtOAc = 2:1) as a yellow solid (150 mg, 73 %),  m.p. = 204-
205
o
C.
 1
H-NMR (300 MHz, CDCl3):   = 4.01 (dd, J = 9.3, 9.2 Hz, 2H, CH2), 4.51 (dd, J = 
8.4,8.3 Hz, 2H, CH2), 4.86 (t, J = 7.6 Hz, 1H, OH), 6.18 (s, 1H, CH), 7.45-7.55 (m, 6H, Ar), 
7.79-7.84 (m, 1H, Ar), 7.92 (d, J = 7.8 Hz, 1H, Ar), 8.01 (d, J = 7.9 Hz, 1H, Ar), 9.11 (s, 1H, 
Ar). 
13
C-NMR (75 MHz, CDCl3):  = 50.5, 62.5 (CH2), 111.6 (CH), 120.7, 125.4 (C), 125.9, 
127.5, 128.5, 128.5, 128.8, 128.8, 129.3, 129.7, 132.7 (CH), 135.8 (C), 138.1, 148.5, 150.2, 
157.8 (C), 178.4 (CO).  IR (ATR): ~ = 3206 (w), 1614, 1480 (s), 1338, 1293 (m), 1176 (w), 
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1156, 1066 (m), 959 (w), 825 (s), 612, 559 (m) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 316 ([M]
+
, 
11), 297 (18), 285 (67), 284 (16), 273 (20), 272 (100), 255 (11), 128 (22). Anal.calcd. (%) for 
C20H16N2O2  (316.1212): C = 75.93, H = 5.10, N = 8.86. Found: C = 75.90, H = 5.08, N = 8.86. 
HRMS (ESI-TOF): calcd. For C20H17N2O2 [M+H]
+
: 317.1285.  Found: 317.1285. 
 
1-(3-Methoxybenzyl)-2-phenylbenzo[b][1,8]naphthyridin-4(1H)-one (5j):  Starting with 1-
(2-chloroquinolin-3-yl)-3-phenylprop-2-yn-1-one (4), (170 mg, 0.6 
mmol), 3-methoxybenzylamine (96 mg, 0.7 mmol), K2CO3 (162 
mg, 1.17 mmole), Pd(PPh3)4 (5 mol%) and DMF (10 ml), reflux at 
120 
o
C for 3 hr, 5j was isolated after column chromatography 
(silica gel, n-heptane/EtOAc = 2:1) as a solid (120 mg, 52%), m.p. 
= 114-116 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 3.67 (s, 3H, OCH3), 6.29 (s, 1H, CH), 6.48-
6.51 (m, 2H, Ar), 6.72 (dd, J = 5.3, 5.3 Hz, 1H, Ar), 7.07 (t, J = 8.1 Hz, 1H, Ar), 7.28-7.59 (m, 
7H, Ar), 7.79-7.85 (m, 1H, Ar), 8.02 (d, J = 8.1 Hz, 1H, Ar), 8.09 (d, J = 8.1 Hz, 1H, Ar), 9.36 
(s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 49.3 (CH2), 55.1 (CH3), 111.7, 112.3, 112.7, 
119.1(CH), 120.6, 125.5 (C), 125.7, 128.2, 128.2, 128.3, 128.3, 128.5, 129.3, 129.3, 129.6, 
132.3 (CH), 135.7 (C), 137.7 (CH), 139.6, 149.2, 149.6, 157.5, 159.6 (C), 178.87 (CO). IR 
(ATR): ~  = 2921 (w), 1660, 1631 (m), 1582 (s), 1486 (w), 1349, 1274, 1158, 1092, 976, 847 
(m), 698 (s) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 393 (11), 392([M]
+
, 54), 391 (100), 283 (10), 
121 (17), 91 (8). Anal.calcd. (%) for C26H19N2O2 (391.1441): C = 74.11, H = 3.46, N = 4.8. 
Found: C = 73.98, H = 3.56, N = 4.77. HRMS (EI): calcd. For C26H19N2O2 [M]
+
 391.1441. 
Found: 391.1444. 
 
1-(2-Chlorobenzyl)-2-phenylbenzo[b][1,8]naphthyridin-4(1H)-one (5k):  Starting with 1-(2-
chloroquinolin-3-yl)-3-phenylprop-2-yn-1-one (4), (170 mg, 0.6 
mmol), 2-chlorobelnzyamine (99 mg, 0.7 mmol), K2CO3 (162 mg, 
1.2 mmol), Pd(PPh3)4 (5 mol%) and DMF (10 ml), reflux at 120 
o
C 
for 3 hr, 5k was isolated after column chromatography (silica gel, n-
heptane/EtOAc = 2:1) as a yellow solid (200 mg, 86%). m.p. = 238-
239 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 5.81 (s, 2H, CH2), 6.33 (s, 1H, CH), 6.76 (d, J = 8.2 
Hz, 1H, Ar), 7.03-7.06 (m, 1H, Ar), 7.12-7.17 (m, 1H, Ar), 7.26-7.31 (m, 3H, Ar), 7.36-7.58 (m, 
4H, Ar), 7.77-7.82 (m, 1H, Ar), 7.95 (d, J = 8.7 Hz, 1H, Ar), 8.07 (d, J = 8.7 Hz, 1H, Ar), 9.38 
(s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 47.6 (CH2), 111.7 (CH), 120.5, 125.6 (C), 125.8, 
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126.8, 127.2, 127.8, 127.9, 128.1, 128.4, 128.5, 128.6, 129.2, 129.3, 129.7 (CH), 132.1 (C), 
132.3 (CH), 135.2, 135.6 (C), 137.6 (CH), 149.1, 149.5, 157.4 (C), 178.7 (CO). IR (ATR): ~ = 
2964 (w), 1616 (s), 1552 (m), 1499 (w), 1410, 1328 (m), 1200 (w), 1147 (m), 1088, 850 (w), 
832 (s), 611 (m) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 397 (43), 396 ([M]
+
, 51), 395 (100), 361 
(19), 283 (15), 125 (18), 89 (7). Anal.calcd. (%) for C25H17OClN2 (396.1029): C = 75.66, H = 
4.32, N = 7.06. Found: C = 75.98, H = 4.46, N = 7.06. HRMS (ESI-TOF): calcd. For 
C25H18OClN2 [(M+H)
+
,
35
Cl]: 397.1102. Found: 397.1104. C25H18OClN2 [(M+H)
+
,
37
Cl]: 
399.1083. Found: 397.1088 
 
1-(3-(1H-Imidazol-1-yl)propyl)-2-phenylbenzo[b][1,8]naphthyridin-4-(1H)-one (5l) : 
Starting with 1-(2-chloroquinolin-3-yl)-3-phenylprop-2-yn-1-one 
(4), (170 mg, 0.6 mmol), N-(3-aminopropyl)imidazole (88 mg, 0.7 
mmol), K2CO3 (162 mg, 1.2 mmol), Pd(PPh3)4 (5 mol%)  and 
DMF (10 ml), reflux at 120 
o
C for 3 hr, 5l was isolated after 
column chromatography (silica gel, n-heptane/EtOAc = 5:1) as a 
yellow solid (135 mg, 70%), m.p. = 229-230 
o
C.
 1
H-NMR (250 
MHz, CDCl3):  = 2.16-2.19 (m, 2H, CH2), 3.91 (t, J = 6.3 Hz, 2H, 
CH2), 4.41 (t, J = 7.8 Hz, 2H, CH2), 6.18 (s, 1H, CH), 6.76 (s, 1H, Ar), 7.02 (s, 1H, Ar), 7.38-
7.43 (m, 3H, Ar), 7.49-7.54 (m, 4H, Ar), 7.81-7.83 (m, 1H, Ar), 8.01 (dd, J =7.3,7.3 Hz, 2H, 
Ar), 9.28 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 30.2, 43.8, 44.5 (CH2), 111.4 (CH), 
120.6 (C), 125.4, 125.8, 127.9, 127.9, 128.0, 129.0, 129.1, 129.3, 129.9, 132.5 (CH), 135.4 (C), 
137.7, 137.8, 137.9 (CH), 149.0, 149.1, 156.5, 156.5 (C), 178.5 (CO). IR (KBr): ~  = 2921 (w), 
1660, 1631 (m), 1582 (s), 1486 (w), 1349, 1274, 1158, 1092, 976, 847 (m), 698 (s) cm
–1
. GC-
MS (EI, 70 eV): m/z (%) = 381 (10), 380 ([M]
+
, 28), 299 (13), 285 (100), 273 (18), 272 (17), 
207 (25).  Anal.calcd. (%) for C24H20ON4 (380.4421): C = 75.77, H = 5.30, N = 14.73. Found: C 
= 75.98, H = 5.46, N = 14.66. HRMS (ESI-TOF): calcd. For C24H21ON4 [M+H]
+
: 381.1719. 
Found: 381.1718. 
 
1-(4-Methoxyphenyl)-2-phenylbenzo[b][1,8]naphthyridin-4(1H)-one (5m): Starting with 1-
(2-chloroquinolin-3-yl)-3-phenylprop-2-yn-1-one (4), (170 mg, 0.6 mmol), p-methoxyanniline 
(76 mg, 0.62 mmol), Cs2CO3 (235 mg, 0.72 mmol), Pd(PPh3)4 (5 mol%) and toluene (10 ml), 
reflux at 90 
o
C for 6 hr, 5m was isolated after column chromatography (silica gel, n-
heptane/EtOAc = 1:1) as a yellow solid (142 mg, 73 %), m.p. = 290-291 
o
C.
 1
H-NMR (300 
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MHz, CDCl3):  = 3.81 (s, 3H, OCH3), 6.43 (s, 1H, CH), 6.84 (d, J = 8.9 Hz, 2H, Ar), 7.12 (d, J 
= 8.9 Hz, 2H, Ar), 7.24-7.36 (m, 5H, Ar), 7.49-7.54 (m, 1H, Ar), 
7.69-7.75 (m, 1H, Ar), 7.82 (d, J = 6.2 Hz, 1H, Ar), 8.04 (d, J = 8.9 
Hz, 1H, Ar), 9.38 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 55.4 
(OCH3), 111.3, 113.7, 113.7 (CH), 120.2, 125.7 (C), 125.7, 128.0, 
128.0, 128.6, 128.7, 129.0, 129.0, 129.1, 131.3, 131.3, 131.9 (CH), 
131.9, 136.1 (C), 137.3, 149.1, 150.9, 157.1, 158.8 (C), 179.2 (CO). 
IR (ATR): ~ = 2921 (w), 1660, 1631 (m), 1582 (s), 1486 (w), 1349, 1274, 1158, 1092, 976, 847 
(m), 698 (s) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 379 (14), 378 ([M]
+
, 65), 377 (100). 
Anal.calcd. (%) for C25H18N2O2 (378.1368): C = 79.35, H = 4.79, N = 7.40. Found: C = 78.98, 
H = 4.69, N = 7.40. HRMS (ESI-TOF): calcd. For C25H19N2O2 [M+H]
+ 
: 379.1441. Found: 
379.1440. 
 
1-(3,4-Dimethoxyphenyl)-2-phenylbenzo[b][1,8]naphthyridin-4(1H)-one (5n): Starting with 
1-(2-chloroquinolin-3-yl)-3-phenylprop-2-yn-1-one (4), (170 mg, 0.6 
mmol), 3,4-dimethoxyanniline (95 mg, 0.62 mmol), Cs2CO3 (235 mg, 
0.72 mmol), Pd(PPh3)4 (5 mol%) and toluene (10 ml), reflux at 90 
o
C 
for 6 hr, 5n was isolated after column chromatography (silica gel, n-
heptane/EtOAc = 2:1) as a yellow solid (150 mg, 76 %), m.p. = 234-
235 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 3.66 (s, 3H, OCH3), 3.81 (s, 
3H, OCH3), 6.35 (s, 1H, C=C), 6.66 (s, 1H  Ar), 6.71 (s, 2H, Ar), 7.15-7.21 (m, 5H, Ar), 7.43 (t, 
J = 7.5 Hz, 1H, Ar), 7.65 (t, J = 7.5 Hz, 1H, Ar), 7.75 (d, J = 9.2 Hz, 1H, Ar), 7.95 (d, J = 8.7 
Hz, 1H, Ar), 9.25 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):   = 55.9, 56.1 (OCH3), 110.3, 
111.4, 114.0 (CH), 120.2 (C), 122.9 (CH), 125.6 (C), 125.7, 128.0 (CH), 128.2, 128.2 (C), 
128.6, 128.8, 128.8, 128.8, 129.1, 129.1, 131.9 (CH), 136.2 (C), 137.3 (CH), 148.4, 148.4, 
148.7, 149.1, 150.8, 157.1 (C), 179.1 (CO). IR (ATR): ~ = 2833 (w), 1633, 1509, 1471 (m), 
1398, 1255 (s), 1208, 1132 (m), 1026 (s), 841 (m), 759, 705 (s) cm
–1
. GC-MS (EI, 70 eV): m/z 
(%) = 409 (18), 408 ([M]
+
, 78), 407 (100), 391 (12), 321 (14). Anal.calcd. (%) for C26H20N2O3 
(408.1474): C = 76.45, H = 4.94, N = 6.86. Found: C = 75.97, H = 4.91, N = 6.84. HRMS (ESI-
TOF): calcd. For C26H21N2O3 [M+H]
+
: 409.1550.  Found: 409.1550. 
 
1-(3,5-Dimethoxyphenyl)-2-phenylbenzo[b][1,8]naphthyridin-4(1H)-on (5o): Starting with 
1-(2-chloroquinolin-3-yl)-3-phenylprop-2-yn-1-one (4), (170 mg, 0.6 mmol), 3,5-
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dimethoxyanniline (95 mg, 0.62 mmol), Cs2CO3 (235 mg, 0.72 mmol), Pd(PPh3)4 (5 mol%) and 
toluene (10 ml), reflux at 90 
o
C for 6 hr, 5o was isolated after column 
chromatography (silica gel, n-heptane/EtOAc = 5:1) as a yellow solid 
(135 mg, 64%), m.p. = 239-240 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 
3.58 (s, 6H, OCH3), 6.28-6.32 (m, 4H, Ar), 7.15-7.22 (m, 5H, Ar), 
7.41 (t, J = 8.7 Hz, 1H, Ar), 7.63 (t, J = 8.7 Hz, 1H, Ar), 7.76 (d, J = 
7.3 Hz, 1H, Ar), 7.93 (d, J = 7.3 Hz, 1H, Ar), 9.22 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 
55.5, 55.6 (OCH3), 100.4, 109.3, 109.4, 111.4 (CH), 120.0, 120.2, 125.6 (C), 125.7, 127.9, 
128.0, 128.7, 128.9, 128.9, 129.1, 131.9 (CH), 136.1 (C), 137.3 (CH), 140.5, 149.1, 149.1, 
150.4, 156.6, 160.4 (C), 179.1 (CO).  IR (ATR): ~ = 3053 (w), 1637 (m), 1582 (s), 1403, 1316 
(m), 1150 (s), 1060 (m), 950 (w), 826, 773, 705 (m), 613 (w) cm
–1
. GC-MS (EI, 70 eV): m/z 
(%) = 409 (15), 408 ([M]
+
, 66), 407 (100), 391 (3), 321 (4), 153(10). Anal.calcd. (%) for 
C26H20N2O3 (408.1474): C = 76.45, H = 4.94, N = 6.86. Found: C = 76.37, H = 4.89, N = 6.85. 
HRMS (ESI-TOF): calcd. For C26H21N2O3 [M+H]
+
: 409.1557. Found: 409.1558. 
 
2-Phenyl-1-(3,4,5-trimethoxyphenyl)benzo[b][1,8]naphthyridin-4(1H)-one (5p): Starting 
with 1-(2-chloroquinolin-3-yl)-3-phenylprop-2-yn-1-one (4), (170 
mg, 0.6 mmol), 3,4,5-trimethoxyanniline (113.13 mg, 0.62 mmol), 
Cs2CO3 (235 mg,0.72 mmol), Pd(PPh3)4 (5 mol%)  and toluene (10 
ml), reflux at 90 
o
C for 6 hr, 5p was isolated after column 
chromatography (silica gel, n-heptane/EtOAc = 6:1) as a yellow solid 
(173 mg, 76.9%), m.p. = 253-254 
o
C.
 1
H-NMR (300 MHz, CDCl3):  
= 3.62 (s, 6H, OCH3), 3.78 (s, 3H, OCH3), 6.35 (s, 1H, CH), 6.39 (s, 2H, Ar), 7.15-7.22 (m, 5H, 
Ar), 7.44 (t, J = 7.6 Hz, 1H, Ar), 7.67 (t, J = 7.6 Hz, 1H, Ar), 7.8 (d, J = 9.1 Hz, 1H, Ar), 7.96 
(d, 1H, J = 9.2 Hz, 1H, Ar), 9.26 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 56.3, 56.3, 61.1 
(OCH3), 108.6, 108.6, 111.4 (CH), 120.1, 125.6, 125.7 (C), 125.8, 128.3, 128.6, 128.6, 128.9, 
129.0, 129.2, 129.4, 132.1 (CH), 134.4, 136.2 (C), 137.4 (CH),137.7, 149.1, 150.5, 152.9, 156.8 
(C), 179.11 (CO).  IR (ATR): ~ = 2964 (w), 1637 (m), 1556 (w), 1495, 1404 (m), 1227 (s), 949, 
854 (w), 825, 712, 643 (m) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 439 (28.08), 438 ([M]
+
, 100), 
437 (62.67), 423 (21.23), 392 (12.47), 391(19.48). Anal.calcd. (%) For C27H22N2O4 (438.1580): 
C = 73.96, H = 5.06, N = 6.39. Found: C = 73.37, H = 4.99, N = 6.35. HRMS (ESI-TOF): calcd. 
For C27H23N2O4 [M+H]
+
: 439.1652. Found: 439.1650. 
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2-Phenyl-1-(3,5-dimethylphenyl)benzo[b][1,8]naphthyridin-4(1H)-one (5q): Starting with 1-
(2-chloroquinolin-3-yl)-3-phenylprop-2-yn-1-one (4), (170 mg, 0.6 
mmol), 3,5-dimethylanniline (75 mg, 0.62 mmol), Cs2CO3 (235 mg, 
0.72 mmol), Pd(PPh3)4 (5 mol%)  and toluene (10 ml), reflux at 90 
o
C 
for 6 hr, 5q was isolated after column chromatography (silica gel, n-
heptane/EtOAc = 3:1) as a yellow solid (112 mg, 58%), m.p. = 255-
256 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 2.27 (s, 6H, CH3), 6.45 (s, 
1H, CH), 6.85 (s, 2H, Ar), 6.91 (s, 1H, Ar), 7.27 (s, 5H, Ar), 7.53 (t, J = 6.9 Hz, 1H, Ar), 7.74 
(t, J = 6.9 Hz, 1H, Ar), 7.85 (d, J = 9.3 Hz, 1H, Ar), 8.10 (d, J = 9.3 Hz, 1H, Ar), 9.37 (s, 1H, 
Ar). 
13
C-NMR (75 MHz, CDCl3):  = 21.1, 21.1 (CH3), 111.2 (CH), 120.1, 125.5 (C), 125.6, 
127.8, 128.1, 128.1, 128.6, 128.7, 128.7,  128.8, 128.9, 129.1, 129.5, 131.9 (CH), 136.1 (C), 
137.3 (CH), 138.0, 138.0, 138.8, 149.1, 150.7, 157.0 (C), 179.9 (CO). IR (ATR): ~ = 3057 (w), 
1628, 1550 (m), 1403 (s), 1335 (m), 138 (s), 1438, 1148, 971, 840 (m), 756 (s), 588 (m) cm
–1
. 
GCMS (EI, 70 eV): m/z (%) = 377 (17), 376 ([M]
+
, 72), 375 (100), 347 (10). Anal.calcd. (%) 
for C26H20N2O (376.1576): C = 82.95, H = 5.35, N = 7.44. Found: C = 82.87, H = 5.29, N = 
7.44. HRMS (ESI-TOF): calcd. For C26H21N2O [M+H]
+
: 377.1648. Found: 377.1642. 
 
2-Phenyl-1-(2,4-dimethoxyphenyl)benzo[b][1,8]naphthyridin-4(1H)-one (5r): Starting with 
1-(2-chloroquinolin-3-yl)-3-phenylprop-2-yn-1-one (4), (170 mg, 0.6 
mmol), 3,5-dimethoxyanniline (126 mg, 0.62 mmol), Cs2CO3 (235 
mg, 0.72 mmol), Pd(PPh3)4 (5 mol%) and toluene (10 ml), reflux at 90 
o
C for 6 hr, 5r was isolated after column chromatography (silica gel, 
n-heptane/EtOAc = 6:1) as a yellow solid (112 mg, 58%), m.p. = 274-
275 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 3.52 (s, 3H, CH3), 3.75 (s, 
3H, CH3), 6.33-6.37 (m, 3H, Ar), 7.03 (d, J = 7.3 Hz, 1H, Ar), 7.18-7.21 (m, 5H, Ar), 7.43 (t, J 
= 10.3 Hz, 1H, Ar), 7.64 (t, J = 10.3 Hz, 1H, Ar), 7.74 (d, J = 8.3 Hz, 1H, Ar), 7.97 (d, J = 8.3 
Hz, 1H, Ar), 9.27 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 55.4, 55.48 (OCH3), 99.0, 
104.1, 110.8 (CH), 120.3, 121.6 (C), 125.4 (CH), 125.6 (C), 127.6, 127.6, 128.4, 128.4, 128.6, 
128.8, 129.1, 131.7, 131.8 (CH), 136.1 (C), 137.1(CH), 149.3, 150.6, 156.2, 157.8, 160.7 (C), 
179.5 (CO). IR (ATR): ~ = 2921 (w), 1660, 1631 (m), 1582 (s), 1486 (w), 1349, 1274, 1158, 
1092, 976, 847 (m), 698 (s) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 408 (M
+
, 3), 379 (4), 378 (28), 
377 (100). Anal.calcd. (%) for C26H20N2O3 (408.1474): C = 82.95, H = 5.35, N = 7.44. Found: 
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C = 82.87, H = 5.29, N = 7.44. HRMS (ESI-TOF): calcd. For C26H21N2O3 [M+H]
+
: 409.1547. 
Found: 409.1549. 
 
1-(4-(Diethylamino)phenyl)-2-phenylbenzo[b][1,8]naphthyridin-4(1H)-one (5s): Starting 
with 1-(2-chloroquinolin-3-yl)-3-phenylprop-2-yn-1-one (4), (170 
mg,0.6 mmol), N,N-diethylbenzene-1,4-diamine (112 mg, 0.62 
mmol), Cs2CO3 (235 mg, 0.72 mmol), Pd(PPh3)4 (5 mol%) and 
toluene (10 ml), reflux at 90
 o
C for 6 hr, 5s was isolated after column 
chromatography (silica gel, n-heptane/EtOAc = 3:1) as a yellow 
solid (167 mg, 77 %), m.p. = 319-320 
o
C.
 1
H-NMR (300 MHz, 
CDCl3):  = 0.31 (t, J = 6.9 Hz, 6H, CH3), 2.49 (q, J = 10.8 Hz, 4H, CH2), 5.59 (s, 1H, CH), 
5.71 (d, J = 8.0 Hz, 2H, Ar), 6.14 (d, J = 8.0 Hz, 2H, Ar), 6.42 (s, 5H, Ar), 6.66 (t, J = 7.6 Hz, 
1H, Ar), 6.87 (t, J = 7.6 Hz, 1H, Ar), 7.04 (d, J = 8.0 Hz, 1H, Ar), 7.19 (d, J = 8.0 Hz, 1H, Ar), 
8.51(s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 12.4, 12.4 (CH3), 44.4, 44.4 (CH2), 111.1, 
111.2, 111.2 (CH), 120.3 (C), 125.5 (CH), 127.1 (C), 127.8, 127.8, 128.5,  128.7, 129.0, 129.1, 
129.1,  130.8, 130.8, 131.7 (CH), 136.6, 136.5 (C), 137.2 (CH), 147.1, 149.2, 151.2, 157.7 (C), 
179.2 (CO). IR (ATR): ~ = 2968 (w), 1634 (m), 1515 (s), 1473, 1262, 1195 (m), 1009 (w), 827 
(m), 741 (s), 701, 605 (m) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 420 (22), 419 ([M]
+
, 72), 418 
(18), 405 (30), 404 (100), 374 (24), 159 (10). Anal.calcd. (%) for C28H25N3O (419.1998): C = 
80.16, H = 6.01, N = 10.02. Found: C = 80.21, H = 6.06, N = 10.02. HRMS (ESI-TOF): calcd.  
For C28H26N3O [M+H]
+
: 420.2070. Found: 420.2070. 
 
1-(4-Ethylphenyl)-2-phenylbenzo[b][1,8]naphthyridin-4(1H)-one (5t): Starting with 1-(2-
chloroquinolin-3-yl)-3-phenylprop-2-yn-1-one (4), (170 mg, 0.6 
mmol), p-ethylanniline (75 mg, 0.62 mmol), Cs2CO3 (235 mg, 0.72 
mmol), Pd(PPh3)4 (5 mol%) and toluene (10 ml), reflux at 90 
o
C for 6 
hr, 5t was isolated after column chromatography (silica gel, n-
heptane/EtOAc = 5:1) as a yellow solid (96 mg, 50%), m.p. = 228-
229 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 1.31 (t, J = 7.8 Hz, 3H, 
CH3), 2.55 (q, J = 10.4 Hz, 2H, CH2), 6.34 (s, 1H, CH),  6.99-7.06 (m, 4H, Ar), 7.14 (s, 5H, 
Ar), 7.41 (t, J = 7.8 Hz, 1H, Ar), 7.61 (t, J = 7.8 Hz, 1H, Ar), 7.72 (d, J = 8.2 Hz, 1H, Ar), 7.94 
(d, J = 8.2 Hz, 1H,  Ar), 9.24 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 15.2 (CH3), 28.4 
(CH2), 111.3 (CH), 120.1, 125.6 (C), 125.7, 127.8,  127.8, 128.6, 128.7, 128.7, 129.0, 129.1, 
57 
 
129.1,  130.2, 130.2, 131.9, 131.9 (CH), 136.1, 136.7 (C), 137.3 (CH), 143.9, 149.1, 150.8, 
157.0 (C), 179.3 (CO). IR (ATR): ~ = 3029, 3004 (w), 1637, 1473 (m), 1184, 1062 (w), 828 (s), 
778, 739, 560 (m), 545 (w) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 377 (12), 376 ([M]
+
, 55), 375 
(100), 345 (6), 217 (6). Anal.calcd. (%) for C26H20N2O (376.1576): C = 82.95, H = 5.35, N = 
7.44.  Found: C = 82.92, H = 5.26, N = 7.43. HRMS (ESI-TOF): calcd. For C26H21N2O [M+H]
+
: 
377.1655. Found: 377.1656. 
 
1-(2-Fluorophenyl)-2-phenylbenzo[b][1,8]naphthyridin-4(1H)-one (5u): Starting with 1-(2-
chloroquinolin-3-yl)-3-phenylprop-2-yn-1-one (4), (170 mg, 0.6 mmol), o-fluoroanniline (76 
mg, 0.62 mmol), Cs2CO3 (235 mg, 0.72 mmol), Pd(PPh3)4 (5 mol%) and toluene (10 ml), reflux 
at 90 
o
C for 6 hr, 5u was isolated after column chromatography 
(silica gel, n-heptane/EtOAc = 3:1) as a yellow solid (62 mg, 29%), 
m.p. = 242-243 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 6.36 (s, 1H, 
CH), 7.01-7.05 (m, 3H, Ar), 7.13-7.18 (m, 6H, Ar), 7.43-7.48 (m, 1H, 
Ar), 7.62-7.68 (m, 2H, Ar), 7.97 (d, J = 8.4 Hz, 1H, Ar), 9.26 (s, 1H, 
Ar). 
19
F-NMR  = - 118.4 (s, 1F, Ar). 13C-NMR (75 MHz, CDCl3):  = 111.3 (CH), 115.7 (C), 
116.1 (CH), 120.0 (C), 124.1, 124.2, 126.1 (d, J = 16 Hz, CF-CH), 126.3 (d, J = 15 Hz, CF-
CH), 128.1, 128.4, 128.5, 129.2, 129.2 (CH), 129.3, 129.4 (C), 130.2, 131.7 (CH), 131.8 (C), 
133.5 (d, J = 10 Hz, CF-CH), 135.1 (d, J = 5Hz, CF-CH), 136.3 (d, J = 15Hz, CF-C), 137.4, 
137.5, 149.2 (C), 179.4 (CO). IR (ATR): ~ = 2919 (w), 1581 (s), 1554, 1209 (m), 1156 (w), 
1031, 950 (m), 851 (w), 774 (s), 562 (m) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 367 (13), 366 
([M]
+
, 52), 365 (16), 348 (26), 347 (100), 346 (7). Anal.calcd. (%) for C24H15FN2O (366.1168): 
C = 78.68, H = 4.13, N = 7.65. Found: C = 78.38, H = 4.10, N = 7.62. HRMS (ESI-TOF): calcd. 
For C24H16FN2O [M+H]
+
: 367.1241. Found: 367.1241. 
 
Synthesis of Benzo[b]pyrazolo[5,1-f][1,6]naphthyridines (21) 
General procedure for synthesis of 2-alkynylquinoline-3-carbaldehydes 19a-d: The known 
products 19a-d were prepared by the following reported procedure:
58
 The reaction of 2 
(0.25 mmol) with alkynes (0.26 mmol) were carried out in the presence of Pd(PPh3)2Cl2 (4 mol 
%), triphenylphosphine (8 mol %) and triethylamine (2 equiv) in CH3CN as a solvent at 80 °C 
under an inert atmosphere for 3-6 hr (tlc control). The reaction mixture was concentrated in 
vacuo and the residue was purified by column chromatography on silica gel using 
EtOAc/hexane as eluent.  
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General procedure for synthesis of Benzo[b]pyrazolo[5,1-f][1,6]naphthyridines 21a-y: 2-
Alkynylquinoline-3-carbaldehyde 19 was added to a solution of tosylhydrazine in EtOH. The 
mixture was stirred at room temperature for 10 min. Then AgOTf was added and the reaction 
mixture was heated to 70 °C. Subsequently, 20 and K3PO4 were added to the mixture. After 
completion of reaction as indicated by TLC, the mixture was diluted with ethyl acetate and 
quenched with H2O. The organic layer was washed with brine, dried over Na2SO4, and 
concentrated under reduced pressure. The residue obtained was purified by flash 
chromatography column on silica gel to provide the desired product 21. 
 
 5-Phenyl-1-propylbenzo[b]pyrazolo[5,1-f][1,6]naphthyridine (21a): Starting with 2-
(phenylethynyl)quinoline-3-carbaldehyde 19a (150 mg, 0.583 mmol), 
tosylhydrazine (186 mg, 1.0 mmol), pentanal 20a (83 mg, 0.96 
mmol), AgOTf (10.8 mg, 10 mol%), K3PO4 (382 mg, 1.8 mmol) in 
EtOH (3 ml), 21a was isolated after column chromatography (silica 
gel, n-heptane/EtOAc = 9:1) as a yellowish solid (162 mg, 82 %), 
m.p. = 150-152 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 1.09 (t, J = 7.3 
Hz, 3H, CH3), 1.80-1.92 (m, 2H, CH2), 3.04 (t, J = 7.8 Hz, 2H, CH2), 7.25 (s, 1H, Ar), 7.44-
7.55 (m, 4H, Ar), 7.67-7.74 (m, 1H, Ar), 7.82-7.87 (m, 3H, Ar), 7.93 (d, J = 8.6 Hz, 1H, Ar), 
8.10 (d, J = 8.6 Hz, 1H, Ar), 8.81 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 14.2 (CH3), 
22.2, 28.2 (CH2), 113.2 (CH), 119.0, 119.74 (C), 126.4 (CH), 126.5, 127.8 (C), 128.2 (CH), 
128.4 (2×CH), 128.8 (CH), 129.5 (2×CH), 129.8, 130.2, 130.4 (CH), 133.3, 133.4 (C), 141.7 
(CH), 143.6, 147.7 (C). IR (ATR): ~ = 1614, 1492 (w), 1460, 1334 (m), 1049 (w), 912 (m), 744 
(s), 617 (m) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 337 (39, [M]
+
), 309 (24), 308 (100), 154 (16). 
HRMS (EI): calcd. For C23H19N3 [M]
+ 
: 337.15735. Found: 337.15732. 
 
1-Hexyl-5-phenylbenzo[b]pyrazolo[5,1-f][1,6]naphthyridine (21b): Starting with 2-
(phenylethynyl)quinoline-3-carbaldehyde 19a (150 mg, 0.583 
mmol), tosylhydrazine (186 mg, 1.0 mmol), octanal 20b (123 mg, 
0.96 mmol), AgOTf (15 mg, 10 mol%), K3PO4 (382 mg, 1.8 mmol) 
in EtOH (3 ml), 21b was isolated after column chromatography 
(silica gel, n-heptane/EtOAc = 9:1) as a yellowish solid (166 mg, 75 
%), m.p. = 103-105 
o
C.
 1
H-NMR (300 MHz, CDCl3):   = 0.87 (t, J = 6.8 Hz, 3H, CH3), 1.34-
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1.36 (m, 4H, CH2), 1.51 (p, J = 7.0 Hz, 2H, CH2), 1.82 (p, J = 7.0 Hz, 2H, CH2), 3.04 (t, J = 7.3 
Hz, 2H, CH2), 7.24 (s, 1H, Ar), 7.49-7.51 (m, 4H, Ar), 7.70-7.73 (m, 1H, Ar), 7.83-7.86 (m, 3H, 
Ar), 7.92 (d, J = 8.1 Hz, 1H, Ar), 8.10 (d, J = 8.2 Hz, 1H, Ar), 8.79 (s, 1H, Ar). 
13
C-NMR (75 
MHz, CDCl3):  = 14.1 (CH3), 22.7, 26.1, 28.89, 29.4, 31.8 (CH2), 113.3 (CH), 119.3, 119.7 
(C), 126.4 (CH), 126.5 (C), 128.1 (CH), 128.4 (2xCH), 128.9, 129.5 (CH), 129.8 (2xCH), 
130.1, 130.3 (CH), 133.3, 133.4 (C), 141.6 (CH), 143.6, 147.7, 147.8 (C). IR (ATR): ~ = 1613, 
1492 (w), 1456 (m), 1170, 1073 (w), 910 (m), 740, 694 (s), 618 (m) cm
–1
. GC-MS (EI, 70 eV): 
m/z (%) = 379 (33, [M]
+
), 309 (24), 308 (100), 154 (6). HRMS (EI): calcd. For C26H25N3 [M]
+
: 
379.20430. Found: 379.20415. 
 
 1-Octyl-5-phenylbenzo[b]pyrazolo[5,1-f][1,6]naphthyridine (21c): Starting with 2-
(phenylethynyl)quinoline-3-carbaldehyde (19a) (150 mg, 0.583 
mmol), tosylhydrazine (186 mg, 1 mmol), decanal (20c) (150 
mg, 0.96 mmol), AgOTf (15 mg, 10 mol%), K3PO4 (382 mg, 
1.8 mmol) in EtOH (3 ml), 21c was isolated after column 
chromatography (silica gel, n-heptane/EtOAc = 9:1) as a 
yellowish solid (161 mg, 68 %), m.p. = 70-72 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 0.78-0.81 
(m, 3H, CH3), 1.17-1.19 (m, 10H, CH2), 1.78 (p, J = 8.3 Hz, 2H, CH2), 3.01 (t, J = 7.7 Hz, 2H, 
CH2), 7.21 (s, 1H, Ar), 7.43-7.45 (m, 4H, Ar), 7.65-7.67 (m, 1H, Ar), 7.81-7.83 (m, 4H, Ar), 
8.03 (d, J = 8.3 Hz, 1H, Ar), 8.73 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 14.1(CH3), 22.7, 
26.1, 28.9, 29.4, 29.5, 29.7, 31.9 (CH2), 118.3 (CH), 119.2, 119.7 (C), 126.3, 126.5, 128.1 (CH), 
128.4 (2×CH), 128.9 (CH), 129.5 (2×CH), 129.7, 130.0, 130.3, 133.3 (CH), 133.4 (C), 141.6 
(CH), 143.5, 147.7, 147.9 (C). IR (ATR): ~ = 1614, 1493 (w), 1459, 1338 (s), 1226, 989 (w), 
911, 857, 694 (m) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 407 (37, [M]
+
), 309 (27), 308 (100), 
154 (6). HRMS (EI): calcd. For C28H29N3 [M]
+
: 407.23560. Found: 407.23578. 
 
 1-Decyl-5-phenylbenzo[b]pyrazolo[5,1-f][1,6]naphthyridine (21d): Starting with 2-
(phenylethynyl)quinoline-3-carbaldehyde (19a) (150 mg, 
0.583 mmol), tosylhydrazine (186 mg, 1 mmol), dodecanal 
(20d) (177 mg, 0.96 mmol), AgOTf (15 mg, 10 mol%), 
K3PO4 (382 mg, 1.8 mmol) in EtOH (3 ml), 21d was 
isolated after column chromatography (silica gel, n-
heptane/EtOAc = 9:1) as a yellowish solid (177 mg, 70 %), 
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m.p. = 56-58 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 0.81 (t, J = 6.6 Hz, 3H, CH3), 1.20-1.21 (m, 
12H, CH2), 1.47-1.49 (m, 2H, CH2), 1.80 (p, J = 8.1 Hz, 2H, CH2), 3.03 (t, J = 7.6 Hz, 2H, 
CH2), 7.23 (s, 1H, Ar), 7.46-7.47 (m, 4H, Ar), 7.68-7.69 (m, 1H, Ar), 7.82-7.83 (m, 3H, Ar), 
7.91 (d, J = 8.1 Hz, 1H, Ar), 8.11 (d, J = 8.5 Hz, 1H, Ar), 8.79 (s, 1H, Ar). 
13
C-NMR (75 MHz, 
CDCl3):  = 14.1 (CH3), 22.7, 26.1, 28.9, 29.4, 29.5, 29.6, 29.7, 29.8, 31.9 (CH2), 113.4 (CH), 
119.3, 119.7 (C), 126.4, 126.5, 128.2 (CH), 128.4 (2×CH), 128.9 (CH), 129.6 (2×CH), 129.8, 
130.1, 130.3 (CH), 133.3, 133.4 (C), 141.7 (CH), 143.5, 147.8, 147.9 (C). IR (ATR): ~ = 2915 
(s), 1614, 1492 (w), 1456 (s), 1340 (m), 1072 (w), 912, 852 (m), 743, 687 (s), 619 (m) cm
–1
. 
GC-MS (EI, 70 eV): m/z (%) = 379 (33, [M]
+
), 309 (24), 308 (100), 154 (6). HRMS (EI): calcd. 
For C30H33N3 [M]
+ 
: 435.26690.  Found: 435.26663.  
 
1-(Non-8-en-1-yl)-5-phenylbenzo[b]pyrazolo[5,1-f][1,6]naphthyridine (21e): Starting with 2-
(phenylethynyl)quinoline-3-carbaldehyde (19a) (150 mg, 
0.583 mmol), tosylhydrazine (186 mg, 1 mmol), 
undecylenicaldehyde (20e) (162 mg, 0.96 mmol), AgOTf (15 
mg, 10 mol%), K3PO4 (382 mg, 1.8 mmol) in EtOH (3 ml), 
21e was isolated after column chromatography (silica gel, n-
heptane/EtOAc = 9:1) as a yellowish solid (146 mg, 60 %), 
m.p. = 77-79 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 1.33-1.35 (m, 8H, CH2), 1.80-1.81 (m, 2H, 
CH2), 1.96-1.98 (m, 2H, CH2), 3.02 (t, J = 7.7 Hz, 2H, CH2), 4.86-4.88 (m, 2H, C=C), 5.71-5.73 
(m, 1H, C=C), 7.22 (s, 1H, Ar), 7.47-7.49 (m, 4H, Ar), 7.67-7.68 (m, 1H, Ar), 7.81 (s, 1H, Ar), 
7.83-7.85 (m, 2H, Ar), 7.90 (d, J =8.5 Hz, 1H, Ar), 8.07 (d, J = 8.5 Hz, 1H, Ar), 8.77 (s, 1H, 
Ar). 
13
C-NMR (75 MHz, CDCl3):  = 26.1 (CH2), 28.9 (2×CH2), 29.1, 29.4, 29.6, 33.8 (CH2), 
113.4 (CH), 114.3 (CH2), 119.2, 119.7 (C), 126.4 (CH), 126.5 (C), 128.1, 128.4 (2×CH), 128.9, 
129.5 (CH), 129.8 (2×CH), 130.0, 130.3 (CH), 133.3, 133.4 (C), 139.1, 141.1 (CH), 143.49, 
147.8, 147.9 (C). IR (ATR): ~ = 2920 (m), 1613, 1492 (w), 1457 (m), 1358 (w), 1336 (m), 
1138, 988 (w), 896, 745, 692 (s), 618 (m) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 420 (11, [M
 
+1]
+
), 419 (34, [M]
+
), 309 (27), 308 (100). HRMS (EI): calcd. For C29H29N3 [M]
+
: 419.23560. 
Found: 419.23542. 
 
2-Methyl-5-phenylbenzo[b]pyrazolo[5,1-f][1,6]naphthyridine (21f): Starting with 2-
(phenylethynyl)quinoline-3-carbaldehyde (19a) (150 mg, 0.583 mmol), tosylhydrazine (186 mg, 
1 mmol), acetone (20f) (56 mg, 0.96 mmol), AgOTf (15 mg,10 mol%), K3PO4 (382 mg, 1.8 
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mmol) in EtOH (3 ml), 21f  was isolated after column chromatography (silica gel, n-
heptane/EtOAc = 9:1) as a yellowish solid (162 mg, 91%), m.p. = 
150-152 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 2.41 (s, 3H, CH3), 6.88 
(s, 1H, Ar), 7.16 (s, 1H, Ar), 7.43-7.45 (m, 4H, Ar), 7.63-7.66 (m, 1H, 
Ar), 7.81 (d, J = 8.1 Hz, 1H, Ar), 7.84-7.87 (m, 2H, Ar), 8.03 (d, J = 
8.2 Hz, 1H, Ar), 8.59 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 
14.3 (CH3), 100.7 (CH), 122.9 (C), 125.4 (CH), 125.5 (C), 126.3 (CH), 127.1 (C), 127.9 (CH), 
128.4 (2×CH), 128.6, 129.5, 129.8 (CH), 130.2 (2×CH), 133.3 (CH), 139.2, 147.3, 148.7, 148.9, 
151.1 (C). IR (ATR): ~ = 1613, 1555, 1494 (w), 1428, 1328 (m), 1180, 858 (w), 793 (m), 747, 
693 (s), 622 (m) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 310 (18, [M
 
+1]
+
), 309 (89, [M]
+
), 308 
(100), HRMS (EI): calcd. for C21H15N3 [M]
+
: 309.12506. Found: 309.12509. 
 
1-Ethyl-2-methyl-5-phenylbenzo[b]pyrazolo[5,1-f][1,6]naphthyridine (21g): Starting with 2-
(phenylethynyl)quinoline-3-carbaldehyde (19a) (150 mg, 0.583 
mmol), tosylhydrazine (186 mg, 1 mmol), 2-pentanone (20g) (83 mg, 
0.96 mmol), AgOTf (15 mg, 10 mol%), K3PO4 (382 mg, 1.8 mmol) in 
EtOH (3 ml), 21g  was isolated after column chromatography (silica 
gel, n-heptane/EtOAc = 9:1) as a yellowish solid (165 mg, 84 %), m.p. = 189-191 
o
C.
 1
H-NMR 
(300 MHz, CDCl3):   = 1.24 (t, J = 7.1 Hz, 3H, CH3), 2.54 (s, 3H, CH3), 2.76 (q, J = 6.3 Hz, 
2H, CH2), 7.13 (s, 1H, Ar), 7.42-7.44 (m, 4H, Ar), 7.64 (t, J = 7.1 Hz, 1H, Ar), 7.84 (d, J = 8.7 
Hz, 1H, Ar), 7.90-7.92 (m, 2H, Ar), 8.03 (d, J = 8.5 Hz, 1H, Ar), 8.74 (s, 1H, Ar). 
13
C-NMR (75 
MHz, CDCl3):  = 10.7, 13.9 (CH3), 20.0 (CH2), 111.1 (C), 112.2 (CH), 119.8 (C), 126.1 (CH), 
126.4 (C), 128.1, 128.2 (CH), 128.6 (2×CH), 128.8 (CH), 129.6 (2×CH), 129.7, 130.1 (CH), 
133.5, 134.5, 143.3, 147.8, 148.1, 155.5 (C). IR (ATR): ~ = 1613, 1555, 1494 (w), 1428, 
1328(m), 1180, 858 (w), 793 (m), 747, 693 (s), 622 (m) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 
338 (24, [M
 
+1]
+
), 337 (100, [M]
+
), 336 (54), 281 (22). HRMS (EI):  calcd. For C23H19N3 [M]
+
: 
337.15735.  Found: 337.15705. 
 
6-Phenyl-2,3-dihydro-1H-benzo[b]cyclopenta[3,4]pyrazolo[5,1-f][1,6]naphthyridine (21h):  
Starting with 2-(phenylethynyl)quinoline-3-carbaldehyde (19a) (150 mg, 0.583 mmol), 
tosylhydrazine (186 mg, 1 mmol), cyclopentanone (20h) (81 mg, 0.96 mmol), AgOTf (15 mg, 
10 mol%), K3PO4 (382 mg, 1.8 mmol) in EtOH (3 ml), 21h was isolated after column 
chromatography (silica gel, n-heptane/EtOAc = 9:1) as a yellowish solid (125 mg, 64 %), m.p. = 
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223-225 
o
C.
 1
H-NMR (250 MHz, CDCl3):  = 2.56 (q, J = 7.6 Hz, 2H, CH2), 2.87 (t, J = 6.7 Hz, 
2H, CH2), 3.01 (t, J = 6.7 Hz, 2H, CH2), 7.09 (s, 1H, Ar), 7.40-7.42 
(m, 4H, Ar), 7.60-7.62 (m, 1H, Ar), 7.76 (d, J = 6.9 Hz, 1H, Ar), 
7.80-7.82 (m, 2H, Ar), 8.01 (d, J = 6.9 Hz, 1H, Ar), 8.53 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 24.3, 25.1, 30.2 (CH2), 111.6 (CH), 
118.8, 121.7 (C), 126.1 (CH), 126.5 (C), 127.7 (2×CH), 128.4, 128.9 
(CH), 129.4 (2×CH), 129.7, 130.1, 130.4 (CH), 132.1, 133.6, 144.3, 147.6, 148.3, 164.1 (C). IR 
(ATR): ~ = 2917, 1633, 1595, 1494 (w), 1438(m), 1288, 1126 (w), 894, 771 (m), 747, 697 (s) 
cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 336 (24, [M
 
+1]
+
), 335 (100, [M]
+
), 334 (74), 167 (15). 
HRMS (EI): calcd. For C23H17N3 [M]
+ 
: 335.14170; Found: 335.14115.  
 
7-Phenyl-1,2,3,4-tetrahydrobenzo[b]indazolo[3,2-f][1,6]naphthyridine (21i): Starting with 
2-(phenylethynyl)quinoline-3-carbaldehyde (19a) (150 mg, 0.583 
mmol), tosylhydrazine (186 mg, 1 mmol), cyclohexanone (20i)  (94 
mg, 0.96 mmol), AgOTf (15 mg, 10 mol%), K3PO4 (382 mg, 1.8 
mmol) in EtOH (3 ml), 21i was isolated after column chromatography 
(silica gel, n-heptane/EtOAc = 12:1) as a yellowish solid (177 mg, 87 
%), m.p. = 235-237 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 1.84-1.86 (m, 4H, CH2), 2.81 (t, J = 
6.9 Hz, 2H, CH2), 3.01 (t, J = 5.9 Hz, 2H, CH2), 7.11 (s, 1H, Ar), 7.42-7.44 (m, 4H, Ar), 7.60-
7.63 (m, 1H, Ar), 7.76 (d, J = 8.3 Hz, 1H, Ar), 7.80-7.83 (m, 2H, Ar), 8.01 (d, J = 8.1 Hz, 1H, 
Ar), 8.52 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 22.9, 22.9, 23.3, 24.2 (CH2), 112.2 (CH), 
118.2, 118.6, 119.6 (C), 126.1 (CH), 126.4 (C), 127.9, 128.4 (2×CH), 128.6 (C), 128.8 (CH), 
129.6 (2×CH), 129.7, 129.8, 130.0 (CH), 133.5, 143.4, 147.8, 151.8 (C). IR (ATR): ~ = 2936, 
1614, 1571 (w), 1449, 1351 (m), 1197 (w), 895, 766 (m), 742 (s), 611 (m) cm
–1
. GC-MS (EI, 70 
eV): m/z (%) = 350 (25, [M
 
+1]
+
), 349 (100, M
+
), 348(47), 321 (30). HRMS (EI): calcd. For 
C24H19N3 [M]
+
: 349.15735. Found: 349.15695. 
 
4-Methyl-7-phenyl-1,2,3,4-tetrahydrobenzo[b]indazolo[3,2-f][1,6]naphthyridine (21j): 
Starting with 2-(phenylethynyl)quinoline-3-carbaldehyde (19a) (150 
mg, 0.583 mmol), tosylhydrazine (186 mg, 1 mmol), 2-
methylcyclohexanone (20j)  (108 mg, 0.96 mmol), AgOTf (15 mg, 10 
mol%), K3PO4 (382 mg, 1.8 mmol) in EtOH (3 ml), 21j was isolated 
after column chromatography (silica gel, n-heptane/EtOAc = 9:1) as a 
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yellowish solid (159 mg, 75 %), m.p. = 157-159 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 1.35 (d, J 
= 5.9 Hz, 3H, CH3), 1.49-152 (m, 1H, CH), 1.80-1.81 (m, 1H, CH2), 2.05-2.07 (m, 2H, CH2), 
3.03-3.05 (m, 3H, CH2), 7.18 (s, 1H, Ar), 7.44-7.46 (m, 4H,  Ar), 7.66-7.68 (m, 1H, Ar), 7.86 
(d, J = 9.5 Hz, 1H, Ar), 7.94-7.96 (m, 2H, Ar), 8.07 (d, J = 8.34 Hz, 1H, Ar), 8.67 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 20.4 (CH3), 22.1, 23.3 (CH2), 29.8 (CH), 31.9 (CH2), 112.1 
(CH), 118.2, 118.6, 119.6 (C), 126.1 (CH), 126.4 (C), 127.9 (CH), 128.4 (2×CH), 128.6 (CH), 
128.8 (2×CH), 129.5 (CH), 129.6 (C), 129.7, 130.0 (CH), 133.4, 143.4, 147.9,151.8 (C). IR 
(ATR) ~ = 2846, 1613, 1567 (w), 1486, 1349 (m), 1138, 895, 856, 765 (m), 742, 694 (s), 611 
(m) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 364 (28, [M
 
+1]
+
), 363 (100, [M]
+
), 362 (28), 334 
(25). HRMS (EI): calcd. For C25H21N3 [M]
+
: 363.17300. Found: 363.17269. 
 
7-Phenyl-11,12,13,14-tetrahydro-10H-benzo[b]cyclopenta[3,4]pyrazolo[5,1-f][1,6]-
naphthyridine (21k): Starting with 2-(phenylethynyl)quinoline-3-
carbaldehyde (19a) (150 mg, 0.583 mmol), tosylhydrazine (186 mg, 1 
mmol), cycloheptanone (20k) (108 mg, 0.96 mmol), AgOTf (15 mg, 
10 mol%), K3PO4 (382 mg, 1.8 mmol) in EtOH (3 ml), 21k was 
isolated after column chromatography (silica gel, n-heptane/EtOAc = 
9:1) as a yellowish solid (133 mg, 63 %), m.p. = 205-207 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 
1.70-1.72 (m, 2H, CH2), 1.85-1.87 (m, 4H, CH2), 2.89-2.92 (m, 2H, CH2), 3.22-3.24 (m, 2H, 
CH2), 7.11 (s, 1H, Ar), 7.42-7.44 (m, 4H, Ar), 7.67-7.69 (m, 1H, Ar), 7.86-7.88 (m, 3H, Ar), 
8.06 (d, J = 8.1 Hz, 1H, Ar), 8.96 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 26.2, 27.1, 28.4, 
29.3, 31.5 (CH2), 112.2 (CH), 118.9, 119.9 (C), 126.2 (CH), 126.3 (C), 128.1(CH), 128.3 
(2×CH), 128.7, 129.6 (CH), 129.7 (2×CH), 129.8, 130.2 (CH), 133.5, 133.6, 143.4, 147.8, 
148.2, 156.8 (C). IR (ATR): ~ = 2922 (m), 1632, 1614 (w), 1477, 1320 (m), 1125 (w), 849, 769 
(m), 744, 692 (s) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 364 (26, [M
 
+1]
+
), 363 (100, [M]
+
), 362 
(46), 334 (23). HRMS (EI): calcd. For C25H21N3 [M]
+
: 363.17300. Found: 363.17242. 
 
 7-Phenyl-10,11,12,13,14,15-hexahydrobenzo[b]cyclopenta[3,4]pyrazolo[5,1-f ][1,6]naph-
thyridine (21l): Starting with 2-(phenylethynyl)quinoline-3-
carbaldehyde (19a) (150 mg, 0.583 mmol), tosylhydrazine (186 mg, 1 
mmol), cycloctanone (20l) (121 mg, 0.96 mmol), AgOTf (15 mg, 10 
mol%), K3PO4 (382 mg, 1.8 mmol) in EtOH (3 ml), 21l was isolated 
after column chromatography (silica gel, n-heptane/EtOAc = 9:1) as a 
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yellowish solid (132 mg, 60 %), m.p. = 165-167 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 1.37-1.39 
(m, 2H, CH2), 1.52 (p, J = 6.8 Hz, 2H, CH2), 1.69 (p, J = 6.1 Hz, 2H, CH2), 1.89 (p, J = 6.1 Hz, 
2H, CH2), 2.88 (t, J = 6.1 Hz, 2H, CH2), 3.15 (t, J = 6.1 Hz, 2H, CH2), 7.11-7.14 (m, 1H, Ar), 
7.43-7.45 (m, 4H, Ar), 7.65-7.68 (m, 1H, Ar), 7.88-7.90 (m, 3H, Ar), 8.04 (d, J = 8.1 Hz, 1H, 
Ar), 8.79 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 21.7, 24.6, 25.1, 25.8, 26.7, 30.0 (CH2), 
111.1 (CH), 115.0, 118.6 (C), 125.1 (CH), 125.4 (C), 127.0 (CH), 127.3 (2×CH), 127.8, 128.4, 
128.6 (CH), 128.7 (2×CH), 129.1 (CH), 132.5, 132.6, 142.4, 146.8, 146.9, 154.4 (C). IR (ATR): 
~ = 3054, 2845, 1633, 1568 (w), 1483, 1438, 1353(m), 1255, 899 (w), 840 (m), 748, 693 (s), 
610 (m) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 378 (29, [M
 
+1]
+
), 377 (100, [M]
+
), 376(21), 349 
(33), 334(38). HRMS (EI): calcd. For C26H23N3 [M]
+
: 377.18865. Found: 377.18819. 
 
Methyl-2-methyl-5-phenylbenzo[b]pyrazolo[5,1-f][1,6]naphthyridine-1-carboxylate (21m): 
Starting with 2-(phenylethynyl)quinoline-3-carbaldehyde (19a) (150 
mg, 0.583 mmol), tosylhydrazine (186 mg, 1.0 mmol), 
methylacetoacete (20m) (111 mg, 0.96 mmol), AgOTf (15 mg, 10 
mol%), K3PO4 (382 mg, 1.8 mmol) in EtOH (3 ml), 21m was isolated 
after column chromatography (silica gel, n-heptane/EtOAc = 9:1) as a 
yellowish solid (180 mg, 84 %), m.p. = 87-89 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 2.58 (s, 3H, 
CH3), 3.98 (s, 3H, OCH3), 7.50-753 (m, 5H, Ar), 7.76-7.78 (m, 1H, Ar), 7.84-7.87 (m, 2H, Ar), 
8.10 (q, J = 7.7 Hz, 2H, Ar), 10.59 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 14.9, 50.7 
(CH3), 107.9 (C), 114.4 (CH), 116.8, 125.4 (C), 125.5, 127.3 (2×CH), 128.4, 128.5, 128.9, 
129.1, 130.5 (CH), 131.9 (C), 135.4 (CH), 139.2, 141.6, 146.3, 147.8, 152.8 (C), 164.4 (CO). IR 
(ATR): ~ = 2924 (w), 1704 (m), 1616 (w), 1533 (m), 1493 (w), 1448, 1257, 1190 (m), 1081 (s), 
855 (m), 744, 688 (s), 628 (m) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 368 (24, [M
 
+1]
+
), 367 
(100, [M]
+
), 366 (62), 336 (33): HRMS (EI): calcd. for C23H17N3 O2 [M]
+
: 367.13153. Found: 
367.13064.  
 
1-Methyl-2,5-diphenylbenzo[b]pyrazolo[5,1-f][1,6]naphthyridine (21n): Starting with 2-
(phenylethynyl)quinoline-3-carbaldehyde (19a) (150 mg, 0.583 mmol), tosylhydrazine (186 mg, 
1.0 mmol),  propiophenone (20n) (129 mg, 0.96 mmol), AgOTf (15 mg, 10 mol%), K3PO4 (382 
mg, 1.8 mmol) in EtOH (3 ml), 21n  was isolated after column chromatography (silica gel, n-
heptane/EtOAc = 9:1) as a yellowish solid (144 mg, 64 %), m.p. = 208-210 
o
C.
 1
H-NMR (300 
MHz, CDCl3):  = 2.69 (s, 3H, CH3), 7.21 (s, 1H, Ar), 7.36-7.38 (m, 7H, Ar), 7.62-7.66 (m, 3H, 
65 
 
Ar), 7.85 (d, J = 8.1 Hz, 1H, Ar), 7.96-7.99 (m, 2H, Ar), 8.04 (d, J = 
8.7 Hz, 1H, Ar), 8.81(s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 
11.9 (CH3), 111.3 (CH), 118.3, 119.8, 126.3 (C), 126.3, 128.1 (CH), 
128.3, 128.5 (2×CH), 128.9, 129.0 (CH), 129.2 (2×CH), 129.6, 129.7 
(CH), 129.8 (2×CH), 130.3 (CH), 133.2, 135.2, 143.2, 147.8, 147.9, 
152.9, 171.2 (C). IR (ATR): ~ = 3053, 1613, 1555, 1493 (w), 1467, 
1327 (m), 1173 (w), 1020, 913, 783 (m), 744, 696 (s) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 386 
(26, [M
 
+1]
+
), 385 (100, [M]
+
), 384 (76), 281 (21). HRMS (EI): calcd. For C27H19N3 [M]
+
: 
385.15735. Found: 385.15666.  
 
 2-(4-Methoxyphenyl)-5-phenylbenzo[b]pyrazolo[5,1-f][1,6]naphthyridine (21o): Starting 
with 2-(phenylethynyl)quinoline-3-carbaldehyde (19a)  (150 mg, 
0.583 mmol), tosylhydrazine (186 mg, 1 mmol), p-
methoxyacetophenone (20o) (144 mg, 0.96 mmol), AgOTf (15 
mg, 10 mol%), K3PO4 (382 mg, 1.8 mmol) in EtOH (3 ml), 21o 
was isolated after column chromatography (silica gel, n-
heptane/EtOAc = 9:1) as a yellowish solid (145 mg, 62 %), m.p. 
= 195-197 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 3.91 (s, 3H, 
OCH3), 7.01 (d, J = 8.2 Hz, 2H, Ar), 7.21 (s, 1H, Ar), 7.41 (s, 1H, Ar), 7.52 (s, 1H, Ar), 7.59-
7.61 (m, 4H, Ar), 7.81-7.82 (m, 1H, Ar), 7.98-8.01 (m, 2H, Ar), 8.04 (d, J = 8.1 Hz, 1H, Ar), 
8.10-8.13 (m, 2H, Ar), 8.23 (d, J = 8.1 Hz, 1H, Ar), 8.92 (s, 1H, Ar). 
13
C-NMR (75 MHz, 
CDCl3):  = 55.3 (OCH3), 97.3, 113.1 (CH), 114.1 (2×CH), 118.1, 125.6 (C), 126.4 (CH), 126.6 
(C), 127.6 (2×CH), 127.9 (CH), 128.2 (2×CH), 129.1, 129.8 (CH), 129.8 (2×CH), 130.4, 130.5 
(CH), 133.1, 139.7, 143.2, 147.3, 148.8, 152.7, 159.9 (C). IR (ATR): ~ = 2924 (w), 1704 (m), 
1616 (w), 1533 (m), 1493 (w), 1448, 1257, 1190 (m), 1081 (s), 855 (m), 744, 688 (s), 628 (m) 
cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 402 (29, [M
 
+1]
+
), 401 (100, [M]
+
), 400 (39). HRMS (EI): 
calcd. For C27H19N3O [M]
+ 
: 401.15226. Found: 401.15168. 
 
 2-Methyl-5-pentylbenzo[b]pyrazolo[5,1-f][1,6]naphthyridine (21p): Starting with 2-(hept-1-
yn-1-yl)quinoline-3-carbaldehyde, (19b) (146 mg, 0.583 mmol), tosylhydrazine (186 mg, 1.0 
mmol), acetone (20f) (56 mg, 0.96 mmol), AgOTf (15 mg, 10 mol%), K3PO4 (382 mg, 1.8 
mmol) in EtOH (3 ml), 21p was isolated after column chromatography (silica gel, n-
heptane/EtOAc = 9:1) as a yellowish solid (127 mg, 72 %), m.p. = 95-97 
o
C. 
1
H-NMR (300 
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MHz, CDCl3):  = 0.89 (t, J = 7.1 Hz, 3H, CH3), 1.39-142 (m, 4H, CH2), 1.88 (dd, J = 8.1, 7.1 
Hz, 2H, CH2), 2.49 (s, 3H, CH3), 3.12 (t, J = 8.1  Hz, 2H, CH2), 
6.89 (s, 1H, Ar), 6.99 (s, 1H, Ar), 7.47 (t, J = 7.1 Hz, 1H, Ar), 7.71 
(t, J = 7.1 Hz, 1H, Ar), 7.86 (d, J = 8.1 Hz, 1H, Ar), 8.11 (d, J = 
8.1 Hz, 1H, Ar), 8.65 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 
14.0, 14.2 (CH3), 22.6, 26.3, 30.8, 31.5 (CH2), 100.4, 109.3 (CH), 
125.4 (C), 126.0 (CH), 126.2 (C), 127.9, 128.9, 130.3, 130.5 (CH), 138.5, 144.9, 147.3, 148.5, 
150.8 (C). IR (ATR) ~ = 3051, 1808 (w), 1639 (s), 1615, 1497 (m), 1326 (s), 1180, 1077 (w), 
973, 903 (m), 754, 732 (s), 587 (m) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 304 (10, [M
 
+1]
+
), 303 
(45, [M]
+
), 302 (17), 248 (22), 247 (100). HRMS (EI): calcd. For C20H21N3 [M]+: 303.17300. 
Found: 303.17270.  
 
5-Pentyl-1-propylbenzo[b]pyrazolo[5,1-f][1,6]naphthyridine (21q): Starting with 2-(hept-1-
yn-1-yl)quinoline-3-carbaldehyde (19b)  (146 mg, 0.583 mmol), 
tosylhydrazine (186 mg, 1.0 mmol), pentanal (20a)  (83 mg, 0.96 
mmol), AgOTf (15 mg, 10 mol%), K3PO4 (382 mg, 1.8 mmol) in 
EtOH (3 ml), 21q  was isolated after column chromatography (silica 
gel, n-heptane/EtOAc = 9:1) as a yellowish solid (138 mg, 72 %), 
m.p. = 88-90 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 0.81 (t, J = 7.1 Hz, 
3H, CH3), 1.11 (t, J = 7.1 Hz, 3H, CH3), 1.38-1.40 (m, 4H, CH2), 
1.78-1.81 (m, 4H, CH2), 2.89 (t, J = 7.1 Hz, 2H, CH2), 3.08 (t, J = 7.1 Hz, 2H, CH2), 7.01 (s, 
1H, Ar ), 7.43-7.46 (m, 1H, Ar), 7.64-7.67 (m, 1H, Ar), 7.78 (s, 1H, Ar), 7.81 (d, J = 8.1 Hz, 
1H, Ar), 8.01 (d, J = 8.1 Hz, 1H, Ar), 8.72 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 14.0, 
14.2 (CH3), 22.2, 22.5, 26.5, 28.1, 30.9, 31.5 (CH2), 110.3 (CH), 118.8, 119.3 (C), 126.0 (CH), 
126.2 (C), 128.1, 128.7, 130.1, 130.2 (CH), 132.8 (C), 141.1 (CH), 145.1, 147.6, 147.7 (C). IR 
(ATR): ~ = 3099 (w), 2927 (m), 1614, 1494 (w), 1462, 1333 (m), 1192, 986 (w), 899, 853, 752, 
647 (s) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 332 (20, [M
 
+1]
+
), 331 (86, [M]
+
), 330(48), 303 
(24), 302 (100), 288 (17). HRMS (EI): calcd. For C22H25N3 [M]
+ 
: 331.20430. Found: 
331.20399.  
 
7-Pentyl-1,2,3,4-tetrahydrobenzo[b]indazolo[3,2-f][1,6]naphthyridine (21r): Starting with 
2-(hept-1-yn-1-yl)quinoline-3-carbaldehyde (19b) (146 mg, 0.583 mmol), tosylhydrazine (186 
mg, 1.0 mmol), cyclohexanone (20i) (94 mg, 0.96 mmol), AgOTf (15 mg, 10 mol%), K3PO4 
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(382 mg, 1.8 mmol) EtOH (3 ml), 21r was isolated after column chromatography (silica gel, n-
heptane/EtOAc = 9:1) as a yellowish solid (131 mg, 66 %), m.p. = 
194-196 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 0.81 (t, J = 7.1 Hz, 
3H, CH3), 1.39-1.42 (m, 4H, CH2), 1.88-1.90 (m, 6H, CH2), 2.89 (t, 
J = 5.1 Hz, 2H, CH2), 3.01-3.06 (m, 4H, CH2), 6.97-7.01 (m, 1H, 
Ar), 7.35-7.43 (m, 1H, Ar), 7.67-7.71 (m, 1H, Ar), 7.81 (d, J = 8.1 
Hz, 1H, Ar), 8.1 (d, J = 8.1 Hz, 1H, Ar), 8.6 (s, 1H, Ar). 
13
C-NMR 
(75 MHz, CDCl3):  = 14.0 (CH3), 22.6, 22.9, 23.0, 23.3, 24.0, 26.4, 30.8, 31.5 (CH2), 77.4, 
108.9 (CH), 113.4, 119.2 (C), 125.8 (CH), 126.2 (C), 127.9, 128.7, 130.0 (CH), 132.8, 145.2, 
147.5,  147.7, 151.4 (C). IR (ATR): ~ = 3054 (w), 2921, 1635, 1573 (m), 1538 (w), 1485 (s), 
1391 (w), 1348 (s), 1129 (m), 977 (w), 855 (s), 787 (m), 759, 696 (s) cm
–1
. GC-MS (EI, 70 eV): 
m/z (%) = 344 (14, [M
 
+1]
+
), 343 (56, [M]
+
), 342 (39), 288 (24), 287 (100), 259 (30). HRMS 
(EI): calcd. For C23H25N3 [M]
+ 
: 343.20430. Found: 343.20376.  
 
3-Methyl-7-pentyl-1,2,3,4-tetrahydrobenzo[b]indazolo[3,2-f][1,6]naphthyridine (21s): 
Starting with 2-(hept-1-yn-1-yl))quinolone-3-carbaldehyde (19b) (146 
mg, 0.583 mmol), tosylhydrazine (186 mg, 1.0 mmol), 3-
methylcyclohexanone (20p) (108 mg, 0.96 mmol), AgOTf (15 mg, 10 
mol%), K3PO4 (382 mg, 1.8 mmol) in EtOH (3 ml), 21s was isolated 
after column chromatography (silica gel, n-heptane/EtOAc = 9:1) as a 
yellowish solid (156 mg, 75 %), m.p. = 162-164 
o
C.
 1
H-NMR (300 
MHz, CDCl3):  = 1.03 (t, J = 6.8 Hz, 3H, CH3), 1.21 (d, J = 6.8 Hz, 
3H, CH3), 1.48-1.51 (m, 5H, CH2), 1.97-2.01 (m, 4H, CH2), 2.53 (q, J = 9.7 Hz, CH), 2.96-3.24 
(m, 5H, CH2), 7.01 (s, 1H, Ar), 7.48-7.53 (m, 1H, Ar), 7.71-7.75 (m, 1H, Ar), 7.88 (d, J = 7.8 
Hz, 1H, Ar), 8.11 (d, J = 8.1 Hz, 1H, Ar), 8.6 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 
14.0, 21.6 (CH3), 22.2, 22.6, 26.3 (CH2), 29.3 (CH), 30.8, 31.4, 31.5, 32.2 (CH2), 108.9 (CH), 
112.9, 119.0 (C), 125.7, 127.8, 128.6, 129.9, 130.1 (CH), 132.6, 145.1, 147.6, 147.7, 151.5 (C). 
IR (ATR): ~ = 3051 (w), 2922, 2851 (m), 1574 (w), 1486 (s), 1369 (m), 1319 (s), 1129 (m), 
977 (w), 900 (m), 826 (w), 757 (s), 653 (m) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 358 (13, [M
 
+1]
+
), 357 (57, [M]
+
), 356 (39), 302 (25), 301 (100), 259 (25). HRMS (EI): calcd. For C24H27N3 
[M]
+ 
: 357.21995. Found: 357.21921. 
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 6-Pentyl-2,3-dihydro-1H-benzo[b]cyclopenta[3,4]pyrazolo[5,1-f][1,6]naphthyridine (21t): 
Starting with 2-(hept-1-yn-1-yl)quinolone-3-carbaldehyde (19b) 
(146 mg, 0.583 mmol), tosylhydrazine (186 mg, 1.0 mmol), 
cyclopentanone (20h) (81 mg, 0.96 mmol), AgOTf (15 mg, 10 
mol%), K3PO4 (382 mg, 1.8 mmol) in EtOH (3 ml), 21t was isolated 
after column chromatography (silica gel, n-heptane/EtOAc = 9:1) as 
a yellowish solid (145 mg, 76 %), m.p. = 152-154 
o
C.
 1
H-NMR (300 
MHz, CDCl3):  = 0.81 (t, J = 7.1 Hz, 3H, CH3), 1.42 (t, J = 7.1 Hz, 6H, CH2), 1.78-1.82 (m, 
2H, CH2), 2.58-2.62 (m, 2H, CH2), 2.89-2.93 (m, 2H, CH2), 2.97-3.03 (m, 2H, CH2), 6.93 (s, 
1H, Ar), 7.38-7.42 (m, 1H, Ar), 7.70-7.73 (m, 1H, Ar), 7.92 (d, J = 8.1 Hz, 1H, Ar), 8.11 (d, J = 
8.1 Hz, 1H, Ar), 8.53 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 11.2 (CH3), 22.5, 24.2, 24.9, 
26.5, 30.2, 30.3, 31.5 (CH2), 77.4, 108.9 (CH), 113.4, 119.2 (C), 125.8 (CH), 126.2 (C), 127.9 
(CH), 128.7 (CH), 130.0 (CH), 132.8, 145.2, 147.5, 147.7, 151.4(C). IR (ATR): ~ = 3050 (w), 
2924, 1481 (m), 1349 (s), 1127, 971 (w), 902, 757 (s), 603 (m) cm
–1
. GC-MS (EI, 70 eV): m/z 
(%) = 330 (11, [M
 
+1]
+
), 329 (55, [M]
+
), 328 (83), 273 (100), 272 (40). HRMS (EI): calcd. For 
C22H23N3 [M]
+ 
: 329.18920. Found: 329.18951.  
 
2-Ethyl-1-methyl-5-pentylbenzo[b]pyrazolo[5,1-f][1,6]naphthyridine (21u): Starting with 2-
(hept-1-yn-1-yl)quinolone-3-carbaldehyde (19b) (146 mg, 0.583 
mmol), tosylhydrazine (186 mg, 1.0 mmol), 3-pentanone (20g) (83 
mg, 0.96 mmol), AgOTf (15 mg, 10 mol%), K3PO4 (382 mg, 1.8 
mmol) in EtOH (3 ml), 21u was isolated after column 
chromatography (silica gel, n-heptane/EtOAc = 9:1) as a yellowish 
solid (171 mg, 89 %), m.p. = 137-139 
o
C.
 1
H-NMR (300 MHz, 
CDCl3):  = 0.87 (t, J = 6.1 Hz, 3H, CH3), 1.31 (t, J = 7.1 Hz, 3H, CH3), 1.42 (t, J = 7.1 Hz, 8H, 
CH2), 1.89-1.93 (m, 2H, CH2), 2.62 (s, 3H, CH3), 7.01 (s, 1H, Ar), 7.53 (t, J = 8.1 Hz, 1H, Ar), 
7.71 (t, J = 8.1 Hz, 1H, Ar), 7.92 (d, J = 8.1 Hz, 1H, Ar), 8.21 (d, J = 8.1 Hz, 1H, Ar), 8.82 (s, 
1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 10.6, 11.2, 13.9 (CH3), 20.0, 22.5, 26.4, 30.8, 31.5 
(CH2), 77.4, 109.9 (CH), 116.4, 120.2 (C), 125.3 (CH), 126.7 (C), 127.5, 128.3, 131.2 (CH), 
133.8, 146.2, 147.1, 147.9, 152.1 (C). IR (ATR): ~ = 3053, 1613, 1555, 1493 (w), 1467, 1327 
(m), 1173 (w), 1020, 913, 783 (m), 744, 696 (s) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 332 (12, 
[M
 
+1]
+
), 331 (50, [M]
+
), 330 (18), 276 (22), 274 (100). HRMS (EI): calcd. For C22H25N3 [M]
+
) 
: 331.20430. Found: 331.20405.  
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7-Cyclopropyl-4-methyl-1,2,3,4-tetrahydrobenzo[b]indazolo[3,2-f][1,6]naphthyridine 
(21v): Starting with 2-(cyclopropylethynyl)quinoline-3-carbaldehyde 
(19c)  (129 mg, 0.583 mmol), tosylhydrazine (186 mg, 1.0 mmol), 3-
methylcyclohexanone (20j) (108 mg, 0.96 mmol), AgOTf (15 mg, 10 
mol%), K3PO4 (382 mg, 1.8 mmol) in EtOH (3 ml), 21v was isolated 
after column chromatography (silica gel, n-heptane/EtOAc = 9:1) as a 
yellowish solid (143 mg, 75 %), m.p. = 92-94 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 0.87 (t, J = 
7.1 Hz, 3H, CH3), 1.18-1.23 (m, 2H, CH2), 1.37-1.42 (m, 6H), 1.85-1.94 (m, 2H, CH2), 3.17 (t, 
J = 7.6 Hz, 2H, CH2), 7.11 (s, 1H, Ar), 7.47-7.53 (m, 1H, Ar), 7.67-7.72 (m, 1H, Ar), 7.91 (d, J 
= 8.1 Hz, 1H, Ar), 8.11 (d, J = 8.1 Hz, 1H,  Ar), 8.81 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3): 
 = 14.3 (CH3), 22.8, 26.5, 30.0, 31.5, 31.8 (CH2), 77.2, 100.6, 110.6 (CH), 117.5, 118.2, 126.3 
(C), 126.7 (CH), 128.2, 128.3 (C), 129.2 (CH), 129.3 (C), 130.5, 130.8 (CH), 131.1, 138.1 (C), 
141.4 (CH). IR (ATR): ~ = 3050 (w), 2951 (m), 2926 (s), 1639, 1443 (m), 1332 (s), 1247 (w), 
921, 740, 614, 528 (m) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 327 (4, [M]
+
), 312 (24), 299 (42), 
286 (100). HRMS (EI): calcd. For C26H17N3 [M]
+
: 327.17325. Found: 327.17307. 
 
5-Cyclopropyl-1-propylbenzo[b]pyrazolo[5,1-f][1,6]naphthyridine (21w): Starting with 2-
(cyclopropylethynyl)quinoline-3-carbaldehyde (19c) (129 mg, 0.583 
mmol), tosylhydrazine (186 mg, 1.0 mmol), pentanal (20a) (83 mg, 0.96 
mmol), AgOTf (15 mg, 10 mol%), K3PO4 (382 mg, 1.8 mmol) in EtOH 
(3 ml), 21w was isolated after column chromatography (silica gel, n-
heptane/EtOAc = 9:1) as a yellowish solid (129 mg, 74 %), m.p. = 227-
229 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 0.94-0.98 (m, 2H, CH2), 1.11 (t, J =  6.7 Hz, 3H, 
CH3), 1.15-1.18 (m, 2H, CH2), 1.78-1.83 (m, 2H, CH2), 2.67-2.72 (m, 1H, CH), 3.01 (t, J = 7.6 
Hz, 2H, CH2), 6.72 (s, 1H, Ar), 7.43 (t, J = 7.6 Hz, 1H, Ar), 7.71 (t, J = 8.1 Hz, 1H, Ar), 7.78-
7.81 (m, 2H, Ar), 8.21 (d, J = 7.9 Hz, 1H, Ar), 8.62 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  
= 8.1, 8.2 (CH2), 11.3 (CH), 14.2 (CH3), 22.2, 28.1 (CH2), 106.8 (CH), 118.9, 119.0 (C), 126.0 
(CH), 126.1 (C), 128.1, 128.6, 130.1, 130.2 (CH), 132.8 (C), 141.3 (CH), 146.8, 147.6, 147.8 
(C). IR (ATR): ~ = 2865 (m), 2819 (s), 2479 (m), 2387 (w), 1390 (s), 1158, 805 (m) cm–1. GC-
MS (EI, 70 eV): m/z (%) = 302 (16, [M
 
+1]
+
), 301 (74, [M]
+
), 300 (25), 286 (32), 273 (22), 272 
(100). HRMS (EI): calcd. For C20H19N3 [M]
+ 
: 301.15735. Found: 301.15695. 
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7-Cyclopropyl-1,2,3,4-tetrahydrobenzo[b]indazolo[3,2-f][1,6]naphthyridine (21x): Starting 
with 2-(cyclopropylethynyl)quinolone-3-carbaldehyde (19c) (129 mg, 
0.583 mmol), tosylhydrazine (186 mg, 1.0 mmol), cyclohexanone (20i) 
(94 mg, 0.96 mmol), AgOTf (15 mg,10 mol%), K3PO4 (382 mg, 1.8 
mmol) in EtOH (3 ml), 21x was isolated after column chromatography 
(silica gel, n-heptane/EtOAc = 9:1) as a yellowish solid (138 mg, 76 %), 
m.p. = 183-185 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 0.93-0.97 (m, 2H, CH2), 1.12-1.17 (m, 2H, 
CH2), 1.87-1.93 (m, 4H, CH2), 2.67-2.71 (m, 1H, CH), 2.89-2.92 (m, 2H, CH2), 2.67-2.71 (m, 
2H, CH2), 6.59-6.62 (s, 1H, Ar), 7.41 (t, J = 7.3 Hz, 1H, Ar), 7.62 (t, J = 7.3 Hz, 1H, Ar), 7.72 
(d, J = 8.1 Hz, 1H, Ar), 7.91 (d, J = 8.1 Hz, 1H, Ar), 8.53 (s, 1H, Ar). 
13
C-NMR (75 MHz, 
CDCl3):  = 8.5, 8.6 (CH2), 11.2 (CH), 22.8, 22.9, 23.2, 24.1 (CH2), 104.9 (CH), 113.5, 118.8, 
125.7 (C), 125.9, 127.9 (CH), 128.4 (C), 129.9, 130.0 (CH), 132.7, 147.0, 147.4, 147.7 (C), 
151.5 (CH). IR (ATR): ~ = 2930, 1614, 1557 (w), 1486 (m), 1200, 1048 (w), 970, 894 (m), 740 
(s), 657, 624 (w) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 314 (22, [M
 
+1]
+
), 313 (100, [M]
+
), 312 
(84), 298 (82). HRMS (EI): calcd. For C21H19N3 [M]
+ 
: 313.15735. Found: 313.15659. 
 
 1-Propylbenzo[b]pyrazolo[5,1-f][1,6]naphthyridine (21y): Starting with 2-
((trimethylsilyl)ethynyl)quinoline-3-carbaldehyde (19d) (147 mg, 0.583 
mmol), tosylhydrazine (186 mg, 1.0 mmol), pentanal (20a) (83 mg, 0.96 
mmol), AgOTf (15 mg, 10 mol%), K3PO4 (382 mg, 1.8 mmol) in EtOH (3 
ml), 21y was isolated after column chromatography (silica gel, n-
heptane/EtOAc = 9:1) as a yellowish solid (122 mg, 81 %), m.p. = 127-
128 
o
C.
 1
H-NMR (300 MHz, CDCl3):  = 1.11 (t, J = 7.1 Hz, 3H, CH3), 1.81 (dt, J = 8.1, 7.1 
Hz, 2H, CH2), 3.02 (t, J = 7.1 Hz, 2H, CH2), 7.13 (d, J = 8.1 Hz, 1H, Ar), 7.48-7.53 (m, 1H, 
Ar), 7.67-7.72 (m, 1H, Ar), 7.77 (s, 1H, Ar), 7.91 (d, J = 8.1 Hz, 1H, Ar), 8.13 (d, J = 7.4 Hz, 
1H, Ar), 8.22 (d, J = 6.9 Hz, 1H, Ar), 8.71 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 14.2 
(CH3), 22.2, 28.0 (CH2), 112.9 (CH), 118.8, 120.1, 126.5 (C), 126.6 (CH) 128.1 (CH), 129.0, 
130.3, 130.5, 131.5 (CH), 132.5 (C), 142.0 (CH), 147.5, 147.6 (C). IR (ATR): ~ = 3053, 1613, 
1555, 1493 (w), 1467, 1327 (m), 1173 (w), 1020, 913, 783 (m), 744, 696 (s) cm
–1
. GC-MS (EI, 
70 eV): m/z (%) = 262 (6, [M
 
+1]
+
), 261 (100, [M]
+
), 233 (19), 232 (50), 205 (11). HRMS (EI): 
calcd. For C26H17N3 [M]
+
: 261.12636. Found: 261.12626.  
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Synthesis of compound (35) 
 
General procedure for compounds 35a-j: A flame dried 100 ml round bottom flask equipped 
with magnetic stir bar was charged with acetonitrile (3 ml). β-Ketoester / β-diketone 31 (0.4 
mmol, 1.0 equiv), 2-(trimethylsilyl)phenyl trifluoromethanesulfonate (30) (0.5 mmol, 1.25 
equiv), and cesium fluoride (1.0 mmol, 2.5 equiv) were sequentially added to the flask. A 
septum was placed on the reaction vessel, and the mixture was then heated at 80 °C for 45-60 
minutes. When benzyne precursor was consumed (TLC analysis), the mixture was extracted 
with brine (4 ml). The aqueous layer was extracted with DCM (3× 4 ml). The organic layers 
were combined and dried over Na2SO4. After filtration, the residue was concentrated under 
reduced pressure and purified by flash chromatography. 
 
Ethyl 2-(2-acetylphenyl)-2-fluoroacetate (35a): Starting with 2-(trimethylsilyl)phenyl 
trifluoromethanesulfonate (30) (186 mg, 0.63 mmol), ethyl 2-fluoro-3-
oxobutanoate (31a) (74 mg, 0.5 mmol), CsF (190 mg, 1.25 mmol) in MeCN (3 
ml), 35a was isolated after column chromatography (silica gel, 2% EtOAc in 
n-heptane) as a colourless oil (80 mg, 71 %). 
1
H-NMR (300 MHz, CDCl3):   
= 1.20 (t, J = 7.4 Hz, 3H, CH3), 2.54 (s, 3H, CH3), 4.15 (q, J = 7.7 Hz, 2H, 
Ar), 6.51 (d, J = 45 Hz, 1H, CH-F), 7.42 (t, J = 7.4 Hz, 1H, Ar), 7.53 (t, J = 
7.4 Hz, 1H, Ar), 7.73 (d, J = 8.2 Hz, 1H, Ar), 7.77 (d, J = 8.2 Hz, 1H, Ar). 
19
F-NMR (63MHz, 
CDCl3):   = -185.6 (s, 1F, CH-F). 
13
C-NMR (75 MHz, CDCl3):   = 14.0, 28.5 (CH3), 61.8 
(CH2), 87.9 (d, J = 177 Hz, F-CH), 126.9 (d, J = 14.3 Hz, CH, Ar), 128.8 (d, J = 1.7 Hz, CH, 
Ar), 129.8 (CH), 132.6 (d, J = 1.4 Hz, CH, Ar), 135.1 (d, J = 18.7 Hz, C, Ar), 136.6 (d, J = 2.8 
Hz, C, Ar), 168.1 (d, J = 25 Hz, CO), 200.7 (CO). IR (ATR): ~  = 2979 (w), 1731(S), 1599, 
1368 (w), 1212, 1023 (s), 888 (m), 759, 695 (s) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 224 ([M]
+
, 
5), 195 (11), 177 (29), 149 (100), 105(13), 77 (10). HRMS (EI): calcd. For C12H13O3F [M]
+
: 
224.0849. Found: 224.0850. 
 
Ethyl 2-(2-(2,2,2-trifluoroacetyl)phenyl)acetate (35b): Starting with 2-(trimethylsilyl)phenyl 
trifluoromethanesulfonate (30) (186 mg, 0.63 mmol), ethyl 4,4,4-trifluoro-3-
oxobutanoate (31b) (92 mg, 0.5 mmol), CsF (190 mg, 1.25 mmol) in MeCN 
(3 ml), 35b was isolated after column chromatography (silica gel, 2% EtOAc 
in n-heptane)  as a colourless oil  (92 mg, 71 %). 
1
H- NMR (300 MHz, 
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CDCl3):  = 1.18 (t, J = 7.2 Hz, 3H, CH3), 3.90 (s, 2H, CH2), 4.08 (q, J = 7.2 Hz, 2H, Ar), 7.28 
(dd,  J = 7.6, 0.8 Hz, 1H, Ar), 7.38 (dt, J = 7.7, 1.2 Hz, 1H, Ar), 7.53 (dt, J = 7.6, 1.3 Hz, 1H, 
Ar), 7.88 (dd, J = 7.8, 1.6 Hz, 1H, Ar). 
19
F-NMR (63MHz, CDCl3):  = -71.3 (s, 3F, CF3).
13
C-
NMR (75 MHz, CDCl3):   = 14.1 (CH3), 40.1, 61.1 (CH2), 116.3 (q, J = 292 Hz, CF3), 127.6 
(CH), 129.9 (C), 130.4 (q, J = 3.8 Hz, CH, Ar), 133.1 (CH), 134.2 (CH), 137.2 (C), 170.6 (CO), 
182.5 (q, J = 34.7 Hz, CO). IR (ATR): ~ = 3218 (w), 1740 (m), 1465, 1405, 1268 (w), 1170 (s), 
1097, 1030, 895 (m), 870, 846 (w), 773, 736, 712 (s), 612, 544 (m) cm
–1
. GC-MS (EI, 70 eV): 
m/z (%) = 260 ([M]
+
, 10), 215 (26), 214 (28), 191 (57), 187 (100), 137 (47), 135 (56), 119 (60), 
90 (37), 89 (40). HRMS (EI): calcd. For C18H11O3F3 [M]
+
: 260.0659. Found: 260.0655. 
 
Methyl 2-(2-(4-fluorobenzoyl)phenyl)acetate (35c): Starting with 2-(trimethylsilyl)phenyl 
trifluoromethanesulfonate (30) (186 mg, 0.63 mmol), methyl 3-(4-
fluorophenyl)-3-oxopropanoate (31c) (98 mg, 0.5 mmol), CsF (190 mg, 
1.25 mmol) in MeCN (3 ml), 35c was isolated after column 
chromatography (silica gel, 2% EtOAc in n-heptane)  as a colourless oil  
(118 mg, 87 %). 
 1
H- NMR (300 MHz, CDCl3):  = 3.45 (s, 3H, CH3), 3.7 
(s, 2H, CH2), 7.02 (t, J = 9.2 Hz, 2H, Ar), 7.23-7.26 (m, 3H, Ar), 7.34-7.39 (m, 1H, Ar), 7.73 
(dd, J = 5.4, 5.2 Hz, 2H, Ar). 
19
F-NMR (63MHz, CDCl3):  = -105.3(s, F).
13
C-NMR (75 MHz, 
CDCl3):  = 37.5 (CH2), 51.3(CH3), 114.4 (d, J = 22.1 Hz, CH, Ar), 125.4 (C), 125.6(CH), 
127.6 (C), 128.7, 129.9, 130.8 (CH), 132.1 (d, J = 9.4 Hz, CH, Ar), 132.8(C), 133.1 (d, J = 2.9 
Hz, CH, Ar), 137.1, 164.6 (d, J = 250 Hz, C, Ar), 170.7, 190.5 (CO).  IR (ATR): ~  = 2997 (w), 
1732, 1656, 1595 (s), 1503, 1434, 1408 (w), 1267, 1223, 1147 (s), 1095, 1010, 941 (w), 918, 
851 (m), 808, 783 (w), 741 (s), 632 (w), 600 (s) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 272 
([M]
+
, 6), 213 (36), 212 (100), 183 (28), 123 (12), 95 (13). HRMS (EI): calcd. For C16H13FO3 
[M]
+ 
: 272.0843. Found: 272.0839. 
 
Ethyl 2-(2-(4-fluorobenzoyl)phenyl)acetate (35d): Starting with 2-(trimethylsilyl)phenyl 
trifluoromethanesulfonate (30) (186 mg, 0.63 mmol), ethyl 3-(4-
fluorophenyl)-3-oxopropanoate (31d) (105 mg, 0.5 mmol), CsF (190 mg, 
1.25 mmol) in MeCN (3 ml), 35d was isolated after column 
chromatography (silica gel, 2% EtOAc in n-heptane) as a colourless oil  
(113 mg, 79 %). 
1
H-NMR (300 MHz, CDCl3):   = 2.03 (t, J = 7.8 Hz, 
3H, CH3), 4.79 (s, 2H, CH2), 4.94 (q, J = 7.1 Hz, 2H, CH2), 8.04 (t, J = 10.1 Hz, 2H, CH, Ar), 
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8.24-8.29 (m, 3H, Ar), 8.36-8.42 (m, 1H, Ar), 8.76 (dd, J = 6.3, 3.9 Hz, 2CH, Ar).
19
F-NMR 
(63MHz, CDCl3):  = -105.3 (s, F). 
13
C-NMR (75 MHz, CDCl3):  = 14.1 (CH3), 38.7, 60.8 
(CH2), 115.4 (d, J = 21.5 Hz, CH, Ar), 126.5, 129.7, 130.9, 131.8 (CH), 133.0 (d, J = 8.6 Hz, 
CH, Ar), 134.0 (C), 134.1 (d, J = 4.5 Hz, C, Ar), 138.5 (C), 165.7 (d, J = 248.6 Hz, C, Ar), 
171.3, 198.5 (CO). IR (ATR): ~ = 2980 (w), 1730, 1656, 1595 (s), 1503 (m), 1446, 1408, 1368, 
1333 (w), 1267, 1147 (s), 1094, 1026, 918, 850 (m), 783 (w), 741 (w), 688 (m), 601 (s) cm
–1
. 
GC-MS (EI, 70 eV): m/z (%) = 286 ([M]
+
, 3), 257 (19), 241 (15), 213 (47), 212 (100), 183 (30), 
165 (12). HRMS (EI): calcd. For C17H15FO3 [M]
+
:  286.0999 ; Found: 286.0992. 
 
Ethyl 2-(2-(4-nitrobenzoyl)phenyl)acetate  (35e): Starting with 2-(trimethylsilyl)phenyl 
trifluoromethanesulfonate (30) (186 mg, 0.63 mmol), ethyl 3-(4-
nitrophenyl)-3-oxopropanoate (31e) (119 mg, 0.5 mmol), CsF (190 mg, 
1.25 mmol) in MeCN (3 ml), 35e was isolated after column 
chromatography (silica gel, 2% EtOAc in n-heptane) as a colourless oil 
(133 mg, 85 %). 
1
H- NMR (300 MHz, CDCl3):  = 1.07 (t, J = 6.9 Hz, 
3H, CH3), 3.88 (s, 2H, CH2), 3.95 (q, J = 5.9 Hz, 2H, CH2), 7.26-7.38 (m, 3H, Ar), 7.41-7.46 (m 
, 1H, Ar), 7.89 (d, J = 8.8 Hz, 2H, Ar), 8.22 (d, J = 9.8 Hz, 2H, Ar). 
13
C-NMR (75 MHz, 
CDCl3):  = 14.1 (CH3), 38.7, 60.9 (CH2), 123.4, 126.7 (CH), 129.1, 129.5 (C), 130.1, 131.1, 
131.7, 132.1, 134.5, 137.1 (CH), 142.8, 150.0 (C), 171.2, 196.2 (CO). IR (ATR): ~ = 2980 (w), 
1727, 1667 (s), 1601 (w), 1521 (s), 1445, 1406 (w), 1343, 1263, 1213, 1153 (s), 1025, 920, 866 
(m), 850 (s), 821, 789 (w), 759 (m), 710 (s), 652 (m) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 313 
([M]
+
, 7), 296 (36), 268 (21), 267(16), 240 (33), 239 (100), 194 (41), 165 (64). HRMS (EI): 
calcd. For C17H15NO5 [M]
+
: 313.0945; Found: 313.0941. 
 
3,3,4,4,5,5,5-Heptafluoro-1-(2-pivaloylphenyl)pentan-2-one (35f): Starting with 2-
(trimethylsilyl)phenyl trifluoromethanesulfonate (30) (186 mg, 0.63 
mmol), 6,6,7,7,8,8,8-heptafluoro-2,2-dimethyloctane-3,5-dione (31f) (74 
mg, 0.5 mmol), CsF (148 mg, 1.25 mmol) in MeCN (3 ml), 35f  was 
isolated after column chromatography (silica gel, 1% EtOAc in n-
heptane) as a colourless oil (93 mg, 50 %). 
1
H-NMR (300 MHz, CDCl3): 
 = 1.25 (s, 9H, 3CH3), 3.42 (s, 2H, CH2), 7.30 (d, J = 7.6 Hz, 1H, Ar), 7.36 (t, J = 8.6 Hz, 1H, 
Ar), 7.59 (t, J = 7.6 Hz, 1H, Ar), 8.17 (d, J = 8.6 Hz, 1H, Ar). 
19
F-NMR (63MHz, CDCl3):  = -
124.9 (m, CF2), -80.5 (m, CF2), -71.4 (CF3). 
13
C-NMR (75 MHz, CDCl3):  = 27.9 (3CH3), 35.6 
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(CH2), 66.1 (C), 99.7- 101.2 (m, CF2), 105.8-106.2 (m, CF2), 119.1-120.3 (m, CF3), 125.5, 
127.6, 129.3, 134.6 (CH), 136.8, 137.7(C), 162.9, 196.3 (CO). IR (ATR): ~ = 3233, 3065, 
2228, 1591 (w), 1489, 1329 (m), 1165 (w), 1068, 929 (m), 857 (w), 779 (m), 747 (s) cm
–1
; GC-
MS (EI, 70 eV): m/z (%) = 372 ([M]
+
, 6), 202 (64), 188 (12), 187 (100), 169 (13), 160 (47), 145 
(32), 131 (18), 89 (43). HRMS (EI): calcd. For C16H15F7O2 [M]
+
: 372.0960; Found: 372.0968. 
 
3-(2-Benzoylphenyl)-1,1,1-trifluoropropan-2-one (35g): Starting with 2-
(trimethylsilyl)phenyl trifluoromethanesulfonate (30) (186 mg, 0.63 mmol), 
4,4,4-trifluoro-1-phenylbutane-1,3-dione (31g) (108 mg, 0.5 mmol), CsF (148 
mg, 1.25 mmol) in MeCN (3 ml), 35g was isolated after column 
chromatography (silica gel, 2% EtOAc in n-heptane) as a colourless oil  (107 
mg, 73%). 
1
H-NMR (300 MHz, CDCl3):  = 4.34 (s, 2H, CH2), 7.21-7.34 (m, 
2H, Ar), 7.36-7.49 (m, 2H, Ar), 7.59 (d, J = 7.6 Hz, 1H, Ar), 7.72 (t, J = 7.6 Hz, 2H, Ar), 7.89 
(d, J = 7.6 Hz, 2H, Ar). 
19
F-NMR (63MHz, CDCl3):  = -71.4 (s, 3F, CF3). 
13
C-NMR (75 MHz, 
CDCl3):  = 37.1 (CH2), 112.4 (C), 116.3 (q, J = 292 Hz, CF3), 126.4, 128.3, 129.1 (CH), 129.7 
(C), 130.2, 130.3, 130.5, 132.9, 133.1, 133.9(CH), 136.7, 138.4(C),182.5 (q, J = 34.5 Hz, 
COCF3), 198.3 (CO).  IR (ATR): 
~ = 3062 (w), 1715 (m), 1659 (s), 1596 (m), 1571, 1485 (w), 
1447, 1269 (m), 1180, 1138 (s), 1000 (w), 935, 733, 698, 664, 639 (s) cm
–1
. GC-MS (EI, 70 
eV): m/z (%) = 292 ([M]
+
,48), 195 (21), 187 (100), 165 (32), 105 (51), 77 (43). HRMS (EI): 
calcd. For C16H11F3O2 [M]
+
: 292.0711. Found: 292.0708. 
 
2,2,2-Trifluoro-1-(2-(2-(naphthalen-2-yl)-2-oxoethyl)phenyl)ethanone (35h): Starting with 
2-(trimethylsilyl)phenyltrifluoromethanesulfonate (30) (186 mg, 
0.63 mmol), 4,4,4-trifluoro-1-(naphthalen-2-yl)butane-1,3-dione 
(31h) (133 mg, 0.5 mmol), CsF (148 mg, 1.25 mmol) in MeCN (3 
ml), 35h was isolated after column chromatography (silica gel, 
2% EtOAc in n-heptane) as a colourless oil (97 mg, 57 %). 
1
H-
NMR (300 MHz, CDCl3):  = 4.14 (s, 2H, CH2), 7.37 (dd, J = 7.6, 7.2 Hz, 1H, Ar), 7.49-7.52 
(m, 2H,Ar), 7.70-7.88 (m, 4H, Ar), 8.04 (d, J = 7.6 Hz, 1H, Ar), 8.08 (d, J = 7.6 Hz, 1H, Ar), 
8.16 (d, J = 8.6 Hz, 1H, Ar), 8.42 (s, 1H, Ar). 
19
F-NMR (63MHz, CDCl3):  = -71.3 (s, 3F, 
CF3). 
13
C-NMR (75 MHz, CDCl3):  = 37.2 (CH2), 117.3 (q, J = 280 Hz, CF3), 120.9(C), 124.4, 
126.7, 126.9, 127.9, 128.3, 128.6, 128.9, 129.1, 129.4, 129.9, (CH), 132.5, 132.7, 134.6 (C), 
135.9 (CH), 138.5 (C), 180.6 (q, J = 33.5 Hz, CO), 198.2 (CO). IR (ATR): ~ = 3058 (w), 1714 
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(m), 1654 (s), 1625, 1596 (m), 1571 1486, 1464, 1446, 1352 (w), 1291, 1275 (m), 1181, 1138 
(s), 982 (w), 937 (s), 865, 825 (w), 784 (m), 750, 732, 663 (s), 602 (m), 574 (w) cm
–1
. GC-MS 
(EI, 70 eV): m/z (%) = 342 ([M]
+
, 7), 258 (100), 245 (34), 228 (24), 155 (45), 127 (100), 114 
(34), 105 (37), 75 (9). HRMS (EI): calcd. For C20H13F3O2 [M]
+
: 342.0868; Found: 342.0869. 
 
1-(2-(2,2,2-trifluoroacetyl)phenyl)propan-2-one (35i): Starting with 2-(trimethylsilyl)phenyl 
trifluoromethanesulfonate (30) (186 mg, 0.63 mmol), 1,1,1-trifluoropentane-2,4-
dione (31i) (77 mg, 0.5 mmol), CsF (103 mg, 1.25 mmol) in MeCN (3 ml), 35i  
was isolated after column chromatography (silica gel, 2% EtOAc in n-heptane) as 
a colourless oil (77 mg, 67%). 
 1
H- NMR (300 MHz, CDCl3):  = 3.09 (s, 3H, 
CH3), 4.19 (s, 2H, CH2), 6.26 (d, J = 7.5Hz, 1H, Ar), 6.37 (t, J = 6.4 Hz,1H, Ar), 
6.59 (t, J = 6.4 Hz,1H, Ar), 7.17 (d, J = 7.4 Hz,1H, Ar). 
19
F-NMR (63MHz, CDCl3):  = -70.8 
(s, 3F, CF3). 
13
C-NMR (75 MHz, CDCl3):  = 19.7 (CH3), 103.5 (CH), 116.6 (q, J = 274.7 Hz, 
CF3), 123.6 (C), 124.8, 127.5, 129.5, 129.9, 134.7 (CH), 136.5 (C), 163.6 (q, J = 34.5 Hz, CO), 
173.1 (CO). IR (ATR): ~ = 2953 (w), 1585, 1402 (m), 1278, 1069 (s), 973 (m), 900, 796, 735, 
694, 672 (s), 639, 555 (m) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 230 ([M]
+
, 10), 179 (32), 185 
(14), 173 (41), 151 (100), 152 (10), 77 (51), 75 (14). HRMS (EI): calcd. For C11H9F3O2 [M]
+
: 
230.0555 ; Found: 230.0557. 
 
2,2,2-Trifluoro-1-(2-(2-(furan-2-yl)-2-oxoethyl)phenyl)ethanone (35j): Starting with 2-
(trimethylsilyl)phenyl trifluoromethanesulfonate (30) (186 mg, 0.63 mmol), 
4,4,4-trifluoro-1-(furan-2-yl)butane-1,3-dione (31j) (119 mg, 0.5 mmol), CsF 
(103 mg, 1.25 mmol) in MeCN (3ml), 35j was isolated after column 
chromatography (silica gel, 2% EtOAc in n-heptane) as a colourless oil  (99 
mg, 70%). 
 1
H- NMR (300 MHz, CDCl3):  = 5.42 (s, 2H, CH2), 6.71 (d, J = 
5.9 Hz, 2H, Ar), 6.85 (t, J = 6.8 Hz, 1H, Ar), 7.42-7.46 (m, 2H, Ar), 7.81 (d, J = 8.8 Hz, 1H, 
Ar), 8.22 (d, J = 8.8 Hz, 1H, Ar). 
19
F-NMR (63MHz, CDCl3):  = -69.8 (s, 3F, CF3). 
13
C-NMR 
(75 MHz, CDCl3):  = 43.7 (CH2), 112.6 (CH), 114.6 (q, J = 274.7 Hz, CF3), 118.4, 127.1, 
127.5, 127.9, 128.5, 128.9 (CH), 129.8 (C), 147.5 (CH), 151.4 (C), 184.2 (q, J = 34.5 Hz,CO), 
207.6 (CO). IR (ATR): ~ = 3150 (w), 1731 (s), 1642 (m), 1478 (s), 1549 (m), 1445 (m), 1228 
(m), 1162 (m), 1003 (m), 815 (m), 746 (s) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 282 ([M]
+
, 2), 
213 (14), 212 (100), 184 (79), 128 (73), 89 (17). HRMS (EI): calcd. For C14H9F3O3 [M]
+
: 
282.0504.  Found: 282.0506. 
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Synthesis of benzo[4',5']imidazo[1',2':1,2]pyrido[4,3-b]indole (37). 
 
 
General procedure for compounds 37 a-e: The reactions were performed following the 
procedure given for the synthesis of products 21 using o-alkynylaldehyde 27 (0.50 mmol), 
amine 36 (0.50 mmol), 10 mol% of AgNO3 in 2.0 mL of H2O at 85 
◦
C for 7-10 hrs (TLC 
control). The reaction mixture was quenched with saturated NH4Cl, followed by extraction with 
ethyl acetate (3 × 15 ml). The residue then obtained, after removing the solvent under reduced 
pressure and was purified by column chromatography on silica gel to afford the pure product 
37. 
 
5-methyl-7-phenyl-5H-benzo[4',5']imidazo[1',2':1,2]pyrido[4,3-b]indole (37a): Starting with 
1-methyl-2-(phenylethynyl)-1H-indole-3-carbaldehyde (27) (129.5 
mg, 0.50 mmol), benzene-1,2-diamine (36a), (54 mg, 0.50 mmol), 
AgNO3 (10 mol%), 37a was isolated after column chromatography 
(silica gel, 2% EtOAc in n-heptane) as a white solid (140 mg, 81 %), 
m.p. = 137-138 
o
C.
 1
H-NMR (300 MHz, CDCl3):   = 3.91 (s, 3H, 
CH3), 6.47 (d, J = 8.3 Hz, 1H, CH), 6.88 (s, 1H, CH, Ar), 6.93 (ddd, J 
= 8.5, 7.1, 1.1 Hz, 1H, Ar), 7.40 (ddd, J = 8.5, 7.1, 1.1 Hz, 1H, Ar), 7.42-7.50 (m, 3H, Ar), 7.61- 
7.71 (m, 5H, Ar), 8.01 (d, J = 8.2 Hz, 1H, Ar), 8.77 – 8.80 (m, 1H, Ar). 13C-NMR (62 MHz, 
CDCl3):  = 29.7 (CH3), 99.7 (CH), 104.7 (C), 109.1, 114.1, 118.9, 119.5, 121.2, (CH), 122.5 
(C) 122.6, 124.3, 124.6, 129.1, 129.1, 129.3, 129.3 (CH), 129.6 (C), 129.9 (CH), 135.2, 138.9, 
139.2, 139.4, 145.6, 147.1 (C). IR (ATR): ~ = 3053, 1613, 1555, 1493 (w), 1467, 1327 (m), 
1173 (w), 1020, 913, 783 (m), 744, 696 (s) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 348 (26.4, [M
 
+1]
 +
), 347 (100, [M]
+
), 346 (14.7), 331 (17.6), 173 (15.8), 166 (7.8). ESI-TOF/MS : calcd. For 
C26H17N3 [M+H]
+
: 348.1500.  Found: 348.1502. 
 
10,11-dichloro-5-methyl-7-phenyl-5H-benzo[4',5']imidazo[1',2':1,2]pyrido[4,3-b]indole 
(37b): Starting with 1-methyl-2-(phenylethynyl)-1H-indole-3-carb-
aldehyde (27) (129.5 mg, 0.50 mmol), 4,5-dichlorobenzene-1,2-
diamine (36b), (87.5 mg, 0.50 mmol), AgNO3 (10 mol%), in 2 ml 
H2O, 37b was isolated after column chromatography (silica gel, 3% 
EtOAc in n-heptane) as a yellowish solid (137 mg, 66 %), m.p. = 
77 
 
114-115 
o
C.
 1
H-NMR (300 MHz, CDCl3):   = 3.14 (s, 3H, CH3), 5.61 (s,1H, Ar), 6.22 (s, 1H, 
Ar), 6.65-7.01 (m, 8H, Ar), 7.22 (s, 1H, Ar), 8.06 (s, 1H, Ar). 
13
C-NMR (75 MHz, CDCl3):  = 
29.9 (CH3), 102.2 (C), 109.6, 114.3, 118.7, 120.4, 120.7, 121.2, 121.8 (CH), 124.7 (C),124.9, 
126.4, 126.8, 126.8 (CH), 127.8, 127.9 (C), 128.6, 128.6 (CH) 137.8, 138.7, 141.8, 143.9, 
148.4, 155.7 (C). IR (ATR): ~ = 3053, 1613, 1555, 1493 (w), 1467, 1327 (m), 1173 (w), 1020, 
913, 783 (m), 744, 696 (s) cm
–1
. GC-MS (EI, 70 eV): m/z (%) = 420 (2.2), 419 (12.5), 418 
(23.4), 417 (62.3), 416 (23.7), 415 (100, [M]
+
), 208 (26.5), 189 (69.9), 182 (21.7), 172 (12.5), 
159 (10.8), 158 (12.5). ESI-TOF/MS (EI): calcd. For C24H15Cl2N3 ([M+H]
 +
, 
35
Cl): 416.0716. 
Found: 416.0721. C24H15Cl2N3 ([M+H]
 +
, 
37
Cl): 418.0691. Found: 416.0694.  
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Appendix 
 
A1 Crystallographic details 
 
 Crstallographic data for 5e. 
 
Table 12 Crstallographic details for 5e 
Identification code IS_MZ10 
Empirical formula C25H26N2O 
Formula weight 370.48 
Temperature 173(2) K 
Wavelength 0.71073 Å 
Crystal system Triclinic 
Space group (H.-M.) 
Space group (Hall) 
P -1 
-P 1 
Unit cell dimensions a = 9.4099 (2) Å        α = 82.8690° 
b = 9.5876 (2) Å        β = 89.3550° 
c =  11.7606 (3) Å      = 74.3840° 
Volume (Z) 1013.68 (4) Å
3
 
Density (calculated) 1.214 Mg/m
3
 
Absorption coefficient 0.074 mm
-1
 
F(000) 396 
Crystal size 0.34 x 0.31 x 0.23 mm
3
 
Θrange for data collection 7.891 to 59.925° 
Reflections collected 5869 
Independent reflections 2986 [R(int) = 0.032] 
Absorption correction multi-scan 
Max. and min. transmission 0.9753  and 0.9832 
Refinement method Full-matrix 
Goodness-of-fit on F
2
 1.064 
Final R indices [I>2σ(I)] R1 = 0.0470,     wR2 =  0.1376 
R indices (all data) R1 = 0.0616,      wR2 = 0.1276 
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Figure 17. Numbering scheme for 1-Heptyl-2-phenylbenzo[b][1,8]naphthyridin-4(1H)-one (5e) 
 
Crstallographic data for 5f 
 
 
 
Figure 18. Numbering scheme for 1-Cyclopropyl-2-phenylbenzo[b][1,8]naphthyridin-4-(1H)-
one (5f)  
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Table 13. Crystal data and structural refinement for 5f 
Identification code IS_MZ11 
Empirical formula C21H16N2O 
Formula weight 312.36 
Temperature 173(2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic 
Space group (H.-M.) 
Space group (Hall) 
P  21/C 
-P 2ybc 
Unit cell dimensions a = 11.0964 (4) Å      α = 90.000° 
b = 15.9489 (5) Å      β = 90.73° 
c =  8.8191 (7) Å        = 90.00° 
Volume (Z) 1560.64 (10) Å
3
 
Density (calculated) 1.329 Mg/m
3
 
Absorption coefficient 0.083 mm
-1
 
F(000) 656 
Crystal size 0.54 x 0.32 x 0.23 mm
3
 
Θrange for data collection 7.891 to 59.925° 
Reflections collected 4557 
Independent reflections 2986 [R(int) = 0.032] 
Absorption correction multi-scan 
Max. and min. transmission 0.9506  and 0.9812 
Refinement method Full-matrix 
Goodness-of-fit on F
2
 1.055 
Final R indices [I>2σ(I)] R1 = 0.0443,     wR2 =  0.1170 
R indices (all data) R1 = 0.0594,      wR2 = 0.1258 
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Crstallographic data for 5k 
 
Table 14. Crystal data and structural refinement for 5k 
Identification code IS_MZ23 
Empirical formula C25H17N2OCl 
Formula weight 396.86 
Temperature 173(2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic 
Space group (H.-M.) 
Space group (Hall) 
P 1 21/C 1 
-P 2ybc 
Unit cell dimensions a = 11.2627 (4) Å      α = 90.000° 
b = 6.9156   (3) Å      β = 94.914° 
c =  24.5274 (9) Å      = 90.00° 
Volume (Z) 1903.38 (13) Å
3
 
Density (calculated) 1.385 Mg/m
3
 
Absorption coefficient 0.220 mm
-1
 
F(000) 824 
Crystal size 0.56 x 0.49 x 0.43 mm
3
 
Θrange for data collection 7.891 to 59.925° 
Reflections collected 4557 
Independent reflections [R(int) = 0.032] 
Absorption correction multi-scan 
Max. and min. transmission 0.8866  and 0.9113 
Refinement method Full-matrix 
Goodness-of-fit on F
2
 1.069 
Final R indices [I>2σ(I)] R1 = 0.0433,     wR2 =  0.1191 
R indices (all data) R1 = 0.0557,      wR2 = 0.1257 
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Figure 19. Numbering scheme for 1-(2-Chlorobenzyl)-2-phenylbenzo[b][1,8]naphthyridin-
4(1H)-one (5k)  
 
 Crstallographic data for 5t  
 
 
Figure 20. Numbering scheme for 1-(4-Ethylphenyl)-2-phenylbenzo[b][1,8]naphthyridin-
4(1H)-one (5t)  
 
83 
 
 
 
Table 15. Crystal data and structural refinement for 5t 
Identification code  av_MZ42b  
Empirical formula  C26H20N2O 
Formula weight  376.44  
Temperature 173(2) K 
Wavelength  0.71073 Å 
Crystal system Monoclinic 
Space group (H.-M.) 
Space group (Hall) 
  C c 
 C - 2yc  
Unit cell dimensions      a = 16.0307  (4) Å      α = 90.000° 
   b = 17.5259  (5) Å      β = 95.2370°  
   c =  6.9720   (2) Å      = 90.00°      
Volume (Z) 1950.62 (9) Å
3 
  
Density (calculated) 1.282 Mg/m
3
 
Absorption coefficient   0.079 mm
-1
 
F(000) 792 
Crystal size   0.61 x 0.13 x 0.09 mm
3
 
Θrange for data collection  7.891 to 59.925° 
Reflections collected  11877  
Independent reflections   [R(int) = 0.032]  
Absorption correction  multi-scan  
Max. and min. transmission 0.9536  and 0.9930 
Refinement method  Full-matrix  
Goodness-of-fit on F
2
  1.018 
Final R indices [I>2σ(I)]  R1 = 0.0391, wR2 =  0.0914 
R indices (all data)  R1 = 0.0455, wR2 = 0.0958 
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Crstallographic data for 21i 
 
Table 16. Crystal data and structural refinement for 21i 
Identification code  IS_MZ94  
Empirical formula  C24H19N3 
Formula weight  349.157  
Temperature 173(2) K 
Wavelength  0.71073 Å 
Crystal system Triclinic 
Space group (H.-M.) 
Space group (Hall) 
 -P1 
 P-1  
Unit cell dimensions   a = 11.9967 (4) Å      α = 70.8560° 
b = 13.6656 (5) Å      β = 83.1840°  
c = 16.3845 (7) Å      = 73.5200°      
Volume (Z) 2432.37 (10) Å
3 
  
Density (calculated) 1.443 Mg/m
3
 
Absorption coefficient   0.562 mm
-1
 
F(000) 1084 
Crystal size   0.64 x 0.29 x 0.12 mm
3
 
Θrange for data collection  7.891 to 59.925° 
Reflections collected 4557  
Independent reflections 14091 [R(int) = 0.032]  
Absorption correction multi-scan  
Max. and min. transmission 0.7151  and 0.9357 
Refinement method Full-matrix  
Goodness-of-fit on F
2
 1.062  
Final R indices [I>2σ(I)] R1 = 0.0410,     wR2 =  0.1012  
R indices (all data) R1 = 0.0639,      wR2 = 0.1104 
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Figure 21. Numbering scheme for 7-Phenyl-1,2,3,4-tetrahydrobenzo[b]indazolo[3,2-
f][1,6]naphthyridin (21i) 
 
Crstallographic data for 21q 
 
 
Figure 22. Numbering scheme for 7-Phenyl-1,2,3,4-tetrahydrobenzo[b]indazolo[3,2-
f][1,6]naphthyridin (21q) 
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Table 17. Crystal data and structural refinement for 21q 
Identification code                                 CH_MZ149  
Empirical formula                            C22H25N3 
Formula weight                                      331.45  
Temperature 173(2) K 
Wavelength  0.71073 Å 
Crystal system Triclinic 
Space group (H.-M.) 
Space group (Hall) 
  -P 1 
 P 2yn  
Unit cell dimensions      a = 7.7666 (2) Å       α = 90.000° 
   b = 22.2827 (6) Å      β = 97.734°  
   c =  17.8505 (5) Å      = 90.000°      
Volume (Z) 3061.12 (14) Å
3 
  
Density (calculated) 1.308 Mg/m
3
 
Absorption coefficient   0.079 mm
-1
 
F(000) 1280 
Crystal size   0.48 x 0.10 x 0.05 mm
3
 
Θrange for data collection  7.891 to 59.925° 
Reflections collected                                                             4557  
Independent reflections                                                 14091 [R(int) = 0.032]  
Absorption correction                                           multi-scan  
Max. and min. transmission 0.7151  and 0.9357 
Refinement method                                                Full-matrix  
Goodness-of-fit on F
2  
                                           1.022  
Final R indices [I>2σ(I)]                                       R1 = 0.1348,     wR2 =  0.1358  
R indices (all data)                                               R1 = 0.0602,      wR2 = 0.1053 
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Crstallographic data for 21w 
Table 18. Crystal data and structural refinement for 21w 
Identification code CH_MZ141  
Empirical formula C20H19N3 
Formula weight 301.38  
Temperature 173(2) K 
Wavelength  0.71073 Å 
Crystal system Monoclinic 
Space group (H.-M.) 
Space group (Hall) 
  -P 1 21/n 1 
 P 2yn  
Unit cell dimensions      a = 7.7666 (2) Å       α = 90.000° 
   b = 22.2827 (6) Å      β = 97.734°  
   c =  17.8505 (5) Å      = 90.000° 
Volume (Z) 3061.12 (14) Å
3 
  
Density (calculated) 1.308 Mg/m
3
 
Absorption coefficient   0.079 mm
-1
 
F(000) 1280 
Crystal size   0.48 x 0.10 x 0.05 mm
3
 
Θrange for data collection  7.891 to 59.925° 
Reflections collected 4557  
Independent reflections 14091 [R(int) = 0.032]  
Absorption correction multi-scan  
Max. and min. transmission 0.7151  and 0.9357 
Refinement method Full-matrix  
Goodness-of-fit on F
2
 1.022  
Final R indices [I>2σ(I)] R1 = 0.1348,     wR2 =  0.1358  
R indices (all data) R1 = 0.0602,      wR2 = 0.1053 
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Figure 23. Numbering scheme for 5-Cyclopropyl-1-propylbenzo[b]pyrazolo[5,1-
f][1,6]naphthyridine (21w) 
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Abbreviations 
Ac Acetyl 
Anal.    Elemental Analysis 
bp. Boiling point  
calcd  Calculated  
CI Chemical Ionization 
COSY   Correlated Spectroscopy 
DEPT Distortionless Enhancement by Polarization Transfer 
dr Diastereomeric ratio 
ee Enantiomeric excess 
Et2O Diethyl ether 
EtOH Ethanol 
GC Gas Chromatography 
GP General Procedure 
EI   Electron Impact 
HMBC Heteronuclear Multiple Bond Correlation 
HPLC High Performance Liquid Chromatography 
HRMS High Resolution Mass Spectrometry 
IR Infrared Spectroscopy 
MS Mass Spectrometry 
mp Melting point  
NaOEt Sodium ethanolate  
nBuLi n-Butyllithium 
NEt3 Triethylamine 
NMR Nuclear Magnetic Resonance  
NOESY Nuclear Overhauser and Exchange Spectroscopy  
ORTEP Oak Ridge Thermal Ellipsoid Plot  
OTf Triflate 
Ph Phenyl 
ppm Parts per million  
Rf Retention factor  
Tf2O Trifluoromethanesulfonic anhydride (triflic anhydride)  
TFA Trifluoroacetic acid  
90 
 
THF Tetrahydrofuran  
TLC Thin Layer Chromatography  
TMS Tetramethylsilane 
Tol Tolyl (p-MeC6H4)  
Bn Benzyl 
Cy Cyclohexyl 
Tos Tosyl (p-MeC6H4SO2) 
CPr Cyclopropyl 
DIPA Disopropylamine 
m/z Mass to charge ratio 
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Summary 
 In chapter one, I have developed a new class of 4-quinolones named as benzo-[1,8]-
naphthyridine-4(1H)-ones, by domino amination/conjugate addition reactions of 1-(2-
chloroquinolin-3-yl)-3-phenylprop-2-yn-1-ones with amines. The purpose of this work is to 
(later) study the pharmacological properties of the benzo[1,8]-naphthyridine-4(1H)-ones. 
 
 
 
 The second chapter contains an efficient route for the synthesis of benzo[b]pyrazolo[5,1-
f][1,6]naphthyridines via silver triflate-catalyzed one-pot tandem reactions. This reaction 
proceeds with good functional group tolerance under mild conditions with high efficiency and 
excellent selectivity. 
 
 
 
 The third chapter includes a high yield route for the synthesis of fluorinated arenes by 
direct acyl-alkylation of benzyne. This facile methodology provides a single step, high yielding 
access to a variety of fluoro-substituted arenes, which are otherwise difficult to obtain. 
 
92 
 
 
 
 The fourth chapter covers a simple strategy for the generation of noval 
benzo[4',5']imidazo[1',2':1,2]pyrido[4,3-b]indole, having indole and benzimidazole as a single 
entity. This reaction proceeds in aqeous medium with high yild and regioselectivity. This noval 
combination could be a potential contributor for biochemical and pharmacological investigation. 
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